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Abstract 
Sulfonamides constitute a vital and diverse class of therapeutic agents. Their means of 
synthesis has often involved the use of unstable sulfonyl chloride species; however, 
recent research has established pentafluorophenyl (PFP) and trichlorophenyl (TCP) 
sulfonate esters as a useful stable alternative to such species. 
This thesis describes an exploration into the reactivity of the bifunctional acceptors 
pentafluorophenyl vinyl sulfonate and trichlorophenyl vinyl sulfonate. Intermolecular 
alkyl radical addition to trichlorophenol vinyl sulfonate mediated by both 1-
ethylpiperidinium phosphate (EPHP) and tributyltin hydride was carried out effectively 
to generate a library of alkyl sulfonates. Notably, this was extended to the synthesis of a 
bifunctional alkyl PFP/TCP sulfonate via a double radical addition protocol which was 
envisaged could be useful in determining the reactivity between PFP and TCP.  
1,3-Dipolar cycloaddition reactions were carried out effectively at the electron-deficient 
olefinic portion of the vinylsulfonates to provide functionalized sulfonate esters with 
excellent regioselectivity. Addition of an α and a β substituent to vinylic portion of PFP 
and TCP vinyl sulfonate changed the electronics and sterics of the sulfonates, however 
functionalised esters with great regioselectivity could still be synthesised. 
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Chapter 1 Introduction 
1.1 Sulfonamides as drugs 
Sulfonamides have, for many years, been widely studied for their chemotherapeutic 
activity.
1
 Sulfonamide-based medicines were the second antimicrobial drugs and the 
first effective chemotherapeutic agents to be available in safe therapeutic dosage 
ranges.
2
 They were the mainstay of therapy for bacterial infections in human being 
before the introduction of penicillin in 1941.
3
 The first sulfonamide, trade named 
Prontosil 1 was first discovered in 1932 although its mode of action was initially not 
known as it was active in vivo but not in vitro. However, it was later discovered that 
the drug was metabolized, releasing the active compound sulfanilamide 2 (Scheme 
1).
3-5
 The application of sulfonamides has greatly been extended from their primary 
function as antimicrobial agents, where they act as competitive inhibitors of the 
enzyme dihydropteroate synthetase (DHPS) – the key enzyme involved in folate 
synthesis, to targets such as COX-II inhibitors, loop diuretics, carbonic anhydrase 
inhibitors and even as an anti-impotence drug.
6
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Scheme 1. Metabolism of pro-drug prontosil 1 to sulfanilamide 2. 
1.1.1 Sulfonamides as antibacterial agents 
Sulfa drugs were amongst the oldest chemically synthesized antimicrobial agents and 
are still widely used today for the treatment of various bacterial, protozoal and fungal 
infections.
1
 Sulfanilamide 2 was discovered to be the active entity in 
microorganisms; it inhibits the synthesis of dihydrofolic acid from p-aminobenzoic 
acid, pteridine, and glutamic acid by inhibition of dihydropteroate synthetase. 
Dihydropteroate synthetase catalyses the conversion of p-aminobenzoate to 
dihydropteroate, a key step in folate synthesis (Figure 1). Folate is necessary for the 
cell to synthesize nucleic acids and in its absence cells will be unable to divide.
3
  
 
2 
 
 
Figure 1. Biochemical pathway in microorganisms.
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Although it was once a very useful antibiotic,
4
 the use of sulfanilamide in therapy as 
a single agent is almost obsolete today due to the development of bacterial resistance 
to its effects and the development of more effective antimicrobial agents. However, 
clinical treatment with sulfonamides has undergone a revival with the use of a 
combination of sulfamethoxazole and trimethoprim to treat urinary tract bacterial 
infections.
7
 In fact, it has been demonstrated that the earlier sulfanilamides such as 
sulfadiazine 3, sulfamethazine 4, and sulfamethoxazole 5 (Figure 2) are better 
antibacterial agents when used in combination with trimethoprim or its derivatives. 
This synergistic effect is due to the inhibition of the sequential stages of a common 
biochemical pathway for the biosynthesis of tetrahydrofolic acid, which is involved 
in the production of purines (see Figure 1).
1
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Figure 2. Sulfonamide antibacterials sulfadiazine 3, sulfamethazine 4 and 
sulfamethoxazole 5. 
1.1.2 Sulfonamides as carbonic anhydrase inhibitors 
Carbonic anhydrases (CAs) are ubiquitous metalloenzymes present in prokaryotes 
and eukaryotes which catalyse the reversible hydration of carbon dioxide to give 
bicarbonate and a proton:
8
  
CO2 + H2O → HCO3
– 
+ H
+
 
This reaction is involved in many physiological and pathological processes, 
including: respiration and transport of CO2 and bicarbonate between metabolizing 
tissues and lungs, pH and CO2 homeostasis, electrolyte secretion in various tissues 
and organs, biosynthetic reactions (such as gluconeogenesis, lipogenesis and 
ureagenesis), bone resorption, calcification and tumorigenicity.
9,10
 Owing to the wide 
distribution of carbonic anhydrase in its various isoforms throughout the body and its 
important physiological function, there is a vast number of possible targets for 
inhibitors, making it an attractive candidate for exploitation. 
Carbonic anhydrases, except for CA III, are inhibited primarily by unsubstituted 
sulfonamides possessing the general formula RSO2NH2 (R = aryl, hetaryl, 
perhaloaryl). For example, acetazolamide 6, methazolamide 7, ethoxzolamide 8 and 
dichlorophenamide 9, dorzolamide 10 and brinzolamide 11 (Figure 3) have being 
employed for nearly 45 years as neurological agents and are also used as 
antiglaucoma/antisecretory drugs.
11
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Figure 3. Sulfonamide inhibitors of carbonic anhydrases. 
1.1.3 Sulfonamides as COX-II Inhibitors 
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to treat arthritis, 
menstrual pain, and headache.
12
 NSAIDs exert their major therapeutic and adverse 
effects by inhibition of cyclooxygenase (COX), a key enzyme for prostanoid 
synthesis.
12
 Although effective, their long-term use is limited by gastrointestinal 
effects such as dyspepsia and abdominal pain and, less often, gastric or duodenal 
perforation or bleeding.
12,13
 However, the discovery of two COX isoforms, a 
constitutive COX-1, serving homeostatic prostanoid synthesis, and an inducible 
COX-2, responsible for proinflammatory prostanoid production, ushered in a new 
generation of NSAIDs, the coxibs, which selectively inhibit the COX-2 isoforms, 
reducing adverse effects.
12
 Celecoxib 12 and valdecoxib 13 (Figure 4) are 
sulfonamide-containing COX inhibitors that have been marketed as safe alternatives 
to NSAIDs for the treatment of pain. However, owing to an increased risk of heart 
attacks and stroke the first generation coxibs have been superseded by inhibitors such 
as etoricoxib 16 which promise reduce of further of NSAID-typical adverse effects. 
The presence of the sulfonamide moiety also makes celecoxib and valdecoxib potent 
carbonic anhydrase inhibitors (see section 1.1.2).
9
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Figure 4. Sulfonamide-based COX-2 inhibitors. 
1.1.4 Sulfonamides as cysteine protease inhibitors 
Cysteine proteases are an important class of enzymes that selectively catalyze the 
hydrolysis of peptide bonds. Uncontrolled, unregulated, or undesired proteolysis can 
lead to many disease states including emphysema, stroke, viral infections, cancer, 
Alzheimer's disease, inflammation, and arthritis.
14
 Cysteine proteases inhibitors thus 
have considerable therapeutic potential in a variety of disease states.  
Caspase-1, also known as interleukin-1β converting enzyme (ICE), was one of the 
first to be discovered in the family of cysteine proteases.
15
 This enzyme is 
responsible for processing the inactive pro-form of interleukin-1β (1L-1β), a 
cytokine involved in the pathogenesis of chronic and acute inflammatory disease 
including arthritis, Alzheimer’s disease, and septic shock, into its active form.16 
Thus, inhibition of caspase-1 would modulate the levels of IL-1β, and thus control 
inflammation. Sharhripour and co-workers have reported diphenyl ether sulfonamide 
17 as a potent inhibitor of caspase-1, Ki = 0.1 μM (Figure 5).
16
 Fosamprenavir 18, 
and its predecessor amprenavir, are HIV protease inhibitors based around a 
sulfonamide scaffold and have been used successfully  in conjunction with reverse 
transcriptase inhibitors for the treatment of AIDS.
6
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Figure 5. Sulfonamide based protease inhibitors. 
1.1.5 Other applications for sulfonamides 
Sulfonamides have been employed in the treatment of a plethora of other 
indications.
17
 For example, pyridinyl sulfonamide sulfasalazine (Azulfidine
®
 19) has 
been approved as an anti-inflammatory pro-drug for the treatment of inflammatory 
bowel disease, including ulcerative colitis and Crohn's disease. It is also effective in 
several types of arthritis, particularly rheumatoid arthritis.
18
 One of the most widely 
used sulfonamide drugs in use today is sildenafil 20, marketed as Viagra
®
. It is a 
drug used to treat erectile dysfunction and pulmonary arterial hypertension (PAH) by 
inhibiting cGMP specific phosphodiesterase type 5, an enzyme that regulates blood 
flow in the penis.
19
 Since becoming available in 1998, sildenafil 20 has been the 
prime treatment for erectile dysfunction with annual sales of $1.6 billion (US) in the 
year 2006.
20
 
N N
H
S
N
N
OH
CO2H
O O
N
N
S
O
CH3
N
H
N
N
N
CH3
CH3
O
H3C
O O
19 20  
Figure 6. Sulfonamide containing drugs sulfasalazine 19 and sildenafil 20. 
In conclusion, sulfonamides represent a diverse and relevant class of therapeutic 
drugs. The sulfonamide group remains a vital motif for the development of more 
effective drugs to treat an increasing portfolio of diseases. Thus the development of 
novel methods for the synthesis of sulfonamides has received a great deal of 
attention. 
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1.2 Synthesis of sulfonamides 
Sulfonamides are important pharmaceutical compounds because they exhibit a wide 
range of biological activities such as anti-cancer, anti-inflammatory and anti-viral 
functions (see Section 1). Sulfonamides have also been used synthetically as 
protecting groups of OH or NH functionalities for easy removal under mild 
conditions.
21
 In this section, some pathways for their synthesis are discussed. 
1.2.1 Sulfonamides from sulfonyl chlorides 
Although many synthetic methods have been currently being reported, sulfonylation 
of amines with sulfonyl chlorides in the presence of a base is still the most 
commonly employed method for the synthesis of sulfonamides.
22,23
  
An example of sulfonamide synthesis involves the reaction of sulfonyl chlorides 
using indium catalysis (Scheme 2).
22
 Indium metal was used because of its stability 
in air at ambient temperature, and also because of its low toxicity. Various reaction 
conditions were evaluated and it was discovered that the reaction was only successful 
when a catalytic amount of indium metal was used. The authors proposed that the 
indium metal reacted with sulfonyl chloride to generate electrophilic species, 
RSO2
+
InCl
–
, which then undergoes reaction with amines, regenerating the active 
indium metal along with the corresponding sulfonamide products and HCl.  
21
+
R NH2
In
CH3CN, RT
S
N
H
R
O O
S
Cl
O O
22 23  
23a: R = Cy, 84%;             23b: R = Bu, 89%;                                                                                        
23c: R = Ph, 82%;            23d: R = Bn, 87% 
Scheme 2. Sulfonamides from sulfonyl chlorides using indium catalysis. 
Another example of sulfonamide synthesis from sulfonyl chlorides that are derived 
from the direct oxidation of thiols using thionyl chloride and hydrogen peroxide was 
described by Bahrami et al. (Scheme 3).
24
 The synthesis used thionyl chloride 
combined with hydrogen peroxide (H2O2) as an inexpensive oxidant for the oxidative 
chlorination of thiol derivatives 24 to the corresponding sulfonyl chlorides. After the 
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formation of the sulfonyl chloride in situ and upon addition of amines 25, the 
corresponding sulfonamides 26 are generated. The reaction proceeds in high yields, 
96-98%, and with short reaction times. The reaction also tolerated a variety of 
substrates bearing either electron-donating or electron-withdrawing substituents. 
24
R1 SH + R
2 NH2
H2O2-SOCl2
CH3CN, Pyridine, RT
N
H
S
R1
25 26
OO
R2
 
26a: R
1
, R
2
 = Ph, 97%                           26c: R
1
 = Ph, R
2
 = PhMe, 96% 
  26b: R
1
 = PhMe, R
2
 = Cy, 98%              26d: R
1 
= PhMe, R
2
 = NH3, 97% 
Scheme 3. Sulfonamides from oxidation of thiols. 
1.2.2 Sulfonamides from sulfonic acids 
Sulfonamides can also be synthesised directly from sulfonic acids but there are only 
a small number of methods available. The first direct route was reported by Caddick 
et al.
25
 Here sulfonic acid salts were activated by triphenylphosphine ditriflate and 
transformed directly to the corresponding sulfonamides or sulfonate ester. 
Triphenylphosphine ditriflate was chosen in the reaction as reagent as it was 
envisaged that reaction with sulfonic acids would generate an intermediate that was 
suitably activated towards nucleophiles. The reaction proved to be successful with a 
variety of substrates being tolerated and excellent yields achieved. It was also found 
that the counter ion of the sulfonic acid salt was important as metal salts of sulfonic 
acid were less soluble and hygroscopic. Substitution of triphenylphosphine oxide for 
polystyrene-supported phosphine oxide obviated any problems of triphenylphosphine 
removal, as the reaction products could be removed by washing the filtrate with 
water. 
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Scheme 4. First synthesis of sulfonamides from sulfonic acid salt. 
Another strategy employed by Pandit and co-workers involved a one-pot procedure 
to synthesise sulfonamides from sulfonic acids and amines using cyanuric chloride 
(2,4,6-trichloro-1,3,5-triazine, TCT) 31 and N,N-dimethylformamide (DMF) at room 
temperature (Scheme 5).
26
 The cyanuric chloride 31 and DMF were complexed 
together at room temperature after which the sulfonic acid 30 and amine were added 
to afford the sulfonamides. Primary, secondary, alkyl, aryl and cyclic amines are all 
tolerated in this reaction and gave excellent yields of sulfonamides 32. 
30
+
S
OH
O O
S
N
H
O O
R
Me
N
N
N
Cl
Cl
Cl
DMF, CH2Cl2
RNH2, RT
Me
31 32
R =
32a, 94% 32b, 87% 32c, 84%  
Scheme 5. Sulfonamide synthesis using cyanuric chloride at RT 
Another example which also employs TCT but under microwave conditions was 
reported by De Luca et al. (Scheme 6).
27
 By addition of TCT to a mixture of sulfonic 
acid and NEt3 in acetone and utilising microwave irridation, the authors were able to 
reduce the reaction time from 20 hours to 20 mins. 
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Scheme 6. Sulfonamide synthesis using cyanuric chloride at MW 
1.2.3 Sulfonamides from sulfonate esters 
Sulfonamides can also be synthesised from sulfonate esters; this is not an approach 
that has gained widespread use but an example that uses this method was reported by 
Bornholdt et al.
28
 Here they employed pentafluorophenol sulfonate esters to 
synthesise heterocyclic sulfonamides (Scheme 7). Addition of the thiols 35 to a 
NaOCl/HCl/CH2Cl2 mixture generated the heterocyclic sulfonyl chlorides 36, which 
were directly converted to the corresponding heterocyclic PFP sulfonate esters 37. 
Subsequent treatment of PFP sulfonate esters 37 with slight excess of either primary 
or secondary amines in CH3CN at RT afforded sulfonamides 38.  
35
Het SH
NaOCl / HCl
CH2Cl2 / H2O
Het S Cl
O
O
PFPOH / NEt3
CH2Cl2
Het S O
O
O
F F
F
FF
3eq amine
CH3CN, RT, 1hr
Het S N
O
O
R1
R2
36
37
98-92%
57-76%
38
Het =
N
N N
NN
S S
N
, , ,
 
Scheme 7. Sulfonamides from heterocyclic PFP sulfonate esters 37.  
Wilden et al. have also reported synthesis of sulfonamides using TCP sulfonate ester 
39, a new class of activated sulfonate esters. The authors report that the TCP leaving 
group was displaced effectively by amines and the reaction was faster using 
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microwave irridation (Scheme 8). This reaction was tolerant to simple nucleophilic 
amines as well as challenging amines for example anilines and hindered amines. 
NH2
H
N
NH2
S
OTCP
O O R1 NH2, NMP, NEt3
140  C, 20 min, MW
S
N
H
O O
R1
83-94%
39 40
°
R1 NH2 =
 
Scheme 8. Sulfonamides from TCP sulfonate esters 39. 
To conclude, synthesis of sulfonamides still relies heavily on the use of sulfonyl 
chlorides or a sulfonyl chloride intermediate which can be trapped by an amine. 
Some sulfonyl chlorides are difficult to prepare or unstable and are not amenable to 
long term storage. As sulfonamides are important in medicinal chemistry, research 
into new ways of synthesising them continues to be an important problem in organic 
synthesis.  
1.3 Radicals and their importance 
Initially thought of as a mere ‘chemical curiosity’, free radical reactions have now 
become a powerful tool for preparative organic synthesis.
29
  Radical chemistry shows 
numerous advantages over its ionic counterpart, including greater functional-group 
tolerance, the frequent use of neutral conditions and a capability to be incorporated 
into elaborate reaction cascades that rapidly increase molecular complexity. 
Furthermore, radical methodology is amenable to ‘green’ chemistry as more 
examples of reactions being performed in water and with a variety of cheap, 
environmentally benign reagents are being reported.
29,30
  
1.3.1 Discovery and development of radical chemistry 
The first significant study of free-radical chemistry was described by Gomberg in 
1900 when he investigated the reaction of triphenylmethyl bromide 41 with silver 
(Scheme 9).
31
 In the absence of oxygen, the reaction yielded a highly reactive solid 
which Gomberg proposed to be compound 43. When in solution, this product existed 
12 
 
in equilibrium with triphenylmethyl radical 42 which was observed to be quite stable. 
By 1911, there was enough experimental evidence to prove the existence of radical 
42 and that the isolated product obtained in the reaction was compound 44.  
43
Ph Br
Ph
Ph
2 + 2Ag
+ 2AgBr
H
Ph
Ph
Ph3C
"Gomberg Product"
Actual 
Product
44
42
Ph
Ph
Ph
Ph
Ph
Ph
41
Ph Ph
Ph
 
Scheme 9. First observation of radicals. 
Formation of less stable and more reactive radicals followed, but it was not until 
1937 that radicals were postulated to be intermediates in a variety of chemical 
reactions. A lot of work continued in this area and by 1970 a number of important 
radical reactions had been developed and numerous targets were prepared using 
radical chemistry. An increasing understanding of the kinetic and the structural 
information paved the way for the development of modern synthetic radical 
chemistry and by 1980, mainstream organic synthesis started to use it routinely in the 
form of the tin hydride methodology.
31
 
1.3.2 Radical initiators 
Radical initiators are substances that can produce radical species under mild 
conditions and promote radical polymerization reactions.
32
 Radical reactions are 
initiated using thermal or photochemical activation to promote homolysis of a weak 
bond. Although some radical chain processes can occur spontaneously at moderate 
temperatures, it is usually desirable to facilitate the chain initiation process by 
deliberate addition of an initiator. Initiators generally possess weak bonds i.e. those 
with small bond dissociation energies. Typical examples include halogen molecules, 
azo compounds, and organic peroxides.
30,33
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1.3.3 Radical chain carriers 
1.3.3.1  Organotin Reagents 
Organotin reagents have been central to the development of modern free-radical 
chemistry and their use still underpins many endeavours in this field.
29
 To date, most 
radical reactions are conducted using tin hydrides (Bu3SnH, Me3SnH, and Ph3SnH) 
with the reactions using tributyltin hydride being some of the most powerful and 
widely applied.
29,31
  
In 1983, Barton et al. reported the synthesis of thiohydroxamate ester 46 from 
carboxylic acid 45, which on reacting with tributyltin hydride gave the acid 
decarboxylation product 47. These esters 46 became known as the Barton esters and 
formed the general method known as the Barton decarboxylation method.
34
 
RCO2H
1. SOCl2 or PCl5
2. N-hydroxypridin-2-thione OR
O
N S
Bu3SnH
AIBN
N S
SnBu3
CO2
R H
+
+
45 46
47
 
Scheme 10. Barton decarboxylation method. 
Shuto et al. also employed the Barton reductive radical decarboxylation as a key step 
in the enantioselective synthesis of haloperidol analogue. They found that even 
though the reaction went quite smoothly with tributyltin hydride as the hydrogen 
donor, the selectivity was quite poor.
35
  
In 2008, Nicolaou et al. reported the total synthesis of adamantaplatensimycin with 
the onset of the synthesis employing a simple radical conjugate addition.
36
 
Commercially available bromoadamantane 48 was added to methyl acrylate using 
tributyl tin hydride mediated by AIBN to afford the corresponding adamantyl methyl 
ester 49 in a 75% yield (Scheme 11). 
14 
 
Br
MeO OBu3SnH, AIBN
methyl acrylate
PhMe, reflux, 2 h
48 49, 75%  
Scheme 11. Synthesis of adamantyl methyl ester 49. 
In 2007, Ley et al. reported the total synthesis of azadirachtin
37
 using a variation of 
the Barton-McCombie reaction
38
 as one of their key steps (Scheme 12). This radical 
cyclisation allowed the generation of the tetrasubstitued alkene 51 which upon 
selective epoxidation provided their target compound. The cyclisation also only 
yielded the desired endo-alkene which the authors suggest was as a result of the 
steric inaccessibility of the tertiary radical formed from an alternative exo attack. 
Hence radical trapping with Bu3SnH had only been possible from the methyl radical 
formed from the endo attack. 
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Scheme 12. Towards the synthesis of azadirachtin. 
Johnston et al. reported the synthesis of two non-natural proline derivatives: (S)- and 
(R)-7-azaindoline-aminoacetate 53, using radical cyclisation of (S)- and (R)-2-
(benzhydrylidene-amino)-3-(2-bromopyridin-3-yl)-propionic acid tert-butyl ester 
52.
39
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Scheme 13. Synthesis of non-natural proline derivatives 53. 
Chen et al. were also able to show the synthetic utility of organotin chemistry in their 
synthesis of 7-deoxytaxol where xanthate 54 was chemoselectively reduced to give 
the 7-deoxy analogue 55 in an excellent yield (Scheme 14).
40
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Scheme 14. Towards the synthesis of 7-deoxytaxol. 
The use of organotin compounds is still widespread in free-radical chemistry; 
however there are several problems associated with these compounds. Organotin 
compounds are toxic (which creates a disposal problem), the formation of tin 
residues often makes workup and product isolation difficult and the experimental 
procedure often requires slow addition of the tri-n-butyltin hydride over several 
hours in order to keep its concentration low. However as these reactions are 
important in organic synthesis, a number of methods have been developed to 
ameliorate these limitations. These include: development of various workup 
procedures for reactions involving stoichiometric R3SnH,
41
 use of catalytic amounts 
of a tin hydride or its precursor and stoichiometric amounts of another hydride (for 
example NaBH4,
42
 or NaCNBH3
43
), use of modified stannanes including fluorous 
stannanes,
44,45
 and use of solid-supported stannanes.
29
 Also, the use of alternatives to 
stannanes, especially silanes, dialkyl phosphites and hypophosphorous acid has 
received a great deal of attention.
45
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1.3.3.2   Non-tin reagents 
1.3.3.2.1 Organophosphorus reagents 
Phosphorus reagents show considerable promise as a substitute for traditional tin 
hydrides. Their attraction arises from their relatively low cost, reduced toxicity and 
ease of removal.
29
 One of the most commonly employed phosphorus reagent is the 
salt 1-ethylpiperidinium hypophosphite (EPHP) 57, which was first applied to radical 
C-C bond forming reactions by Graham et al.
46
 They were able to show that EPHP 
could be used in radical cyclisations onto various alkene side-chain units of both aryl 
iodide and alkyl bromide substrates such as 56 to generate the cyclised product 58 in 
a 64% yield (Scheme 15).   
I
O
EPHP 57
Benzene, Reflux
O
64%
56
58
N
CH3
P
H
HO OH
57  
Scheme 15. Use of EPHP in radical cyclisation. 
Using 1-ethylpiperidinium hypophosphite (EPHP) 57 as a radical reducing agent, 
Torii et al. have reported deoxygenation of nucleosides in the their synthesis of 2,3-
dideoxyinosine.
47
 Deoxygenation of bisxanthate 59 to alkene 60 was readily 
achieved in an excellent yield.  In contrast to the case of tin reduction, the isolation 
and purification of alkene 60 was efficient because there was no metal contamination 
(Scheme 16). 
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Scheme 16. Towards the synthesis of 2,3-dideoxyinosine. 
An attractive feature of phosphorus based reagents is their water solubility. However, 
whilst the radical-chain carrier, EPHP hypophosphite, is water-soluble, many organic 
compounds are not and, as a result if the reaction is to be carried out in aqueous 
media, it is often crucial that a surfactant or phase-transfer reagent is added.
29
 Jang et 
al.
48
 were able to combine this water solubility feature of EPHP with the 
enantioselective synthesis in their chemistry (Scheme 17). In this reaction, 
hypophosphite salt 63 acts as the radical-chain carrier, surfactant and chiral additive, 
capable of inducing high enantioselectivity (up to 98% ee). The optimum reaction 
medium comprised a mixture of dichloromethane and water, with pure water or pure 
dichloromethane resulting in greatly reduced yield. 
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Scheme 17. Use of hypophosphite salt in aqueous medium. 
The use of EPHP radical chain carrier in intermolecular carbon-carbon bond 
formation was reported by Jang et al.
49
 Using 1-adamantyl iodide 64 as a model 
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compound, the authors were able to carry out intermolecular addition to various 
alkenes 65 under mild reaction condition with great success (Scheme 18).  
I
+
R
EPHP, Et3B
dioxane, O2, rt
R = SO2Ph P(O)(OEt)2 C(O)OCH3
, ,
66, 80-94%64
65
R
 
Scheme 18. EPHP in intermolecular reactions. 
The use of phosphorus-based radical reagents should continue to gain wider 
acceptance as the reagents are cheaper, less toxic and more readily removed than 
their tin counterparts. Their use in aqueous reaction media also makes them even 
more attractive especially as environmental considerations become more important.  
1.3.3.2.2 Organosilane reagents 
Organosilanes have been a popular alternative to tin hydrides for nearly twenty 
years.
50
 Compared to tin hydrides, organosilanes are less effective hydrogen-atom 
donors and this makes them ideal reagents for reactions that are plagued by 
premature reduction.
51
 Hitchcock et al. reported the synthesis of (–)-zearalenone, a 
14-membered ring macrocycle,
52
 utilising tris(trimethylsilyl)silane as the radical 
donor. When bromide 67 was treated with tris(trimethylsilyl)silane and AIBN under 
high dilution in toluene at 85 °C, it underwent a clean 14-endo-trig cyclisation to (S)-
(+)-zearalenone dimethyl ether 68, which was produced as a white crystalline solid in 
55% yield. 
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67 68  
Scheme 19. Synthesis of (–)-zearalenone 68. 
1.3.3.2.3 Germanium hydrides 
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Triorganogermanes are also potential replacements for organotin reagents. They are 
perceived to be less harmful than tin hydrides, although full toxicology studies have 
yet to be performed. The two most common germanium hydrides used are 
tributylgermanium hydride and tri-(2-furyl) germanium hydride.
29
 
Tributylgermanium hydride is readily prepared in one step from germanium (IV) 
chloride and is also commercially available. One advantage of tributylgermanium 
hydride over its organotin equivalent can be seen in the cyclisation of amide 69 to 
lactam 70 as when organotin is used there is premature reduction to produce 
compound 71 (Scheme 20).
29
 Further uses of germanium hydrides that have been 
reported include the reduction of bromides
53
 and aromatic azides to amines.
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Scheme 20. Germanium hydrides in radical cyclisation. 
In conclusion, there is considerable utilisation of free radical chemistry in modern 
organic synthesis. For free radical reactions to be truly useful in organic synthesis it 
must be chemo-, regio-, diastereo-, and/or enantio selective. By due consideration of 
reagents, solvents, etc., it is quite possible, in most synthetic routes, to devise a 
radical process that is capable of effecting a highly selective transformation.  
1.4 1,3-Dipolar cycloaddition with nitrones 
The 1,3-dipolar cycloaddition reaction, also known as the Huisgen cycloaddition or 
Huisgen reaction, is an extremely powerful, yet mild, means of producing carbon-
carbon bonds as well as carbon-oxygen and carbon-nitrogen bonds.
55-58
 The ring 
constructive power of this reaction is now well appreciated and has been employed 
by numerous groups in the total synthesis of alkaloids and other nitrogen-containing 
natural products.
59
 The reactants of these cycloadditions are a 1,3-dipole and a 
dipolarophile, often a substituted alkene (Scheme 21). 
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Scheme 21. Cycloaddition between a 1,3-dipole and a dipolarophile. 
1.4.1 Selectivity in the 1,3-dipolar cycloaddition of nitrones with alkenes 
The 1,3-dipolar cycloaddition reaction of nitrones with alkenes gives isoxazolidines. 
In this reaction, three contiguous chiral centres can be formed as shown in the 
reaction between nitrone 72 and 1,2-disubstituted alkene 73 (Scheme 22).
56
 The 
relative stereochemistry at C-4 and C-5 is always controlled by the geometric 
relationship of the substituents on the alkene. 
N
O
N
O
+ 4
5
72 73 74  
Scheme 22. Formation of chiral isoxazolidines. 
The 1,3-dipolar cycloaddition of nitrones with substituted alkenes shows varying 
degrees of regio- and stereo-selectivity depending on the electronic and steric effects 
of the substituents. With normal and electron-rich monosubstituted alkenes, the 
cycloadditions result in the regiospecific formation of 5C-isoxazolidines. However, 
with electron-deficient alkenes, usually a regioisomeric mixture of adducts are 
obtained, and in some cases complete reversal in the regioselectivity is observed 
leading to the isolation of 4C-isoxazolidines as the sole products.
60
 The nitrone can 
also approach the alkene in an endo or exo attack resulting in two possible 
diastereoisomers (Scheme 23). 
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Scheme 23. Formation of 5C- and 4C- regioisomers. 
While the frontier molecular orbital treatment is remarkably successful in explaining 
the regioselectivity and reactivity phenomena,
61
 the secondary orbital interactions 
and steric factors usually dictate the stereochemical outcome of these 
cycloadditions.
55,56
  
1.4.1.1  1,3-Dipolar cycloaddition with electron deficient alkenes 
Before FMO theory, the regioselectivity of 1,3-dipolar cycloadditions had perplexed 
many workers in the field. This was because the regioselectivity for nitrone 
cycloadditions onto monosubstituted ethylenes was originally believed to proceed in 
a unidirectional fashion, giving 5-substituted adducts regardless of the alkene 
substituent.
62
 However, using  the frontier orbital method to rationalize the effect of 
substituents on rates and regioselectivity of 1,3-dipolar cycloadditions, Houk et al. 
predicted and proved that a unidirectional addition to both electron-rich and electron-
deficient monosubstituted dipolarophiles would no longer be observed when the 
dipolarophile is made highly electron deficient.
63
 His work showed that when mono-
substituted electron-deficient dipolarophiles such as phenyl vinyl sulfone, 
nitroethylene and cyanoacetylene, reversal to give the 4C-substituted cycloadduct 76 
as the major product occurred (Scheme 24). 
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Scheme 24. 1,3-dipolar cycloaddition with electron deficient dipolarophiles. 
They also showed that on increasing the steric bulk around the nitrone nitrogen, it 
was possible to switch the regiospecificity to the 5C cycloadduct 77 irrespective of 
the electron deficient character of the dipolarophile (Scheme 25). 
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Scheme 25. 1,3-dipolar cycloaddition with bulky substituents on nitrone. 
Padwa et al. also found that electron deficient nitroethylene reacts readily with N-
methyl nitrone to give a mixture of cis and trans 4C-substituted isoxazolines.
55
  
1.4.2  Nitrone 1,3-Dipolar cycloaddition in synthesis 
As previously noted, the 1,3-dipolar cycloaddition of a nitrone with an olefin is an 
extremely powerful, yet mild, means of producing carbon-carbon bonds as well as 
carbon-oxygen and carbon-nitrogen bonds.
56
 The powerful nature of this reaction is 
now well appreciated and numerous natural and unnatural products have been 
prepared by synthetic routes that have a 1,3-dipolar cycloaddition as a crucial step in 
their synthesis. Additionally, the potential for control of the contiguous stereocentres 
in these heterocycles affords additional synthetic opportunities.  Consequently, this 
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reaction has become recognized as an extremely important transformation in the 
repertoire of the synthetic organic chemist. 
1,3-Dipolar cycloaddition have been used for the synthesis of nucleosides, and potent 
antibiotic and antiviral agents.
64
  An example of this is provided by Chiacchio et al. 
in their synthesis of isoxazolidinylthymines 80.
65
 Here, a variety of C-functionalised 
chiral nitrones were used to enforce enantioselection in their cycloaddition with vinyl 
acetate. It was observed that asymmetric induction was modest when using dipoles 
whose chiral auxiliary does not maintain a fixed geometry and so cannot completely 
direct the addition to the nitrone. After poor results with menthol ester and methyl 
lactate-based nitrones, they were able to prepare and separate isoxazolidine 79a and 
its diastereomer 79b using the N-glycosyl nitrone 78, derived from D-ribofuranose. 
Adduct 79a was coupled with thymine before removal of the sugar auxiliary to 
afford N,O-nucleoside 80.  
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Scheme 26. Synthesis of isoxazolidinylthymines 80. 
More recently, Bortolini et al. have reported a more environmentally acceptable 
approach to the synthesis of a variety of non-easily-available 4’-aza-2’,3’-dideoxy 
nucleosides 83. Using a direct 1,3-dipolar cycloaddition between nitrones 82 and 
vinyl nucleobases 81, the reaction was assisted by microwave irradiation, in the 
absence of solvent.
66
 The cycloaddition reaction proceeded smoothly and it was 
possible to synthesize nucleosides 83 in good yields and short reaction times (10-50 
mins). It was also possible to use the vinyl nucleobases in the reaction in their 
unprotected form. 
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Scheme 27. Synthesis of 4’-aza-2’,3’-dideoxy nucleosides 83. 
In conclusion, these examples illustrate the utility of nitrones in current organic 
synthesis, thus demonstrating that 1,3-dipolar cycloaddition is an important 
methodology for the construction of interesting biologically active molecules. 
1.5 Chemistry of pentafluorophenyl/trichlorophenyl vinyl 
sulfonate 
As discussed earlier, the sulfonamide unit is very important in medicinal chemistry.  
Because of this vast potential and the relative challenges associated with their 
preparation, new strategies to functionalized sulfonamides are continually being 
sought. This has led to the discovery and introduction of  pentafluorophenyl 
sulfonate ester as a stable alternative to sulfonyl chlorides by Caddick et al.
67
 Much 
of the work of Caddick has focused on the chemistry of sulfonate ester 85 – a 
bifunctional acceptor, which was easily prepared from commercially available 
pentafluorophenol and 2-chloroethane-1-sulfonyl chloride
68
 that would be 
susceptible to attack from both radical and nucleophilic species. In addition, owing to 
the electron withdrawing nature of the PFP group, the sulfur centre would be 
susceptible to nucleophilic attack especially by amines, to make sulfonamides. To 
date, it has been found that the PFP sulfonate ester group is stable to a variety of 
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conditions including column chromatography, acidic and basic workup procedures 
and aqueous conditions. 
PFPO
S
O O
85  
Figure 7. Structure of pentafluorophenyl vinyl sulfonate 85.   
1.5.1 Radical chemistry 
Caddick et al. have reported intermolecular tin-mediated radical addition of alkyl 
halides to PFP vinyl sulfonate mediated by tributyl hydride.
67
 Reactions of 85 with 
alkyl radicals gave alkyl sulfonates 86 in good to excellent yields (Scheme 28). 
Caddick et al. also found that the reaction was not limited to simple alkyl or 
stabilized radical species but could be used in the synthesis of a derivatized sugar 
(for example 86d) or amino species. 
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Scheme 28. Intermolecular radical addition with PFP vinyl sulfonate. 
The alkyl sulfonate ester 86d was treated with amines to displace the 
pentafluorophenol group which furnished the sulfonamides 87 in a good yield 
(Scheme 29). 
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Scheme 29. Aminolysis of sulfonate ester 86d. 
It was found that the aminolysis reaction proceeded when a strong base such as DBU 
or sodium hydride was present in the reaction medium. Because of this observation, 
they postulated that the reaction mechanism went via the deprotonation to the 
sulfonate moiety, followed by rapid extrusion of pentafluorophenol.
67
  
Caddick et al. have also reported regioselective and diastereoselective 1,3-dipolar 
cycloaddition of PFP vinyl sulfonate ester 85 with a range of N-methyl nitrones to 
generate the a range of isoxazolidines 89.
68
 Cycloadditions to give isoxazolidines 89 
were readily achieved upon reaction of vinyl sulfonate 85 with 1-2.5 eq. of nitrones 
88 in toluene at 110 C (Scheme 30). Cycloadditions were successful with a variety 
of C-aryl, 89a-c, C-heteroaryl, 89d, and C-alkyl nitrones, 89e, with the highest yields 
obtained with electron rich nitrones, for example 89b and 89d. In all cases, with the 
exception of 89a, cycloaddition of nitrones 88 with vinyl sulfonates 89 afforded only 
the corresponding C-4 trans isoxazolidines 89 with no evidence for the C-5 
substituted isomers 90. 
 
27 
 
R
PhMe
110  C N
O
R
S
88a-e
N
O
R
85
89
O N
S
90
PFPO
S
O O PFPO
O O
PFPO
O O
°
 
89a, 67% 89b, 70%
MeO
89c, 47% 89d, 75% 89e, 54%
R =
O
F
 
Scheme 30. 1,3-dipolar cycloaddition reaction with PFP vinyl sulfonate 85. 
Caddick et al. have exemplified the utility of the isoxazolidine sulfonate 89 in the 
synthesis of β-sultams 91, sulfur analogues of β-lactams, via selective ring cleavage 
of the N-O bond.
69
 Reduction of the isoxazolidine N-O bond of 89 with Mo(CO)6 
afforded intermediate amine sulfonates which upon cyclisation gave β-sultams 91 in 
moderate yields (Scheme 31). 
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Scheme 31. Synthesis of β-sultams 91. 
Despite the synthetic advantages of the PFP esters, there has been a degree of 
resistance to their use on anything other than a small scale due to cost and perceived 
toxicity. This led to the introduction of 2,4,6-trichlorophenol (TCP) sulfonate
70
 92 as 
an ideal replacement due to its known lower toxicity and its low cost. TCP sulfonate 
92 was synthesised from its corresponding sulfonic acid salt and triphenylphosphine 
ditriflate (see Scheme 1.1.6.2). The reactivity of TCP sulfonate 92 with amines was 
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then investigated (Scheme 32).
71
 The aminolysis reaction of sulfonates 92 with 
amines 93 was readily achieved generating sulfonamide 94 in good to excellent 
yield. The reaction was tolerant to both simple nucleophilic amines and more 
challenging examples, such as anilines and hindered amines. 
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Scheme 32. Aminolysis of TCP sulfonates 92. 
In conclusion, Caddick et al. have shown from their comprehensive work that PFP 
(and more recently TCP) sulfonate esters, whether alkyl or aryl, are excellent 
alternatives to sulfonyl chlorides as many reactions can be carried out with the 
sulfonate present and thus provide a new route towards the synthesis of highly 
desirable sulfonamides. 
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Chapter 2 R&D: Studies on the intermolecular 
radical addition reactions of TCP vinyl sulfonate 
2.1 Aim 
The aim of this work was to explore the scope of intermolecular radical reactions of 
trichlorophenyl (TCP) vinyl sulfonate 95 (Figure 8). It had previously been found 
that pentafluorophenyl vinyl sulfonate can undergo radical addition mediated by 
tributyltin hydride (Section 1.4), and the present investigation is an extension of this 
work to trichlorophenyl vinyl sulfonates particularly their reactions with alkyl and 
acyl radicals. 
O
S
O O
ClCl
Cl
95  
Figure 8. Structure of TCP vinyl sulfonate 95. 
2.2 Intermolecular radical addition using alkyl radicals 
Intermolecular radical reactions provide an attractive means of carbon–carbon bond 
formation due to their mild conditions and functional group tolerance. The most 
common and reliable way of generating alkyl radical involves reaction of halide or 
related precursor with tributyltin hydride and this had proven to be successful with 
PFP-vinyl sulfonate precursor. However, it was of interest to explore the use of tin-
free radical reaction chemistry for this type of transformation. The use of 
phosphorous-centred radicals was an area of interest because of the relatively low 
cost. Low toxicity and commercial availability of 1-ethylpiperidinium hypophosphite 
(EPHP) 57, led it to be chosen as a suitable radical chain carrier.  
2.2.1 Synthesis of trichlorophenyl (TCP) vinyl sulfonate 
Trichlorophenol (TCP) vinyl sulfonate was synthesized by the treatment of 
commercially available 2-chloroethane 1-sulfonyl chloride 97 with a suspension of 
trichlorophenol 96 and triethylamine (Scheme 33). This reaction is temperature 
sensitive as the starting materials decompose rapidly above 0 °C. As the addition of 
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the suspension of trichlorophenol and triethylamine is exothermic, it was added 
dropwise ensuring that the temperature remained below 0 °C. It was however found 
that maintaining the internal temperature at –50 °C and reduction of the equivalents 
of amine used from 3 to 2.3 lowered the amount of decomposition and the yield of 
the vinyl sulfonate 95 increased to 90% (Table 1, entry 3).  
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Scheme 33. Synthesis of TCP vinyl sulfonate 95. 
Table 1. Optimisation results for the synthesis of TCP vinyl sulfonate 95. 
Entry No NEt3 (eq) Temperature (°C) Yield (%) 
1 3 0 44 
2 3 –50 66 
3 2.3 –50 90 
 
2.2.2 Alkyl radical addition to TCP vinyl sulfonate 
With TCP vinyl sulfonate 95 synthesised, radical additions were carried out. These 
reactions were mediated by EPHP 57, as Caddick et al. had been successful 
mediating reactions with PFP acrylate with this chain carrier.
72
 Their work also 
showed that alkyl bromides gave poor yields in these reactions and alkyl iodides 
were better substrates. Using their protocol (10 eq of EPHP, Et3B/O2, CH2Cl2) as a 
bench mark, a set of small scale reaction was carried out to find the optimum 
reaction conditions for vinyl sulfonate 95 to generate alkyl sulfonate 98. 
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Scheme 34. Optimisation reaction of radical addition to TCP vinyl sulfonate 95. 
Table 2. Optimisation reaction results for Scheme 34. 
Entry 
No  
RI 
EPHP 57 
(eq) 
Solvent Initiator Temp. 
(°C) 
Yield   
(%) 
1 i-Pr-I 5 1,4-dioxane Air RT <5 
2 i-Pr-I 5 1,4-dioxane Air/Et3B RT 47 
3 i-Pr-I 5 CH2Cl2 Air/Et3B RT 43 
4 i-Pr-I 5 1,4-dioxane Air/Et3B 0  58 
5 i-Pr-I 5 CH2Cl2 Air/Et3B 0  62 
6 t-Bu-I 5 CH2Cl2 Air/Et3B 0  59 
7 t-Bu-I 3 CH2Cl2 Air/Et3B 0  50 
8 t-Bu-I 7.5 CH2Cl2 Air/Et3B 0  64 
9 t-Bu-I 10 CH2Cl2 Air/Et3B 0  63 
 
Optimisation of the reaction conditions for the radical addition of secondary and 
tertiary radicals to TCP vinyl sulfonate indicated that higher concentrations of chain 
carrier gave higher yields although the maximum yield was achieved at 7.5 eq of 
EPHP 57 (Table 2, entry 8) and increasing the concentration any further did not 
improve the yield. In addition, air alone did not initiate the free radical chain 
effectively (Table 2, entry 1) however the reaction with triethylborane/air mixture at 
low temperature was found to proceed smoothly. This was best achieved by passing 
a volume of air through the reaction solution under a static inert atmosphere. The 
temperature of the reaction was also critical as there was an improvement in the yield 
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on lowering the temperature of the reaction (Table 2, entries 3 and 5). The reactions 
were also particularly facile requiring a reaction time of just 5 mins and the major 
side products, hypophosphite derived, could be removed with an aqueous work-up. 
Having established the optimum conditions (7.5 eq, Et3B/air, 0 °C, CH2Cl2) to 
addition to vinyl sulfonate 95, a variety of alkyl iodides incorporating different 
functional groups were used (Figure 9). 
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Scheme 35. Intermolecular radical addition to TCP vinyl sulfonate 95 using EPHP. 
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Figure 9. Results of Scheme 35. 
The yields of the alkyl sulfonate 98 were generally moderate to good, although lower 
yields were observed with the primary alkyl halides. The low yield could be 
attributed to significant amounts of iodide reduction products which were observed 
in the crude NMR spectrum. Together with the iodide reduction, one of the other 
possible side reactions that can become more dominant is the addition of the ethyl 
radical generated from triethylborane to vinyl sulfonate 95. This ethyl radical is very 
reactive and would add much more readily and this effect is seen quite dramatically 
in the yields low of products 98f and 98h.  Here significant amounts of the iodide 
reduction and ethyl radical addition were obtained even at low temperatures giving 
products 99 and 100 respectively (Figure 10). 
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Figure 10: Isolated side products 
2.2.3 Intermolecular radical addition using tributyltin hydride 
Although the use of EPHP as a chain carrier was successful, problems with the 
efficiency of the reaction particularly with primary iodides as mentioned above 
limited the scope of the methodology. In order to expand the generality of the 
reaction, Bu3SnH was used as the radical chain carrier using the procedure from 
Caddick et al.
72
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Scheme 36. Intermolecular radical addition to TCP vinyl sulfonate 95 using Bu3SnH.  
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Figure 11. Results from Scheme 95. 
Using the chain carrier, Bu3Sn
•
, formed by reaction with AIBN in refluxing toluene 
produced the corresponding alkyl sulfonate esters in moderate to good yields. The tin 
residue was removed by stirring the reaction mixture with potassium fluoride for 18 
hours and then filtering the insoluble tin fluoride through Celite
®
. The effectiveness 
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of this intermolecular radical addition is exemplified in the addition of the primary 
halides particularly in producing 98f and 98h, which were previously unsuccessful 
with EPHP 57 as the chain carrier but was successful in the presence of Bu3SnH. 
However, as before significant amounts of halide reduction and HI elimination 
products were isolated. 
Encouraged by these results, the scope of this reaction was expanded further by 
preparing a bifunctional alkyl TCP/ PFP sulfonate via a double radical addition 
protocol (Scheme 37). It was envisaged that the product of this double addition could 
be used to explore the reactivity of PFP and TCP in a two-directional synthesis. 
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102a: n = 1
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Scheme 37. Double intermolecular radical addition 
An initial trial of the halide exchange at room temperature over 24 hours gave a 
mixture of the iodo-product 102 and the unreacted chloro-starting material 101. 
Increasing the temperature to 50 °C improved the conversion ratio and the iodide 102 
thus obtained was used in the following step without purification. Radical addition to 
PFP vinyl sulfonate using iodides 102a and 102b gave the desired bifunctional 
TCP/PFP sulfonates 103a and 103b in moderate yields.  
2.3 Intermolecular acyl radical addition to vinyl 
sulfonates 
The generation of acyl radicals and their reactions with alkenes has long been 
recognised as a useful and practical method of generating carbon-carbon bonds.
73,74
 
Acyl radicals were first reported by Kharasch et al.
75
 in 1949 where the peroxide-
initiated free radical of aldehydes were added to simple olefins. The method was then 
extended to the more productive use of electron-deficient alkenes.
76
 Since then 
additional free radical chain initiation methods have been introduced, and examples 
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of intramolecular and intermolecular acyl radical-alkene addition reactions have been 
described.
74
  
One of such examples includes the hydroacylation reaction reported by Caddick et 
al. In their report, keto-sulfonates 105 were generated by mixing the vinyl sulfonates 
85 or 95 with aldehydes 104 in ethereal solvents such as dioxane and ethylene glycol 
dimethyl ether, at room temperature.
77
 The authors found that the transformation 
proceeds with a variety of aliphatic aldehydes. They found however that the isolated 
yields for reactions with the PFP-derived olefin 85 are generally lower than those 
with the corresponding TCP-derivative although the reactions were universally faster 
with the PFP substrate. The lower yields were attributed to the reduced stability of 
PFP groups to purification by flash chromatography on silica gel.  
R1
O
H 1,4-dioxane
  air, 21  C
SO3R
SO3R
O
R1
104 105
°
 
Scheme 38. Synthesis of keto-sulfonate 105. 
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Figure 12. Results from Scheme 38. 
The authors also attempted the hydroacylation reaction with aromatic aldehydes but 
they were unsuccessful.
78
 Other ways of generating acyl radicals were then 
investigated. Of the three possible ways of generating acyl radicals,
79
 generation 
from homolytic rupture of a RC(O)-X is still the most widely applied particularly in 
the generation of these radicals by reaction of the corresponding selenoesters with tin 
hydride.  
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2.3.1 Synthesis of selenoesters 
To synthesise the selenoester required, the procedure reported by Braga et al.
80
 
employing indium was used. This procedure utilised mild conditions (reflux in 
CH2Cl2 for 18 hours) and the selenoester 108 was synthesised in an excellent yield 
(Scheme 39).  
R1 Cl
O
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Ph
Se
Se
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R1 SePh
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In0
106a-c 107 108a-c  
SePh
O
MeO
SePh
O
Cl
SePh
O
O2N
108a, 85% 108b, 80% 108c, 65%  
Scheme 39. Synthesis of selenoester 108. 
2.3.2 Acyl radical addition to TCP vinyl sulfonate 
With the selenoesters 108a-c in hand, the reaction with vinyl sulfonate 95 and 
selenoester 108a was investigated using tributyltin hydride initiated by AIBN as used 
in synthesis by Boger et al. (Scheme 40).
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Scheme 40. Acyl radical addition to TCP vinyl sulfonate 95. 
Selenoester 108a was added to vinyl sulfonate 95 and heated to reflux for 2 hours. 
TLC analysis of the reaction indicated formation of a new product spot during the 
reaction, and analysis of NMR spectrum of the crude reaction mixture showed 
formation of expected product 109 along with unreacted starting materials 95 and 
108a. However, analysis of NMR spectrum of the isolated product after column 
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chromatography did not correspond to the expected product 109. Instead, some of the 
NMR peaks corresponded to enone 110. Several attempts using the same conditions 
gave similar results. Presumably the formation of enone 110 is encouraged by both 
the elevated reaction temperature (110 °C) and the purification on silica gel. 
Although some of the enone 110 was isolated, it was quite unstable and rapidly 
decomposed so it was not fully characterised. To confirm that the enone 110 was 
been formed a trapping reaction was carried out using a thiol. It was envisaged that 
upon formation of enone 110, the thiol would add in a Michael addition to generate 
the thiol 111. The radical addition reaction using selenoester 108a was carried out 
with vinyl sulfonate 95 mediated with tributyltin hydride and heated to reflux for 2 
hours (Scheme 41). DBU and thiol were added to the reaction mixture after two 
hours and the reaction monitored by TLC. TLC analysis showed formation of a new 
spot after 30 minutes.   
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PhMe, 110   C
O
OMe
110
°
+
95
TCPO
S
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Scheme 41. Trapping reaction using a thiol. 
Despite several attempts at this reaction using same conditions, efforts towards 
isolating any product 111 proved futile. 
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2.4 Summary 
This study has established TCP vinyl sulfonate has a good substrate for free radical 
addition reactions. The alkyl radical addition reactions were successfully carried out 
using tin-free protocol, using EPHP 57 initiated by Et3B/air and tin protocol,  
Bu3SnH initiated by AIBN to generate alkyl radicals. Although the EPHP 57 
protocol was successful, it was greatly limited by its efficiency particularly with 
primary alkyl radicals. Notably, the success of the double intermolecular radical 
addition to prepare bifunctional TCP/PFP sulfonates could be applied in our 
continued investigation in the reactivity of the vinyl sulfonates. 
The acyl radical addition reaction was not as successful as its alkyl counterpart in 
generating the corresponding acyl sulfonates. We suggest this was due to the 
formation of an enol after the addition and subsequent elimination to generate the 
enone. An attempt at trapping the reactive enone with thiols proved unsuccessful.  
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Chapter 3 R&D: Studies on the 1,3-dipolar 
cycloaddition reactions of PFP/TCP vinyl 
sulfonate 
3.1 Aim 
Previous work within the group has shown PFP vinyl sulfonate to be a good 
dipolarophile.
68,72
 The aim of this project is to continue this research and explore the 
reactivity of the vinyl sulfonates in 1,3-dipolar cycloaddition particularly with TCP 
vinyl sulfonate. 
3.2 Synthesis of Nitrones 
Nitrones are readily available compounds that can be obtained from aldehydes, 
amines, imines and oximes, and are well known to behave as 1,3-dipoles in 
cycloaddition reactions to form a variety of stable five membered heterocyclic ring 
systems.
56,57
 Nitrones (or azomethine oxides) are one of the most widely studied 
dipoles
57
 and were prepared in excellent yield via the condensation of aldehyde 112 
with an N-substituted hydroxylamine 113 (Scheme 42).
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Scheme 42. Synthesis of N-methyl nitrone 114. 
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Table 3. Results obtained from Scheme 42. 
Product No R-group Yield (%) 
114a Ph 70 
114b p-MeO.C6H4 67 
114c p-NO2 C6H4 50 
114d C10H7 80 
114e Furyl 65 
114f Cyclopropyl 80 
 
In addition to using N-methyl nitrone 114, our studies also utilised N-PMB nitrone 
118 (see Scheme 43), whereby the PMB protecting group can be removed to allow 
for further manipulations of the product. The PMB-hydroxylamine 117 was 
synthesised by reacting anisaldehyde 115 with hydroxylamine.HCl and then reducing 
the resulting oxime 116 with NaBH3CN.
81
 With hydroxylamine 117 in hand, N-PMB 
nitrones 118a-e were synthesised using a variety of aldehydes incorporating electron-
withdrawing and electron-donating properties. The reaction proceeded very smoothly 
usually not requiring purification although recrystallising the crude product gave 
easy to handle material. 
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Scheme 43. Synthesis of N-PMB nitrone 118. 
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Table 4. Results from obtained Scheme 43. 
Product No R-group Yield (%) 
118a p-MeO.C6H4 75 
118b o-Cl. C7H4 65 
118c Ph 72 
118d Cyclohexyl 60 
118e C10H7 92 
 
3.3 1,3-Dipolar cycloaddition of vinyl sulfonate with nitrone 
The success of the cycloaddition of PFP vinyl sulfonate 85 with N-Me nitrones to 
yield regio- and diastereo- selective isoxazolines,
68
 encouraged the extension of the 
chemistry to TCP vinyl sulfonate as this would give a more cost effective and less 
toxic route to the isoxazoline intermediates. We were particularly interested in the 
reactivity of N-PMB nitrones in the cycloaddition reaction. Using N-PMB nitrone 
118a, optimisation reaction was carried out using vinyl sulfonate 85 (Scheme 44).  
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Scheme 44. Optimisation of cycloaddition to PFP vinyl sulfonate 85. 
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Table 5. Optimisation reaction results of Scheme 44. 
Entry No Nitrone (eq) Time (hrs) Temp (°C) Yield (%) 
1 2 18  23 38 
2 2 3 23 58 
3 1 3 110 64 
 
Cycloaddition with 2 equivalents of nitrone 118a at 23 °C for 18 hours gave 
isoxazolidine 119a in a poor yield of 38%. This yield was improved to 58% by 
shortening the reaction time to 3 hours. However, the highest yield was obtained 
when the reaction was carried out using 1 equivalent of nitrone 118a at reflux for 3 
hours (Table 5, entry 3). Using the optimal conditions (reflux for 3 hours using 1 
equivalent of nitrone) a small collection of N-PMB isoxazolidines were synthesised. 
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Scheme 45. Synthesis of N-PMB isoxazolidines 119 and 120.  
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Figure 13. Results from Scheme 45. 
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The reaction with TCP vinyl sulfonate 95 was slower and gave a lower yield than 
PFP vinyl sulfonate 85 (Figure 14, 119b and 120b). The electronics of the R-group 
on the nitrone seemed to have an effect on the yield of the reaction. With electron 
donating groups (Figure 14, 119a and 120a), the yield obtained was moderate, but a 
much lower yield was obtained with the electron withdrawing group (Figure 14, 
120c).  
The yields obtained using the N-PMB nitrone compared favourably with those 
obtained previously within the group using the simple N-Me nitrones.
81
 Comparing 
the NMR spectra obtained with the NMR spectra of isoxazolidines previously 
synthesised by Mok
81
 confirmed that the products obtained from the reactions with 
the N-PMB nitrones were in all cases the trans 4C-isoxazolidines. 
3.3.1 Cycloaddition with β-phenyl PFP vinyl sulfonate 
Cycloaddition with β-phenyl vinyl sulfonate was next investigated as a means of 
exploring the reactivity scope of the vinyl sulfonates. Formation of β-phenyl 
vinylsulfonates 122 and 123 was achieved by reacting commercially available 
sulfonyl chloride 121 with the corresponding alcohol at –78 °C (Scheme 46).  
Cl
S
O O R-OH, NEt3, DCM
    -78   C
Ph RO
S
O O
Ph
122: R = PFP, 81%
123: R = TCP, 86%
121
°
 
Scheme 46. Synthesis of β-phenyl vinyl sulfonates 122 and 123. 
Having the phenyl group in the β position changes the sterics and the electronics of 
the vinyl sulfonate; however, it was envisaged that if the cycloaddition occurred, it 
would probably require elevated temperatures. An initial study towards reaction 
optimisation involved examination of the effect of temperature and nitrone 
concentration on the reaction of vinyl sulfonate 122 with nitrone 114b in toluene 
(Scheme 48). 
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Scheme 47. Optimised reaction with β-Ph vinyl sulfonate 122. 
Table 6. Results of optimised reaction obtained from Scheme 47. 
Entry 
Temp 
(°C) 
Nitrone   
(eq) 
Time    
(hrs) 
Yield      
(%) 
114 recovered 
(%) 
1 50  2 18 5 34 
2 110  2 4 61 23 
3 110  2 18 35 28 
4 110  1.5 4 53 25 
5 110 5 4 57 7* 
* 20% aldehyde recovered 
It was pleasing to observe cycloaddition to give isoxazolidine 124a was readily 
achieved upon reaction of vinyl sulfonate 122 with nitrone 114a in toluene. In all 
cases analysis of the NMR spectrum confirmed only the 4C isomer was formed. Also 
only one distereoisomer was obtained although the relative stereochemistry was 
unknown at this stage. From the results obtained, the highest yield (61%) was 
obtained at reflux in toluene for 4 hours using 2 eq of nitrone 114 although this was 
just at 77% conversion to 124a as 23% vinyl sulfonate 122 was recovered.  
As the conversion from the starting material was not 100%, we envisaged that the 
reaction could be forced to completion by addition of an extra equivalent of nitrone 
during the reaction. However, when this reaction was carried out with the addition of 
extra nitrone one hour into the reaction, there was an improvement on the yield from 
61% to 70%, but the corresponding aldehyde, 20%, and the starting vinyl sulfonate 
122, 5%, were also isolated (Scheme 48).  
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Scheme 48. 1,3-Dipolar cycloaddition reaction of β-Ph vinyl sulfonate 122 using 
extra equivalent of nitrone 
Following the success of cycloaddition with nitrone 114b with PFP vinyl sulfonate 
122, other functionalized nitrones were employed in the cycloaddition reaction to 
investigate the scope of the reaction with both PFP and TCP vinyl sulfonates 122 and 
123 respectively. 
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Scheme 49. 1,3-Dipolar cycloaddition reaction of β-Ph vinyl sulfonate 122 and 123. 
Table 7. Results obtained from Scheme 49. 
Entry Product No R
1
 Yield (%) Recovered SM (%) 
1 124a p-MeO.C6H4 61 20 
2 124b Ph 61 18 
3 124c p-Br.C6H4 57 20 
4 124d Cyclopropane 0 25 
5 124e Cyclohexane 33 22 
6 124f p-NO2 .C6H4 12 25 
7 124g C10H7 65 21 
8 125a p-MeO.C6H4 44 20 
9 125b Ph 60 20 
10 125c p-Br.C6H4 25 27 
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The yields obtained for this reaction varied between 0% and 61%; however, in all 
cases these were not a 100% conversion of vinyl sulfonate 122 and 123. The 
variation in the yields obtained could be attributed to the stability of the nitrone 
(Table 7, entry 5 and 6) and its solubility (Table 7, entry 6). The yields of these 
reactions were improved by either reducing the temperature (Table 8, entry 1) or 
leaving the reaction for longer (Table 8, entry 2).  
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Scheme 50. 1,3-Dipolar cycloaddition reaction using β-Ph vinyl sulfonate 122. 
Table 8. Improved reaction results of Scheme 50. 
Entry R Conditions Yield (%) 
1 cyclopropane 80 °C, 18 hrs 22 
2 p-NO2.C6H4 110 °C, 48 hrs 27 
 
3.4 Cycloaddition studies with α-Br PFP/TCP vinyl 
sulfonates 
The investigation continued with an examination of the potential of this reaction to 
be applied to the synthesis of the analogous isoxazole. After some model studies by 
Mok,
81
 it was proposed that this reaction could be achieved by the use of α-bromo-
PFP-vinyl sulfonate 126, an established alkyne alternative within the group and a 
direct replacement for PFP vinyl sulfonate 85 in the cycloaddition reaction. Once the 
isoxazolidine 127 was formed, aminolysis could be carried out to form the 
sulfonamide 128. It was then envisaged that deprotection of the PMB group followed 
by oxidation would yield compound 129 and subsequent elimination on HBr would 
yield isoxazole 130 (Scheme 51).   
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Scheme 51. Proposed reaction pathway for the synthesis of isoxazole 130. 
Previous work within the group showed that the use of N-Me nitrone 114g
81
 under 
the previously described conditions for cycloaddition (1.5 eq. nitrone and 1 eq. of 
dipolarophile in refluxing toluene) gave no product after 20 hours with only 
recovered starting material. However, upon addition of base, a mixture of products 
131-133 were obtained (Scheme 52).
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Scheme 52. 1,3-Dipolar cycloaddition of α-Br vinyl sulfonate 126. 
It was postulated that the cycloaddition was in fact proceeding via a stepwise process 
bearing some similarity to the Baylis-Hillman reaction
82
 and this would account for 
the formation of product 131 (Scheme 53). 
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Scheme 53. Proposed reaction mechanism for the formation of isoxazolidine 131. 
Other tertiary bases were tested in this reaction and the analyses of the results 
showed that using 0.1 eq of DABCO at RT, it was possible to eliminate the de-
brominated product 132, reduce the amount of the 5C-product 133 and also increase 
the overall yield obtained.
81
 The mechanism for this reaction remained unclear and 
therefore further studies were needed to explore the reactivity of the α-Br vinyl 
sulfonate 126 and its reaction scope. 
3.4.1 Cycloaddition reaction of α-Br PFP/TCP vinyl sulfonate – 
optimisation with a range of nitrones  
The synthesis of brominated PFP vinyl sulfonate 126 and brominated TCP vinyl 
sulfonate 135 were achieved via a radical mediated process analogous to that 
described by Mok.
81
 The brominated vinyl sulfonates was readily afforded in two 
stages. The first stage was the radical addition of bromine to vinyl sulfonate 
mediated by AIBN in chloroform followed by addition of NEt3 to the residue from 
the first stage at RT leading to the elimination of HBr (Scheme 54). 
RO
S
O O
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O O
Br
1. Br2, AIBN, CHCl3
2. NEt3, DCM, RT
126: R = PFP, 70%
135: R = TCP, 65%
85: R = PFP
95: R = TCP  
Scheme 54. Synthesis of α-Br vinyl sulfonate 126 and 135. 
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With sulfonates 126 and 135 synthesised, optimisation studies for the cycloaddition 
were carried out using brominated vinyl sulfonate 135 with N-PMB nitrone 118a in 
toluene at reflux. Optimisation of the reaction showed that highest yield of 
isoxazolidine 136a was obtained when brominated vinyl sulfonate 135 was reacted 
with N-PMB nitrone at 110 °C for two hours (Table 9, entry 3). At a longer reaction 
time (Table 9, entry 4) the reaction only resulted in decomposed material. 
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Scheme 55 
Table 9. Results obtained from Scheme 55. 
Entry  Time (hrs) Temp. (°C) Yield (%) 
1 6 90  64 
2 18 90  60 
3 2 110  75 
4 18  110  decomposed 
 
Using the optimal conditions (2 eq of nitrone at 110 °C for 2 hours), the 
cycloaddition reaction was carried out using other nitrones incorporating both 
electron-donating and electron-withdrawing groups. 
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Scheme 56. 1,3-Dipolar cycloaddition reaction using N-Me nitrones 114. 
Table 10. Results obtained from Scheme 56. 
Entry Product No R
1
 Yield (%) 
1 136a Ph 78 
2 136b p-MeO.C6H4 70 
3 137a Ph 71 
4 137b p-MeO.C6H4 72 
5 137c p-Cl.C6H4 82 
6 137d p-Br.C6H4 76 
7 137e 2-Br-furyl 45 
8 137f furyl 36 
9 137g p-NO2.C6H4 46* 
* diastereoisomers 
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Scheme 57. 1,3-Dipolar cycloaddition using N-PMB nitrones 118. 
Table 11. Results obtained from Scheme 57. 
Entry Product No R
1
 Yield (%) 
1 138a Ph 81* 
2 138b p-MeO.C6H4 71 
3 138c p-Br.C6H4 65 
4 138d C10H7 54* 
5 138e p-Cl.C6H4 52 
6 139a Ph 65* 
7 139b p-MeO.C6H4 86 
8 139c p-Br.C6H4 37 
* diastereoisomers 
The cycloaddition reactions were successful in yielding the isoxazolidines in 
moderate to good yield. It was observed that the reactions with N-Me nitrones gave 
best yields at a reaction time of 30 minutes but the reaction times of the reactions 
with the N-PMB nitrones varied between 30 minutes and 2 hours. There was no 
obvious correlation between the yield and the nature of the nitrone and the alkene, as 
good yields were obtained both with electron-withdrawing and electron-donating 
groups (Table 10, product no 137b-d), although poor yields were also obtained for 
electron-withdrawing group (Table 10, product no 137e-g).  
Analysis of the NMR spectra confirmed that the substituted isoxazolidines produced 
were all 4C isomers i.e. the reaction was regio-specific, although the reaction was not 
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distereo- selective as mixtures of diastereoisomers were formed in some reactions 
(Table 10 and 11, product no 137g, 138a and 139a).  
3.4.2 Catalysis of cycloaddition reaction of α-Br PFP/TCP vinyl 
sulfonate 
As described earlier (section 3.4), previous work by Mok had shown the 
cycloaddition reaction with α-Br PFP vinyl sulfonate 126 and nitrone 114g gave an 
improved yield on the addition of 0.1 eq of DABCO although the reaction was non-
selective. From the results obtained in section 6.4.1, it was obvious that the 
cycloaddition reaction needed a shorter reaction time otherwise decomposition was 
observed. With this knowledge, the next stage was to investigate the 1,3-dipolar 
cycloaddition reaction of the brominated vinyl sulfonate with nitrone and its possible 
catalysis by bases. Using simple tertiary and secondary bases, the cycloaddition 
reaction was carried out with substrates 126 and 114b. The cycloaddition reactions 
were all successful and gave good yields. However there was not any clear 
distinction between the yields of the isoxazolidine and the bases used, although the 
isolated product was still the 4C regioisomer. Subsequent investigations were carried 
out with DABCO as base due to its ease of handling as a crystalline solid. 
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Scheme 58. Possible catalysis of the 1,3-dipolar cycloaddition. 
Table 12. Results obtained from Scheme 58. 
Entry  Base (0.1eq) Yield (%) 
1 - 73 
2 DABCO 72 
3 NEt3 74 
4 DBU 63 
5 Piperidine 67 
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Next, the effect of base on the 1,3-dipolar cycloaddition of brominated vinyl 
sulfonate 126 and brominated vinyl sulfonate 135 and a range of nitrones 114 and 
118 were investigated. The two reactions, with base - method A and without - 
method B, were carried out in parallel.  
RO
S
O O
Br
N
OMe
R1
+
RO
S
O O
N
O
Br
R1
Me
A. DABCO (0.1 eq), PhMe, reflux
114
126: R = PFP
135: R =TCP
 B. PhMe, reflux
136, R = TCP
137, R = PFP 
Scheme 59. Effect of base on the cycloaddition reaction using N-Me nitrone 114. 
Table 13. Results obtained from Scheme 59. 
Entry Product No R
1
 Method A (%) Method B (%) 
1 136a Ph 72 78 
2 136b p-MeO.C6H4 65 70 
3 136c p-Cl.C6H4 81 82 
4 137a Ph 70 69 
5 137b p-MeO.C6H4 72 71 
6 137c p-Br.C6H4 76 71 
 
 
 
 
54 
 
RO
S
O O
Br
N
OPMB
R1
+
RO
S
O O
N
O
Br
R1
PMB
A. DABCO (0.1 eq), PhMe, reflux
118126, R = PFP
135, R = TCP
 B. PhMe, reflux
138, R = TCP
139, R = PFP  
Scheme 60 
Table 14. Results obtained from Scheme 60. 
Entry Product No R
1
 Method A (%) Method B (%) 
1 138a Ph 58* 70* 
2 138b p-MeO.C6H4 73 75 
3 138d C10H7 54* 30* 
4 139a Ph 65* 67* 
5 139b p-MeO.C6H4 75 72 
6 139d p-Br.C6H4 75 65 
*diastereoisomers observed 
The reactions with DABCO were generally successful and gave good yields overall. 
However, there were great inconsistencies with the yields obtained. In some 
reactions, the yield obtained from the reaction with DABCO was much higher than 
the reaction without (Table 14, entry 6), while in other cases, the reaction without 
DABCO gave the better yield (Table 14, entry 1). 
 It was now imperative to assign the diastereoisomer from the cycloaddition reaction 
and X-ray crystallographic analysis of a typical example 137a confirmed that this 
was the trans-isomer (Figure 15).  
55 
 
   137a
PFPO
S
O O
N
O
Br
Me
Ph
 
Figure 14. X-ray crystallography of isoxazolidine 137a. 
3.4.2.1 Cycloaddition reaction of α-Br PFP/TCP vinyl sulfonate at RT 
The results obtained from the addition of catalytic base at 110 °C were inconclusive 
as there was only a slight difference in the yields between the reactions of 
brominated vinyl sulfonate and nitrone (Table 13 and 14). The initial reaction by 
Mok with PFP vinyl sulfonate 118 and nitrone indicated an improvement at room 
temperature (Section 3.4); therefore the cycloaddition reaction was carried out with 
(Method A) and without (Method B) DABCO at room temperature (Scheme 62/ 
Table 15). 
PFPO
S
O O
Br
PFPO
S
O O
N
O
Br
R
Me
A. 114, DABCO (0.1 eq), PhMe (2-5hrs)
B. 114, PhMe (2-5hrs)
126
PFPO
S
O O
N
O
Br
R
Me
+
A. 118, DABCO (0.1 eq), PhMe (2-5hrs)
B. 118, PhMe (2-5hrs)
PFPO
S
O O
N
O
Br
R
PMB
PFPO
S
O O
N
O
Br
R
PMB
+
137
139
140
141
Scheme 61. 1,3-Dipolar cycloaddition reaction at RT. 
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Table 15. Results obtained from Scheme 61. 
Entry  R R1 
Yield A (%)/  
(137/140)* 
Yield B (%)/ 
(137/140)* 
1 Me Ph 
71  
(3:1) 
67 
(3:2) 
2 Me p-MeO.C6H4 
70 
(3:1) 
64 
(3:1) 
3 Me p-Br.C6H4 
77 
(3:1) 
74 
(1:3) 
Entry R R1 
Yield A (%)/ 
(139/141)* 
Yield B (%)/ 
(139/141)* 
4 PMB Ph 
65 
(2:1) 
66 
(2:1) 
5 PMB p-Br.C6H4 
37 
(3:1) 
20 
(2:1) 
                              * determined by 
1
H NMR spectroscopic analysis 
The cycloaddition reaction at room temperature was successful in producing an 
overall good yield of brominated isoxazolidines. The reaction time varied for each 
nitrone used with N-Me nitrones 114 proceeding more rapidly. The reactions 
produced two inseparable diastereoisomers and NMR analysis of the peaks 
attributable to major isomer confirmed it to be identical to that derived for reaction of 
vinyl sulfonate 126 and nitrone 114 at reflux (section 3.4.1). In all reactions of the 
reactions, there was also the starting α-bromo vinyl sulfonate 126 isolated which 
varied for each reaction. The isolated diastereoisomers were the 4C regioisomer 
which still followed predicted behaviour of electron deficient dipolarophiles.  
3.4.3 Cycloaddition with α-Br, β-Ph vinyl sulfonate 
The reactivity of the β-phenyl vinyl sulfonate 122 was modified by incorporating 
bromine into the α position in order to evaluate the effect on its reactivity as a 
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dipolarophile. The synthesis of this substrate 142 was carried out using previously 
established procedure (Section 3.3.1) in excellent yield, 83%. 
PFPO
S
O O
Ph
1. Br2, CHCl3
2. NEt3, DCM PFPO
S
O O
Ph
Br
142, 83%
122
 
Scheme 62. Synthesis of PFP vinyl sulfonate 142. 
Initial studies on the cycloaddition reaction of α-Br,β-Ph vinyl sulfonate 142 were 
carried out using nitrone 114b (Scheme 63). 
PFPO
S
O O
N
O
Ph
Me
+
PFPO
S
O O
Ph
Br
MeO
Br
N
OMe
OMe
PhMe
142
143
114b
 
Scheme 63. 1,3-Dipolar cycloaddition reaction using vinyl sulfonate 142. 
Table 16. Results obtained from Scheme 63. 
Temp (°C) Time Yield (%) 
110  7 hrs SM recovered 
110  18 hrs SM recovered 
50  72 hrs 3 
23  7 days SM recovered 
 
It was quite disappointing that the reaction did not give a better yield than 3%; 
however analysis of the NMR spectrum showed that the product was obtained with 
excellent regio- and stereo-selectivity. The regioisomers were assigned from the 
analysis of the NMR spectrum as the 4C isomer; however it has not been possible to 
assign the relative stereochemistry.   
58 
 
3.4.4 NMR Experiments on the cycloaddition reaction 
NMR monitored reactions were carried out to analyse the reaction time and products 
of the cycloaddition reactions. These NMR monitored reactions were carried out at 
room temperature as the cycloaddition reactions at RT were slower and any 
intermediate formed could be monitored. An internal standard, 1,4-dioxane, was used 
to allow yields to be determined by the integration of the 1H NMR spectrum 
(Scheme 64 and 65).  
From the reactions with DABCO, it was observed that the initial isomer formed was 
trans isomer 137 with the formation of cis isomer 140 following 90 minutes later 
(Graphs 1 and 3). After 24 hours, the concentration of cis isomer 140 peaked at its 
highest although it was still the minor isomer with a ratio of 2:1 137:140. After three 
weeks, there was a change in the ratio with trans isomer 137 being the major 
product. The reactions without DABCO showed cis isomer 140 being the major 
product initially (Graphs 2 and 4).  After 24 hours, cis isomer 140 was still the major 
isomer with a ratio of 2.5:1 140:137; however there was a change in ratio with trans 
isomer 137 becoming the major product after 3 weeks. In all cases, the starting vinyl 
sulfonate 126 is consumed in parallel with the formation of the products however, 
with the exception of the reaction with DABCO (Graph 1), the starting material is 
not completely consumed and remains in the reaction.  
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PFPO
S
N
O
Me
Br
O O
PFPO
S
O O
Br
N
OMe
Ph
+
A or B
A: DABCO (0.1 eq), 1,4-dioxane (0.5 eq), d6-benzene, RT
B: 1,4-dioxane (0.5 eq), d6-benzene, RT
PFPO
S
N
O
Me
Br
O O
+
137a 140a
126 114a
 
Scheme 64 
  
Graph 1 
 
Graph 2 
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PFPO
S
N
O
Me
Br
O O
PFPO
S
O O
Br
+
A or B
A: DABCO (0.1 eq), 1,4-dioxane (0.5 eq), d6-benzene, RT
B: 1,4-dioxane (0.5 eq), d6-benzene, RT
PFPO
S
N
O
Me
Br
O O
+
137c 140c
126
114c
N
OMe
Br Br Br
 
Scheme 65 
 
Graph 3 
 
Graph 4 
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One rationale to explain why cis isomer 140 was formed first can be seen in the 
report by Boyle et al. It was noted in 1971 by Boyle et al.
83
 that nitrones derived 
from aromatic aldehydes possessed a configuration in which the C-aryl and N-alkyl 
groups are in a trans relationship. However, formation of cis and trans adducts led 
them to examine for the first time the possibility that the trans-form of their nitrone, 
144a, was in equilibrium with a small amount of the cis-form, 144b, and that the two 
transition states – 145a and 145b leading to cis and trans adducts were accessible 
(Scheme 66). 
N
H Me
N
H
Ph
O
Me
N
Ph
O Me
H
N
H
O Me
Ph
O N
Me
Ph
H
O N
Me
H
Ph
anti, 144a syn, 144b
anti, 145a syn, 145b
anti, 146a syn, 146b
O
Ph
 
Scheme 66. Trans and cis nitrone in equilibrium. 
They were able to conclude after further research that the favoured transition state for 
their nitrone was the one in which substituents are cis and the predominant adduct 
was the cis adduct. The existence of the cis-form of the nitrone therefore accounts for 
the formation of the cis-isomer 133, however this isomer must be unstable due to 
steric hindrance and decomposes by cycloreversion. This cycloreversion could 
account for the observation of α-bromo vinyl sulfonate and aldehyde (from 
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decomposed nitrone) starting materials isolated after column chromatography. It was 
still unclear however why the reactions with DABCO gave the trans isomer as the 
major product even from the onset of the reaction, and this is an area that still needs 
further investigation. 
 
3.5 Summary 
This research has shown TCP and PFP vinyl sulfonates as excellent dipolarophiles 
for 1,3-dipolar cycloaddition. Their reactions with nitrones are both regio- and 
diastereo-specific producing isoxazolidines in good yields. Extending the chemistry 
of the vinyl sulfonates by carrying out cycloadditions with β-substituted vinyl 
sulfonates was also successful. The isoxazolidines were also produced regio- and 
diastereo-selectively although the relative stereochemistry was not confirmed. 
Installing a leaving group, Br on the vinyl sulfonate did not change the reactivity of 
the vinyl sulfonates as a dipolarophile and cycloaddition of this species successfully 
generated 4C-anti-isoxazolidines as single diastereoisomers at reflux temperature, 
with inseparable diastereoisomers formed at room temperature. Catalysis of the 
reaction by addition of bases was not conclusive as there was only a slight 
improvement on the yield. 
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3.6 Conclusions/Future Work 
This thesis has demonstrated the versatile reactivity of bifunctional acceptors 
pentafluorophenyl and trichlorophenyl vinyl sulfonates. Trichlorophenyl vinyl 
sulfonate displays similar reactivity to pentafluorophenyl sulfonate. Intermolecular 
radical addition to trichlorophenyl vinyl sulfonate was successful and a small library 
of alkyl sulfonates were synthesised. The success of the intermolecular radical 
addition was extended to the formation of bifunctional TCP/PFP alkyl sulfonate. 
This bifunctional sulfonate could be used to in future to investigate the reactivity of 
TCP and PFP functional groups. 
Cycloaddition reactions with pentafluorophenyl vinyl sulfonate and trichlorophenyl 
vinyl sulfonate were successful and generated regio- and distereo- selective 
isoxazolidines. Cycloaddition with phenyl vinyl sulfonates extends the substitution 
available and a small library of substituted isoxazolidines were synthesised which 
were also regio- and distereo- selective. Cycloaddition using α-Br PFP vinyl 
sulfonate was unaffected by the presence of base at high temperature. However, at 
low temperature there was a change in the rate of isomerisation from kinetic to 
thermodynamic product which could be an effect of the base. 
In future work, the versatility of PFP and TCP vinyl sulfonates could be applied to 
the formation of seven membered rings. It is envisaged that reacting PFP or TCP 
vinyl sulfonate with a diamine would result in a seven membered ring being formed 
via a Michael addition to the vinylic portion of the sulfonate followed by 
displacement of the PFP/TCP group. 
Overall, this research has shown vinyl sulfonates are suitable precursors for the 
formation of a variety of alkyl and cyclic sulfonates which are amenable for further 
manipulations.    
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Chapter 4 Experimental 
4.1 General Experimental 
All reagents were purchased from Aldrich or AlfaAesar and were used as received 
without further purification unless otherwise stated. All reactions were monitored by 
thin-layer chromatography (TLC) on pre-coated silica gel plates (254m). Flash 
column chromatography was carried out with Kiesegel 60M 0.04/0.063mm (200-400 
mesh) silica gel.  
4.2 Instrumentation 
1
H NMR spectra were recorded at 300 MHz, 400 MHz, 500 MHz and 600 MHz and 
13
C NMR at 75 MHz, 100 MHz, 125 MHz and 150 MHz on a Bruker AMX300, 
AMX400, AMX500 and AMX600 respectively at ambient temperature as described 
below. The chemical shifts () for 1H and 13C are quoted relative to residual signals 
of the solvent on the ppm scale. Coupling constants (J values) are reported in Hertz 
(Hz). Multiplicities for 
1
H NMR are reported as singlet (s), doublet (d), triplet (t), 
quartet (q), broad (br) and multiplet (m); or some combination of these. Multiplicities 
for 
13
C NMR were determined using distortionless enhancement by phase transfer 
(DEPT) spectral editing technique and are reported as singlet (s), doublet (d), triplet 
(t), quartet (q), based on the anticipated multiplicity in a non-decoupled spectrum. 
For compounds bearing a pentafluorophenyl group the 
13
C NMR signals from this 
group are not reported due to a high degree of C-F coupling. Mass spectra were 
obtained on a VG70-SE mass spectrometer. Infrared spectra were obtained on a 
Shimadzu FTIR-8700 Fourier Transform Infrared Spectrophotometer or Perkin 
Elmer Spectrum 100 FTIR Spectrometer operating in ATR mode. Melting points 
were measured with a Gallenkamp apparatus and are uncorrected.  Elemental 
analyses were carried out at the Department of Chemistry, University College 
London. 
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4.3 Radical addition procedures 
Ethenesulfonic acid 2,4,6-trichlorophenyl ester [95] 
TCPO
S
O O
 
2-Chloroethane sulfonyl chloride 97 (18.1 g, 0.11 mol) was dissolved in CH2Cl2 (125 
mL) and cooled to -50 °C. 2,4,6-trichlorophenol 96 (20.0 g, 0.10 mol) and NEt3 (42.2 
mL, 0.30 mol) were pre-mixed in CH2Cl2 (25 mL) and added dropwise over 1 hour 
to the stirred solution of 2-Chloroethane sulfonyl chloride ensuring that the 
temperature remains below 0 °C. The reaction was allowed to warm to 20 °C and 
stirred for a further 1 hour after which it was diluted with Et2O (50 mL) and washed 
with 2 M HCl (50 mL) and sat. NaHCO3 (50 mL). The organic layer was dried 
(MgSO4) and concentrated in vacuo. The crude product was purified by flash column 
chromatography (10-100% Et2O in Petroleum ether 40-60 °C) to yield the title 
compound 95 as a white solid (15.7 g, 0.05 mol, 54%). 
MP 50.5 – 51.0 °C. 
1
H NMR (300 MHz, CDCl3)  7.40 (2 H, s, ArH); 6.93 (1 H, dd, J = 9.9 Hz,        
16.6 Hz, CH), 6.58 (1 H, dd, J = 0.8 Hz, 16.6 Hz, CHH), 6.23 (1 
H, dd, J = 0.8 Hz, 9.9 Hz, CHH).  
13
C NMR (75 MHz, CDCl3)  141.9 (s), 133.1 (d), 131.4 (s), 130.8 (t), 129.2 
(d), 129.1 (d).  
IR (neat) 2852 (br, -CH), 1562 (s, C=C), 1377 (s, S=O) cm
-1
. 
LRMS (CI) 288 [(M+H)
+
, 
37
Cl, 96%], 286 [(M+H)
+
, 
35
Cl, 94%], 199, [16], 
197, [14]. 
HRMS (CI) calcd for C8H6Cl3O3S (M+H)
+
 286.9103, found 286.9104. 
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Procedure A: Radical addition using EPHP  
To a solution of ethenesulfonic acid 2,4,6-trichlorophenyl ester 95 (1 mmol) and 
EPHP  57 (7 mmol) in CH2Cl2 (10 mL/mmol) was added the alkyl halide (2 mmol) 
and the solution was cooled to 0 °C. Et3B (1 mmol) was added and a syringe filled 
with air was passed through the reaction. After 5 mins, the reaction mixture was 
diluted with Et2O (20 mL/mmol), washed with 2M HCl (15 mL/mmol) and sat. 
aqueous NaHCO3 (15 mL/mmol). The organic layer was dried (MgSO4) and 
concentrated in vacuo. The crude product was purified by flash column 
chromatography (10-50% Et2O in petroleum ether 40-60 °C). 
Procedure B: Radical addition using Bu3SnH 
To a solution of ethenesulfonic acid 2,4,6-trichlorophenyl ester 95 (1 mmol) in dry 
toluene (30 mL/mmol) was added AIBN (20 mg/mmol) and the alkyl halide (3 
mmol) and the solution was heated to 110 °C. Tri-n-butyltin hydride (2.5 mmol) was 
added dropwise over 20 mins and the reaction heated for a further 2 hours. Potassium 
fluoride (3.0 g/mmol) was added and the resulting suspension stirred vigorously for 
16 hours.
 
The suspension was filtered through Celite
®
 and the filterate concentrated 
in vacuo. The crude product was purified by flash column chromatography (10-100% 
Et2O in petroleum ether 40-60 °C). 
 
3,3-Dimethylbutane-1-sulfonic acid 2,4,6-trichlorophenyl ester [98a] 
TCPO
S
O O
 
Using procedure A to afford the title compound 98a as a white solid (190 mg, 0.55 
mmol, 64%); 
Using procedure B to afford the title compound 98a as a white solid (440 mg, 1.28 
mmol, 74%); 
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MP 91.0 – 92.0 °C. 
1
H NMR (300 MHz, CDCl3)  7.41 (2 H, s, ArH), 3.53 (2 H, m, CH2), 1.97 
(2 H, m, CH2), 0.99 (9 H, s, (CH3)3). 
13
C NMR (75 MHz, CDCl3)  132.9 (s), 130.7 (s), 129.2 (d), 51.2 (t), 36.6 
(t), 30.3 (s), 28.9 (q). (1 x s not observed). 
IR (neat) 2923 (s, -CH), 2852 (s, -CH), 1558 (w, C=C), 1460 (s), 1377 (s, 
S=O) cm
-1
. 
LRMS (EI) 346 [M
+.
, 
37
Cl, 15%], 344 [M
+.
, 
35
Cl, 13%], 198 [100], 167 [25]. 
HRMS (EI) calcd for C12H15Cl3O3S (M
+.
) 343.9807, observed 343.9802. 
 
3-Methylbutane-1-sulfonic acid 2,4,6-trichlorophenyl ester [98b] 
TCPO
S
O O
 
Using procedure A to give the title compound 98b as a colourless oil (180 mg, 0.55 
mmol, 63%); 
Using procedure B to give the title compound 98b as a colourless oil (430 mg, 1.30 
mmol, 74%);  
1
H NMR (300 MHz, CDCl3)  7.39 (2 H, s, ArH), 3.49 (2 H, m, CH2), 1.94 
(2 H, m, CH2), 1.83 (1 H, sept, J = 6.6 Hz, CH), 0.99 (6 H, d, J = 
6.6 Hz, (CH3)2).  
13
C NMR (75 MHz, CDCl3)  142.1 (s), 132.9 (s), 130.7 (s), 129.2 (d), 52.8 
(t), 31.9 (t), 27.3 (d), 22.0 (q).  
IR (neat) 3080 (m, -CH), 2960 (s, -CH), 1560 (s, C=C), 1443 (s), 1383 (s, 
S=O) cm
-1
. 
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LRMS (EI) 332 [M
+.
, 
37
Cl, 23%], 330 [M
+.
, 
35
Cl, 21%], 196 [100], 169 [20]. 
HRMS (EI) calcd for C11H13Cl3O3S (M
+.
) 329.9651, observed 329.9646. 
2-Cyclohexylethanesulfonic acid 2,4,6-trichlorophenyl ester [98c] 
TCPO
S
O O
 
Using procedure A to give the title compound 98c as a white solid (230 mg, 0.62 
mmol, 72 %); 
Using procedure B to give the title compound 98c as a white solid (470 mg, 1.26 
mmol, 72 %);  
MP 60.0 – 61.5 °C. 
1
H NMR (300 MHz, CDCl3)  7.40 (2 H, s, ArH), 3.65 (2 H, m, CH2), 1.99 
(2 H, m, CH2), 1.72 (4 H, m, 2 x CH2), 1.25 (1 H, m, CH), 1.23 (4 
H, m, 2 x CH2), 0.99 (2 H, m, CH2). 
13
C NMR (75 MHz, CDCl3)  132.9 (s), 130.7 (s), 129.2 (d), 52.5 (t), 36.6 
(d), 32.8 (t), 30.2 (t), 26.3 (t), 25.9 (t). (1 x s not observed). 
IR (neat) 2922 (s, -CH), 2852 (s, -CH), 1562 (m), 1445 (s), 1379 (s, S=O) 
cm
-1
. 
LRMS (EI) 372 [M
+.
, 
37
Cl, 18%], 370 [M
+.
, 
35
Cl, 16%], 196 [100], 169 [22]. 
HRMS (EI) calcd for C14H15Cl3O3S (M
+.
) 369.99639, observed 369.99563. 
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Hexane-1-sulfonic acid 2,4,6-trichlorophenyl ester [98d] 
TCPO
S
O O
 
 
Using procedure A to give the title compound 98d as a light yellow oil (150 mg, 0.44 
mmol, 51%);  
Using procedure B to give the title compound 98d as a clear oil (320 mg, 0.92 mmol, 
53%); 
1
H NMR (300 MHz, CDCl3)  7.40 (2 H, s, ArH), 3.55 (2 H, t, J = 8.0 Hz, 
CH2), 2.05 (2 H, m, CH2), 1.56 (2 H, m, CH2), 1.37 (4 H, m, 2 x 
CH2), 0.93 – 0.88 (3 H, m, CH3). 
13
C NMR (75 MHz, CDCl3)  142.1 (s), 132.9 (s), 130.7 (s), 129.2 (d), 54.3 
(t), 31.1 (t), 27.9 (t), 23.6 (t), 22.3 (t), 13.9 (q).  
IR (neat) 2920 (s, -CH), 2890 (s, -CH), 1552 (m), 1440 (s, C=C), 1378 (s, 
S=O) cm
-1
. 
LRMS (EI) 346 [M
+.
, 
37
Cl, 15%], 344 [M
+.
, 
35
Cl, 13%], 196 [100]. 
HRMS (EI) calcd for C12H15Cl3O3S (M
+.
) 343.9807, observed 343.9802. 
 
4-Methylpentane-1-sulfonic acid 2,4,6-trichlorophenyl ester [98e] 
TCPO
S
O O
 
Using procedure A to give the title compound 98e as a light yellow oil (100 mg, 0.29 
mmol, 33%); 
Using procedure B to give the title compound 98e as a clear oil (390 mg, 1.13 mmol, 
65%); 
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1
H NMR (300 MHz, CDCl3)  7.51 (2 H, s, ArH), 3.52 (2 H, t, J = 8.0 Hz, 
CH2), 2.06 (2 H, m, CH2), 1.63 (1 H, sept, J = 6.7 Hz, CH), 1.40 
(2 H, m, CH2), 0.99 (6 H, d, J = 6.7 Hz, (CH3)2).  
13
C NMR (75 MHz, CDCl3)  142.1 (s), 132.9 (s), 130.7 (s), 129.2 (d), 54.5 
(t), 37.3 (t), 27.7 (d), 22.3 (q), 21.6 (t).  
IR (neat) 2957 (m, -CH), 2872 (w), 1558 (s, C=C), 1443 (s, C=C), 1383 (s, 
S=O) cm
-1
. 
LRMS (EI) 346 [M
+.
, 
37
Cl, 15%], 344 [M
+.
, 
35
Cl, 13%], 196 [100]. 
HRMS (EI) calcd for C12H15Cl3O3S (M
+.
) 343.9807, observed 343.9798. 
 
6-(2,4,6-Trichlorophenoxysulfonyl)-hexanoic acid methyl ester [98h] 
TCPO
S
O O
O
O
 
Using procedure B to give the title compound 98h as a light yellow oil (340 mg, 0.94 
mmol, 50%);  
1
H NMR (300 MHz, CDCl3)  7.40 (2 H, s, ArH), 3.67 (3 H, s, 
CH3), 3.55 – 3.50 (2 H, m, CH2), 2.36 (2 H, t, J = 7.2 Hz, 
CH2), 2.05 – 2.15 (2 H, m, CH2), 1.76 – 1.66 (2 H, m, 
CH2), 1.62 – 1.52 (2 H, m, CH2). 
13
C NMR (75 MHz, CDCl3)  173.6 (s), 142.0 (s), 132.9 (s), 130.6 
(s), 129.2 (d), 54.0 (t), 51.6 (q), 33.5 (t), 27.6 (t), 24.2 (t), 
23.4 (t). 
IR (neat) 2928 (s, -CH), 2855 (s, -CH), 1732 (s, C=O), 1560 (m), 
1445 (s, C=C), 1375 (s, S=O) cm
-1
; 
LRMS (CI-Methane) 391 [(M+CH3)
+
, 
35
Cl, 10%], 359 [60], 181 [30], 163 [75], 
71 
 
131 [35]. 
HRMS (CI-Methane) calcd for C13H15Cl3O5S (M+H)
+
 356.98857, observed 
356.98985. 
2-tert-Butoxycarbonylamino-5-(2,4,6-trichlorophenoxysulfonyl)-
pentanoic acid methyl ester [98f] 
TCPO
S
O O
O
O
HN O
O
 
 Using procedure B to give the title compound 98f as a white solid (320 mg, 0.64 
mmol, 37 %);  
MP 67.0 – 68.5 °C. 
1
H NMR (300 MHz, CDCl3)  7.51 (2 H, s, ArH), 5.15 (1 H, d, J = 7.6 Hz, 
NH), 4.56 – 4.19 (1 H, m, CH), 3.76 (3 H, s, CH3), 3.57 (2 H, 
apparent q, CH2), 2.23 – 1.79 (4 H, m, 2 x CH2), 1.43 (9 H, s, 
(CH3)3). 
13
C NMR (75 MHz, CDCl3)  172.4 (s), 141.9 (s), 133.0 (s), 130.6 (s), 129.2 
(d), 65.8 (t), 53.5 (t), 52.6 (d), 50.4 (q), 31.2 (t), 28.3 (q). (2 x s not 
observed). 
IR (neat) 3369 (m), 2853 (br, -CH), 1732 (m, C=O), 1678 (m, C=O), 1518 
(m, C=C), 1456 (s, C=C), 1377 (s, S=O) cm
-1
. 
LRMS (FAB) 514 [(M+Na)
+
, 
35
Cl, 85%] 
HRMS (FAB) calcd for C17H22Cl3NNaO7S (M+Na)
+
 513.78308, observed 
513.78298. 
  
 
72 
 
6-Chlorohexane-1-sulfonic acid 2,4,6-trichlorophenyl ester [101b] 
TCPO
S
O O
Cl 
Using procedure B to yield the title compound 101b as a colourless oil (342.5 mg, 
0.905 mmol, 52%). 
1
H NMR (300 MHz, CDCl3)  7.40 (2 H, s, ArH), 3.56 – 3.46 (4 H, m, 2 x 
CH2), 2.19 – 2.08 (2 H, m, CH2), 1.86 – 1.79 (2 H, m, CH2), 1.62 
– 1.47 (4 H, m, 2 x CH2). 
13
C NMR (75 MHz, CDCl3)  132.9 (s), 130.7 (s), 129.2 (d), 128.8 (d), 
123.8 (s), 49.8 (t), 45.0 (t), 33.1 (t), 27.7 (t), 26.8 (t), 23.4 (t). 
 
6-Iodohexane-1-sulfonic acid 2,4,6-trichlorophenyl ester [102b] 
TCPO
S
O O
I 
6-Chlorohexane-1-sulfonic acid 2,4,6-trichlorophenyl ester 101b (1.04 g, 2.75 mmol) 
was dissolved in acetone (30 mL) and sodium iodide (0.78 g, 5.50 mmol) was added 
in portions and the reaction heated to 56 °C and stirred for 48 hours. The mixture 
was filtered and the white solid residue was washed with acetone. The filtrate was 
concentrated in vacuo to obtain a yellowish solid to which was added Et2O. The 
organic layer was filtered and concentrated to obtain the title compound 102b as a 
light yellow solid (0.94 g, 2.12 mmol, 77%). 
1
H NMR (300 MHz, CDCl3)  7.40 (2 H, s, ArH), 3.56 – 3.41 (2 H, m, 
CH2), 3.13 – 3.09 (2 H, m, CH2), 1.86 – 1.79 (4 H, m, 2 x CH2), 
1.62 – 1.47 (4 H, m, 2 x CH2). 
13
C NMR (75 MHz, CDCl3)  132.9 (s), 130.7 (s), 129.2 (d), 128.8 (d), 
123.8 (s), 49.8 (t), 34.0 (t), 30.4 (t), 27.3 (t), 23.4 (t). 
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Octane-1,8-disulfonic acid pentafluorophenyl ester 2,4,6-trichlorophenyl 
ester [103b] 
TCPO
S
O O
S
OPFP
O O  
To a solution of ethenesulfonic acid pentafluorophenyl ester 85 (260 mg, 0.95 mmol) 
in dry toluene (30 mL) was added AIBN (20 mg) and 6-iodohexane-1-sulfonic acid 
2,4,6-trichlorophenyl ester 102b (0.89 g, 1.89 mmol) and the solution heated to 110 
°C. Tri-n-butyltin hydride (0.64 mL, 2.38 mmol) was added dropwise over 20 mins 
and the reaction heated for a further 2 hours. Potassium fluoride (3.0 g) was added 
and the resulting suspension stirred vigorously for 16 hours. The suspension was 
filtered through celite and the filtrate concentrated in vacuo. The crude product was 
purified by flash column chromatography (10 – 100% Et2O in petroleum ether 40 – 
60 °C) to generate the title compound 103b as a white solid (390 mg, 0.63 mmol, 
66%). 
MP 89.0 – 91.0 °C. 
1
H NMR (300 MHz, CDCl3)  7.40 (2 H, s, ArH), 3.55 (2 H, t, J = 7.7 Hz, 
CH2), 3.44 (2 H, t, J = 7.7 Hz, CH2), 2.14 – 1.99 (4 H, m, 2 x 
CH2), 1.60 – 1.42 (8 H, m, 4 x CH2). 
13
C NMR (75 MHz, CDCl3)  142.1 (s), 132.9 (s), 130.6 (s), 129.2 (d), 54.2 
(t), 28.6 (t), 28.0 (t), 27.9 (t), 23.6 (t), 23.5 (t), 23.5 (t). 
IR (neat) 2924 (s, -CH), 2853 (s, -CH), 1518 (m), 1464 (s, C=C), 1377 (s, 
S=O) cm
-1
. 
LRMS (FAB) 643 [(M+Na)
+
, 
35
Cl, 20%], 553 [10], 499 [10], 360 [20]. 
HRMS (FAB) calcd for C12H15Cl3NaO3S (M+Na)
+
 640.9428, observed 
640.94344. 
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4.4 Nitrone Procedures
81
 
4-Methoxy benzaldehyde oxime [116]   
MeO
N
OH
 
Hydroxylamine hydrochloride (20.0 g, 0.26 mol) and triethylamine (69.7 mL, 0.49 
mol) was added to a stirred solution of anisaldehyde (20.0 g, 0.15 mmol) in CH2Cl2 
(500 mL) and the reaction was stirred at 25 °C for 2 hrs after which it was cooled in 
an ice-bath. NaHCO3 (200 mL) was added to the cooled mixture and the organic 
layer was separated. The aqueous layer was extracted with CH2Cl2 (100 mL) and the 
organic layers were combined together and concentrated in vacuo to yield the crude 
which was purified by flash chromatography (10-100%  EtOAc in petroleum ether 
40-60 °C) to afford the title compound 116 as a white solid (22.0 g, 0.15 mol,  99%). 
MP 72-74 °C. 
1
H NMR (300 MHz, CDCl3)  9.22 (br s, 1 H, OH), 8.13 (s, 1 H, CHN), 
7.52 (d, J = 8.7 Hz, 2 H, ArH), 6.91 (d, J = 8.7 Hz, 2 H, ArH), 
3.82 (s, 3 H, OCH3). 
13
C NMR (75 MHz, CDCl3)  161.1 (s), 150.0 (d), 128.6 (d), 124.6 (s), 
114.3 (d), 55.4 (q). 
IR (neat) 3170 (br, -OH), 2839 (w), 1607 (s, C=N), 1512 (s, C=C), 1441 
(w), 1250 (s) cm
-1
. 
LRMS (CI) 152 [(M+H)
+
, 100%]. 
HRMS (CI) calcd for C8H10NO2 (M+H)
+
 152.0712, found 152.0708. 
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N-(4-Methoxybenzyl)-hydroxylamine [117]  
MeO
HN
OH
 
Concentrated HCl (7 mL) was added to a stirred solution of 4-methoxy benzaldehyde 
oxime 116 (5.00 g, 33.1 mmol) and NaBH3CN (4.10 g, 66.2 mmol) in MeOH (50 
mL) at 0 °C. After addition, the reaction mixture was allowed to stir at 25 °C for 4 
hrs. 6 M KOH was added until pH was approximately 9 and the reaction mixture was 
concentrated in vacuo. The crude was then extracted with brine (50 mL), dried 
(MgSO4) and concentrated in vacuo to afford the title compound 117 as a yellowish 
solid (3.63 g, 23.7 mmol). 
MP 80.0-82.0
 
°C. 
1
H NMR (300 MHz, CDCl3)   7.23 (d, J = 8.6 Hz, 2 H, ArH), 6.86 (d, J = 
8.6 Hz, 2 H, ArH), 6.12 (br s, 1 H, NH), 3.91 (s, 2 H, CH2NH), 
3.78 (s, 3 H, OCH3). 
13
C NMR (75 MHz, CDCl3)  159.2 (s), 130.5 (d), 128.9 (s), 113.9 (d), 57.6 
(t), 55.3 (q). 
IR (neat) 3210 (br, -OH), 2837 (w), 1610 (s), 1511 (s), 1250 (s) cm
-1
. 
LRMS (EI) 153 [M
+.
, 90%]. 
HRMS (EI) calcd for C8H11NO2 (M
+.
) 153.0784, found 153.0795. 
 
Procedure C: Formation of N-(4-methoxybenzyl) nitrones [118]  
To a stirring solution of N-(4-methoxybenzyl)-hydroxylamine 117 (1.0 mol) in 
CH2Cl2 (30 mL/mol) was added the corresponding aldehyde (1.5 mol) and MgSO4 
(2.0 mol). The mixture was stirred at 40 °C overnight, then the resulting suspension 
was filtered and the resulting residue was washed thoroughly with CH2Cl2 (2 x 50 
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mL/mol). The combined organic fractions were concentrated in vacuo to yield a solid 
that was recrystallised (EtOAc/petroleum ether 40-60 °C) to give the title compound. 
 
N-(4-Methoxybenzyl)-N-(4-methoxyphenyl) methylidene amine oxide 
[118a] 
N
O
OMe
MeO  
Using procedure C to yield a white solid that was recrystallised (EtOAc in petroleum 
ether 40-60 °C) to give the title compound 118a as a white solid (1.30 g, 4.9 mmol, 
75%).  
MP 127-129 °C. 
1
H NMR (300 MHz, CDCl3)  8.18 (d, J = 9.1 Hz, 2 H, ArH), 7.37 (d, J = 
8.6 Hz, 2 H, ArH), 7.25 (s, 1 H, CHN), 6.90 (d, J = 8.6 Hz, 2 H, 
ArH), 6.88 (d, J = 9.1 Hz, 2 H, ArH), 4.92 (s, 2 H, NCH2Ar), 3.80 
(s, 3 H, OCH3), 3.79 (s, 3 H, OCH3). 
13
C NMR (75 MHz, CDCl3)  161.1 (s), 160.1 (s), 133.6 (d), 130.9 (d), 
130.6 (d), 125.5 (s), 123.5 (s), 114.3 (d), 113.7 (d), 70.1 (t), 55.3 
(q). 
IR (neat) 3007 (w), 2837 (w), 1603 (s, C=N), 1512 (s, C=C), 1239 (s), 1025 
(s) cm
-1
. 
LRMS (EI) 271 [M
+.
, 12%], 121 [100 ], 91 [ 31]. 
HRMS (EI) calcd for C16H17NO3 (M
+.
) 271.1203, found 271.1208. 
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N-(4-Methoxybenzyl)-N-phenylmethylidene amine oxide  [118c]
(81)
  
N
O
OMe
 
Using procedure C to yield a white solid that was recrystallised (EtOAc/petroleum 
ether 40-60 °C) to give the title compound 118c as white crystals (1.10 g, 4.7 mmol, 
72%):  
MP 96-97
 
°C. 
1
H NMR (300 MHz, CDCl3)  8.18-8.21 (m, 2 H, ArH), 7.38-7.42 (m, 5 H, 
ArH), 7.33 (s, 1 H, CHN), 6.93 (d, J = 8.6 Hz, 2 H, ArH), 4.99 (s, 
2 H, CH2N), 3.82 (s, 3 H, OCH3). 
13
C NMR (75 MHz, CDCl3)  160.2 (s), 133.8 (d), 130.9 (d), 130.5 (s), 
130.4 (d), 128.6 (d), 128.4 (d), 125.3 (s), 114.4 (d), 70.7 (t), 55.4 
(q). 
IR (neat) 3051 (w), 2934 (w), 1610 (s, C=N), 1514 (s, C=C), 1250 (s), 1026 
(s) cm
-1
. 
LRMS (FAB) 264 [(M+Na)
+
, 48%], 199 [63], 173 [100]. 
HRMS (FAB) calcd for C15H15NO2Na (M+Na)
+
 264.1000, found 264.1004. 
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N-(2-Chlorophenyl) methylidene-N-(4-methoxybenzyl)amine oxide [118b]  
N
O
OMe
Cl  
Using procedure C to yield a white solid that was recrystallised (EtOAc in petroleum 
ether 40-60 °C) to give the title compound 118b as a white solid (1.20 g, 4.9 mmol, 
65%).  
MP 142-144 °C. 
1
H NMR (300 MHz, CDCl3)   9.32-9.26 (m, 1 H, ArH), 7.89 (s, 1 H, 
CHN), 7.46-7.25 (m, 5 H, ArH), 6.94 (d, J = 8.6 Hz, 2 H, ArH), 
5.02 (s, 2 H, NCH2Ar), 3.82 (s, 3 H, OCH3). 
13
C NMR (75 MHz, CDCl3)  132.7 (s), 131.0 (d), 129.4 (d), 129.0 (d), 
128.1 (s), 127.1 (d), 113.0 (d), 55.3 (q). 
IR (neat) 3007 (w), 2837 (w), 1612 (s, C=N), 1513 (s, C=C), 1238 (s), 1031 
(s) cm
-1
. 
LRMS (EI) 277 [M
+.
,
37
Cl, 4%], 275 [M
+.
,
35
Cl, 12%], 121 [100], 89 [41]. 
HRMS (EI) calcd for C15H14ClNO2 (M
+.
) 275.0708, found 275.0711. 
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N-(4-Methoxybenzyl)-N-naphthalen-2-ylmethylidene amine oxide [118e]
  
N
O
OMe
 
Using procedure C to yield a white solid that was recrystallised (EtOAc in petroleum 
ether 40-60 °C) to give the title compound 118e as a cream solid (2.60 g, 8.9 mmol, 
92%). 
MP 155-158 °C. 
1
H NMR (300 MHz, CDCl3)  9.22 (s, 1 H, CHN), 7.78-7.91 (m, 4 H, 
ArH), 7.47-7.51 (m, 3 H, ArH), 7.44 (d, J = 8.6 Hz, 2 H, ArH), 
6.95 (d, J = 8.6 Hz, 2 H, ArH), 5.03 (s, 2 H, NCH2Ar), 3.82 (s, 3 
H, OCH3).  
13
C NMR (75 MHz, CDCl3)  135.3 (d), 134.1 (s), 133.1 (s), 129.2 (d), 
128.4 (d), 128.0 (d), 127.8 (s), 127.6 (d), 127.4 (d), 126.5 (d), 
125.7 (d), 54.5 (q). 
IR (neat) 3053 (w), 2932 (w), 1610 (s, C=N), 1514 (s, C=C), 1249 (s), 1021 
(s) cm
-1
. 
LRMS (EI) 291 [M
+.
, 38], 275 [15], 139 [40], 121 [100]. 
HRMS (EI) calcd for C19H17NO2 (M
+.
) 291.1254, found 291.1260. 
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N-Cyclohexylmethylidene-N-(4-methoxybenzyl)amine oxide [118d]
  
N
O
OMe
 
Using procedure C to yield a white solid that was recrystallised (EtOAc in petroleum 
ether 40-60 °C) to give the title compound 118d as a white solid (1.10 g, 4.4 mmol, 
60%). 
MP 92-95 °C. 
1
H NMR (300 MHz, CDCl3)  7.29 (d, J = 8.6 Hz, 2 H, ArH), 6.88 (d, J = 
8.6 Hz, 2 H, ArH), 6.38 (d, J = 7.2 Hz, 1 H, CHN), 4.77 (s, 2 H, 
NCH2Ar), 3.79 (s, 3 H, OCH3), 2.88-3.01 (m, 1 H, CHCHN), 
1.76-1.86 (m, 2 H, cyclohexyl-H), 1.58-1.70 (m, 3 H, cyclohexyl-
H), 1.01-1.41 (m, 5 H, cyclohexyl-H). 
13
C NMR (300 MHz, CDCl3)  144.2 (d), 52.6 (q), 44.2 (d), 28.7 (t), 25.8 
(t), 25.1 (t). 
IR (neat) 3063 (w), 2924 (s, CH), 1612 (s, C=N), 1513 (s, C=C), 1238 (s), 
1031 (s) cm
-1
. 
LRMS (EI) 247 [M
+.
, 8%], 230 [16], 121 [100], 91 [33]. 
HRMS (EI) calcd for C15H21NO2 (M
+.
) 247.1567, found 247.1561. 
 
Procedure D: Formation of N-methyl nitrones [114]  
To a stirring solution of N-methylhydroxylamine (1.5 mol) in CH2Cl2 (30 mL/mol) 
was added benzaldehyde (1.0 mol) and MgSO4 (3.0 mol). The mixture was stirred at 
40 °C for 2 hours. The resulting suspension was filtered and the resulting residue was 
washed thoroughly with CH2Cl2 (2 x 50 mL/mol). The combined organic fractions 
were concentrated in vacuo to yield a solid that was recrystallised (EtOAc/petroleum 
ether 40-60 °C) to give the title compound. 
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N-(4-Methoxyphenyl) methylidene-N-methylamine oxide [114b]
  
Me
N
O
OMe 
Using procedure D to yield a white solid that was recrystallised (EtOAc in petroleum 
ether 40-60 °C) to give the title compound 114b as a white solid (11.0 g, 0.07 mol, 
67%). 
MP 81 - 82 °C. 
1
H NMR (300 MHz, CDCl3)  8.20 (m, 2 H, ArH), 7.29 (s, 1 H, CH), 6.92 
(m, 2 H, ArH), 3.86 (s, 6 H, 2 x CH3). 
13
C NMR (75 MHz, CDCl3)  161.0 (s), 135.0 (d), 130.4 (d), 123.4 (s), 
113.8 (d), 55.6 (q), 53.9 (q). 
IR (neat) 3399 (w), 3007 (w), 2840 (w), 1601 (s, C=N), 1506 (s, C=C), 
1412 (s) cm
-1
. 
LRMS (EI) 165 [M
+.
, 100%]. 
HRMS (EI) calcd for C9H11NO2 (M
+.
) 165.0790, found 165.0791. 
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N-Methyl-N-phenylmethylidene amine oxide [114a]
  
Me
N
O
 
Using procedure D to yield a white solid that was recrystallised (EtOAc in petroleum 
ether 40-60 °C) to give the title compound 114a as a white solid (10.0 g, 0.07 mol, 
70%). 
MP 89-91 °C. 
1
H NMR (300 MHz, CDCl3)  8.23 – 8.20 (m, 2 H, ArH), 7.44 – 7.40 (m, 3 
H, ArH), 7.37 (s, 1 H, CH), 3.87 (s, 3 H, CH3). 
13
C NMR (75 MHz, CDCl3)  135.3 (d), 130.5 (s), 130.4 (d), 128.7 (d), 
128.4 (d), 54.4 (q). 
IR (neat) 3058 (w), 1601 (s, C=N), 1594 (s, C=C), 1405 (s) cm
-1
. 
LRMS (EI) 135 [M
+.
, 99%]. 
HRMS (EI) calcd for C8H9NO (M
+.
) 135.0684, found 135.0682. 
 
N-Methyl-N-(4-nitrophenyl) methylidene amine oxide [114c]
 
Me
N
O
NO2 
Using procedure D to yield an orange solid that was recrystallised (EtOAc in 
petroleum ether 40-60 °C) to give the title compound 114c as a yellow-orange solid 
(3.75 g, 24.9 mmol, 50 %). 
MP 218-220 °C. 
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1
H NMR (300 MHz, CDCl3)  8.44 (d, J = 9.1 Hz, 2 H, ArH), 8.27 (d, J = 
9.1 Hz, 2 H, ArH), 8.10 (s, 1 H, CH), 3.85 (s, 3 H, CH3). 
13
C NMR (75 MHz, CDCl3)  146.9 (s), 136.7 (s), 132.7 (d), 128.3 (d), 
123.7 (d), 54.7 (q). 
IR (neat) 3055 (w), 2986 (w), 1594 (s, NO2), 1423 (s) cm
-1
. 
LRMS (EI) 180 [M
+.
, 100%]. 
HRMS (EI) calcd for C8H8N2O3 (M
+.
) 180.0535, found 180.0526. 
 
N-Methyl-N-naphthalen-2-ylmethylidene amine oxide [114d]
  
Me
N
O
 
Using procedure D to yield a cream solid that was recrystallised (EtOAc in 
petroleum ether 40-60 °C) to give the title compound 114d as a white solid (3.12 g, 
19.9 mmol, 80 %).  
MP 127-128 °C. 
1
H NMR (300 MHz, CDCl3)  9.19 (s, 1 H, CH), 7.94 – 7.80 (m, 4 H, ArH), 
7.54 – 7.47 (m, 3 H, ArH), 3.90 (s, 3 H, CH3). 
13
C NMR (75 MHz, CDCl3)  135.3 (d), 134.1 (s), 133.1 (s), 129.2 (d), 
128.4 (d), 128.0 (d), 127.8 (s), 127.6 (d), 127.4 (d), 126.5(d), 
125.7 (d), 54.5 (q). 
IR (neat) 2995 (w), 1576 (s, C=C), 1402 (s) cm
-1
. 
LRMS (EI) 185 [M
+.
, 100%]. 
HRMS (EI) calcd for C12H11NO (M
+.
) 185.0841, found 185.0844. 
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N-Furan-2-ylmethylidene-N-methylamine oxide [114e]
  
Me
N
O
O
 
Using procedure D to yield a brown solid that was recrystallised (EtOAc/petroleum 
ether 40-60 °C) to give the title compound 114e as brown needles (1.96 g, 16.2 
mmol, 65%). 
MP 96-98 °C. 
1
H NMR (300 MHz, CDCl3)  7.72 (d, J = 3.5 Hz, 1 H, CHO), 7.53 (s, 1 H, 
CHN), 7.45 (d, J = 1.7 Hz, 1 H, CHCO), 6.53 – 6.52 (m, 1 H, 
OCHCHCH), 3.80 (s, 3 H, CH3). 
13
C NMR (75 MHz, CDCl3)  148.1 (s), 143.7 (d), 126.4 (d), 115.5 (d), 
112.4 (d), 52.7 (q). 
IR (neat) 3140 (w), 1596 (s, C=C), 1483 (s), 1401 (s), 1229 (s) cm
-1
. 
LRMS (EI) 125 [M
+.
, 98%]. 
HRMS (EI) calcd for C6H7NO2 (M
+.
) 125.0477, found 125.0479. 
 
N-Cyclopropylmethylidene-N-methylamine oxide [114f]
  
Me
N
O
 
Using procedure D to yield a yellow oil as the title compound 114f (1.58 g, 15.9 
mmol, 80%).  
1
H NMR (300 MHz, CDCl3)  6.07 (d, J = 8.5 Hz, 1 H, CHN), 3.56 (s, 3 H, 
CH3), 2.18-2.30 (m, 1 H, CH(CH2)2), 0.92-0.99 (m, 2 H, CH2CH), 
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0.57-0.60 (m, 2 H, CH2CH). 
13
C NMR (75 MHz, CDCl3)  143.2 (d), 51.8 (q), 9.3 (d), 6.9 (t), 6.6 (t). 
IR (neat) 3007 (w), 1630 (s, C=N), 1402 (s), 1227 (s), 1134 (s) cm
-1
. 
LRMS (EI) 99 [M
+.
, 68%]. 
HRMS (EI) calcd for C5H9NO (M
+.
) 99.0684, found 99.0690. 
 
4.5 1,3-Dipolar cycloaddition procedures 
 
Ethenesulfonic acid pentafluorophenyl ester [85]
  
PFPO
S
O O
 
2-Chloroethanesulfonyl chloride (5.7 mL, 0.054 mol) was dissolved in CH2Cl2 (75 
mL) and cooled to -10 °C. Pentafluorophenol (10.0 g, 0.054 mol) and NEt3 (22.7 mL, 
0.163 mol) were pre-mixed in CH2Cl2 (25 mL) and added dropwise over 1 hour to 
the stirred solution of 2-chloroethanesulfonyl chloride ensuring that the temperature 
remains below 0 °C. The reaction was allowed to warm up to room temperature and 
stirred for a further 1 hour after which it was diluted with Et2O (50 mL) and washed 
with 2M HCl (50 mL) and sat. NaHCO3 (50 mL). The organic layer was dried 
(MgSO4) and concentrated in vacuo. The crude product was purified by flash column 
chromatography (10-100% Et2O in petroleum ether 40-60 °C) to yield the title 
compound 85 as a light yellow oil (8.90 g, 0.032 mol, 60%). 
1
H NMR (300 MHz, CDCl3)  6.75 – 6.55 (1 H, m, CH), 6.42 (1 H, dd, J = 
0.6 Hz, 17.1 Hz, CHH), 6.29 (1 H, dd, J = 0.6 Hz, 9.8 Hz, CHH). 
13
C NMR (75 MHz, CDCl3)  136.2 (s), 133.2 (d), 131.7 (d). 
IR (neat) 3123 (w), 3080 (w), 1522 (s, C=C), 1393 (s, S=O) cm
-1
. 
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LRMS (EI) 274 [M
+.
, 33%, 184 [76], 136 [38], 117 [25], 105 [17], 91 [77], 27 
[100]. 
HRMS (EI) calcd for C8H3F5O3S (M
+
) 273.9723, found 273.9727. 
 
2-(4-Methoxybenzyl)-3-(4-Methoxybenzyl)-isoxazolidine-4-sulfonic acid 
pentafluorophenyl ester [119a]  
PFPO
S
N
O
O O
PMB
MeO  
To ethenesulfonic acid pentafluorophenyl ester 85 (200 mg, 0.74 mmol) in dry 
toluene (5 mL) was added N-(4-methoxybenzyl)-N-(4-methoxyphenyl) methylidene 
amine oxide 118a (200 mg, 0.74 mmol) and DABCO (8.0 mg, 0.074 mmol) and the 
mixture was stirred at reflux for 3 hours. The reaction was concentrated in vacuo, 
and the crude residue was purified by flash chromatography (10-100% Et2O in 
petroleum ether 40-60 °C) to give the title compound 119a as a yellow solid (380 
mg, 0.70 mmol, 93%). 
MP 118-119
 
°C. 
1
H NMR (300 MHz, CDCl3)  7.57 (d, J = 8.0 Hz, 2 H, ArH), 7.47-7.39 (m, 
3 H, ArH), 7.26 (d, J = 8.8 Hz, 2 H, ArH), 6.87 (d, J = 8.8 Hz, 2 
H, ArH), 4.61 (dd, J = 10.4, 2.4 Hz, 1 H, SCHCHH), 4.42-4.49 
(m, 1 H, SCHCHH), 4.29-4.36 (m, 2 H, SCH and NCH), 3.97 (d, J 
= 14.2 Hz, 1 H, NCHHAr), 3.82 (d, J = 14.2 Hz, 1 H, NCHHAr), 
3.78 (s, 3 H, CH3), 3.64 (s, 3 H, CH3). 
13
C NMR (75 MHz, CDCl3)  160.1 (s), 159.1 (s), 136.2 (s), 130.2 (d), 129.1 
(d), 128.5 (s), 114.5 (d), 113.7 (d), 73.6 (d), 71.4 (d), 66.9 (t), 58.8 
(t), 55.2 (q), 54.4 (q). 
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IR (neat) 3007 (w), 2837 (w), 1612 (s), 1513 (s, C=C), 1238 (s), 1031 (s) 
cm
-1
. 
 
2-(4-Methoxybenzyl)-3- phenyl isoxazolidine-4-sulfonic acid pentafluoro 
phenyl ester [119b] 
PFPO
S
N
O
O O
PMB
 
To ethenesulfonic acid pentafluorophenyl ester 85 (230 mg, 0.83 mmol) in dry 
toluene (5 mL) was added N-(4-methoxybenzyl)-N-phenylmethylidene amine oxide 
118c (200 mg, 0.83 mmol) and the mixture was stirred at reflux for 3 hours. The 
reaction was concentrated in vacuo, and the crude residue was purified by flash 
chromatography (10-100% Et2O in petroleum ether 40-60 °C) to give the title 
compound 119b as a white solid (310 mg, 0.61 mmol, 72%). 
MP 88-92
 
°C. 
1
H NMR (300 MHz, CDCl3)  7.52-7.56 (m, 2 H, ArH), 7.36-7.45 (m, 3 H, 
ArH), 7.23 (d, J = 8.6 Hz, 2 H, ArH), 6.84 (d, J = 8.6 Hz, 2 H, 
ArH), 4.61 (dd, J = 10.4, 2.4 Hz, 1 H, SCHCHH), 4.42-4.49 (m, 1 
H, SCHCHH), 4.29-4.36 (m, 2 H, SCH and NCH), 3.97 (d, J = 
14.2 Hz, 1 H, NCHHAr), 3.82 (d, J = 14.2 Hz, 1 H, NCHHAr), 
3.78 (s, 3 H, OCH3). 
13
C NMR (75 MHz, CDCl3)  159.1 (s), 136.2 (s), 130.2 (d), 129.1 (d), 
128.5 (s), 128.1 (d), 113.7 (d), 73.6 (d), 71.4 (d), 66.9 (t), 58.8 (t), 
55.2 (q). 
IR (neat) 2957 (w), 1513 (s, C=C), 1468 (w), 1249 (s), 1020 (s) cm
-1
. 
LRMS (FAB) 516 [(M+H)
+
, 10%], 154 [100]. 
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HRMS (FAB) calcd for C23H19F5NO5S (M+H)
+
 516.0904, found 516.0900. 
  
2-(4-Methoxybenzyl)-3-(4-methoxyphenyl)-isoxazolidine-4-sulfonic acid 
2,4,6-trichlorophenyl ester [120a] 
TCPO
S
N
O
O O
PMB
MeO  
To ethenesulfonic acid 2,4,6-trichlorophenyl ester 95 (200 mg, 0.70 mmol) in dry 
toluene (5 mL) was added N-(4-methoxybenzyl)-N-(4-methoxyphenyl) methylidene 
amine oxide 118a (190 mg, 0.70 mmol) and DABCO (8.0 mg, 0.07 mmol) and the 
mixture was stirred at reflux for 3 hours. The reaction was concentrated in vacuo, 
and the crude residue was purified by flash chromatography (10-100% Et2O in 
petroleum ether 40-60 °C) to give the title compound as a white solid (230 mg, 0.42 
mmol, 60%). 
MP 59-60 °C. 
1
H NMR (300 MHz, CDCl3)  7.56 (d, J = 9.3Hz, 2 H, ArH), 7.36 (s, 2 H, 
ArH), 7.23 (d, J = 9.1 Hz, 2 H, ArH), 6.94 (d, J = 8.97 Hz, 2 H, 
ArH), 6.82 (d, J = 8.77, 2 H, ArH), 4.61 (m, 1 H, SCHCHH), 
4.42-4.49 (m, 2 H, SCHCHH), 4.29-4.36 (m, 1 H, SCHCH), 3.97 
(d, J = 13.8 Hz, 1 H, NCHHAr), 3.82 (d, J = 13.8 Hz, 1 H, 
NCHHAr), 3.78 (s, 6 H, 2 x CH3). 
13
C NMR (75 MHz, CDCl3)  160.3 (s), 159.3 (s), 141.2 (s), 136.6 (s), 129.1 
(d), 128.8 (d), 123.8 (s), 114.2 (d), 113.7 (d), 73.6 (d), 71.4 (d), 
66.9 (t), 56.9 (t), 55.2 (q), 55.1 (q). 
IR (neat) 2930 (w), 2836 (w), 1737 (w), 1611 (m), 1561 (m), 1511 (s, C=C), 
1440 (s, C=C), 1383 (s, S=O). 
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LRMS (EI) 559 [M
+.
, 
37
Cl, 89%], 557 [M
+.
, 
35
Cl 87%]. 
HRMS (EI) calcd for C24H21Cl3NO3S (M
+
) 557.01784, found 557.01877. 
 
2-(4-Methoxybenzyl)-3-phenyl-isoxazolidine-4-sulfonic acid 2,4,6-
trichlorophenyl ester [120b] 
TCPO
S
N
O
O O
PMB
 
To ethenesulfonic acid 2,4,6-trichlorophenyl ester 95 (200 mg, 0.70 mmol) in dry 
toluene (5 mL) was added N-(4-methoxybenzyl)-N-phenylmethylidene amine oxide 
118c (170 mg, 0.70 mmol) and DABCO (8.0 mg, 0.07 mmol) and the mixture was 
stirred at reflux for 3 hours. The reaction was concentrated in vacuo, and the crude 
residue was purified by flash chromatography (10-100% Et2O in petroleum ether 40-
60 °C) to give the title compound 120b as a white solid (270 mg, 0.51 mmol, 75%). 
MP 50-51
 
°C; 
1
H NMR (300 MHz, CDCl3)  7.53 (d, J = 8.3 Hz, 2 H, ArH), 7.34 (s, 2 H, 
ArH), 7.41-7.32 (m, 3 H, ArH), 7.24 (d, J = 9.1 Hz, 2 H, ArH),  
6.89 (d, J = 8.8 Hz, 2 H, ArH), 4.61 (d, J = 6.7 Hz, 1 H, SCH), 
4.44-4.55 (m, 2 H, SCHCHH), 4.39 (d, J = 6.7 Hz, 1 H, NCH), 
3.91 (d, J = 13.6 Hz, 1 H, NCHHAr), 3.82 (d, J = 13.6 Hz, 1 H, 
NCHHAr), 3.78 (s, 3 H, OCH3). 
13
C NMR (75 MHz, CDCl3)  159.1 (s), 141.7 (s), 136.7 (s), 133.2 (s), 130.5 
(d), 130.2 (d), 129.2 (d), 129.1 (d), 128.8 (d), 128.2 (d), 123.8 (s), 
113.8 (d) 74.7 (d), 71.7 (d), 67.3 (t), 58.9 (t), 55.3 (q). (1 x s not 
observed). 
IR (neat) 2253 (w), 1613 (m), 1561 (m), 1513 (s, C=C), 1441 (s, C=C), 
90 
 
1386 (s, S=O) cm
-1
. 
LRMS (EI) 529 [M
+.
, 
37
Cl, 5%], 527 [M
+.
, 
35
Cl, 3%], 121 [100]. 
HRMS (EI) calcd for C23H20Cl3NO5S (M
+
) 527.01223, found 527.01168. 
 
3-(2-Chlorophenyl)-2-(4-methoxybenzyl)-isoxazolidine-4-sulfonic acid 
2,4,6-trichlorophenyl ester [120c] 
TCPO
S
N
O
O O
PMB
Cl  
To ethenesulfonic acid 2,4,6-trichlorophenyl ester 95 (200 mg, 0.70 mmol) in dry 
toluene (5 mL) was added N-(2-chlorophenyl) methylidene-N-(4-
methoxybenzyl)amine oxide 118b (190 mg, 0.70 mmol) and DABCO (8.0 mg, 0.07 
mmol) and the mixture was stirred at reflux for 3 hours. The reaction was 
concentrated in vacuo, and the crude residue was purified by flash chromatography 
(10-100% Et2O in petroleum ether 40-60 °C) to give the title compound 120c as a 
white waxy solid (190 mg, 0.34 mmol, 49%). 
1
H NMR (300 MHz, CDCl3)  7.53 (d, J = 7.5 Hz, 2 H, ArH), 7.41-7.19 (m, 
6 H, ArH), 6.89 (d, J = 8.6 Hz, 2 H, ArH),  4.98 (d, J = 6.96 Hz, 1 
H, SCHCHH), 4.73-4.49 (m, 3 H, SCHCHCHH), 3.91 (d, J = 13.6 
Hz, 1 H, NCHHAr), 3.82 (d, J = 13.6 Hz, 1 H, NCHHAr), 3.78 (s, 
3 H, OCH3). 
13
C NMR (125 MHz, CDCl3)  159.1 (s), 141.8 (s), 134.7 (s), 133.9 (s), 
133.2 (s), 130.5 (s), 130.4 (d), 130.1 (d), 130.0 (d), 129.2 (d), 
128.7 (d),127.5 (d), 113.8 (d), 73.9 (d), 67.6 (t), 59.1 (t), 55.3 (d), 
31.0 (q). 
IR (neat) 2930 (w), 2836 (w), 1737 (w), 1611 (m), 1561 (m), 1511 (s, C=C), 
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1440 (s, C=C), 1383 (s, S=O). 
LRMS (EI) 563 [M
+.
, 
37
Cl, 5%], 561 [M
+.
, 
35
Cl, 3%]. 
HRMS (EI) calcd for C23H19Cl4NO5S (M
+
) 560.97326, found 560.97326. 
 
1-Bromo-ethenesulfonic acid 2,4,6-trichlorophenyl ester [135] 
TCPO
S
O O
Br  
Bromine (4.5 mL, 87.5 mmol) in CHCl3 (30 mL) was added dropwise to a stirring 
suspension of TCP vinyl sulfonate 95 (12.0 g, 43.8 mmol) and AIBN (0.5 g) in 
CHCl3 (150 mL). After addition, AIBN was added (0.50 g) and the reaction mixture 
stirred at reflux for 4 hours, followed by 40 hours at 20 °C. The solvent was removed 
in vacuo and the crude oil remaining re-suspended in CH2Cl2 (100 mL). To this 
stirring solution was added NEt3 (9.2 mL, 65.7 mmol) and the reaction stirred at 20 
°C for 3 hrs. The reaction mixture was washed with 2M hydrochloric acid (100 mL), 
the organic layer dried (MgSO4), filtered and concentrated in vacuo. The crude 
residue was purified by flash chromatography (10-100% Et2O in petroleum ether 40-
60 °C) to give the title compound 135 as a white solid (14.0 g, 38.2 mmol, 87%).  
MP 54 -56 °C 
1
H NMR (400 MHz, CDCl3) δ 7.41 (2 H, s, ArH), 7.02 (1 H, d, J = 3.5 Hz, 
CHH), 6.44 (1 H, d, J = 3.5 Hz, CHH). 
13
C NMR (125 MHz, CDCl3) δ 147.1 (s), 133.5 (s), 131.4 (t), 130.8 (s), 
129.5 (d), 121.7 (s). 
IR (neat) 3114 (w), 3081 (w), 3029 (w), 1561 (s, C=C), 1439 (s, C=C), 
1390 (s, S=O) cm
-1
. 
LRMS (EI) 371 [M
+.
, 
81
Br, 
37
Cl, 5%], 369 [M
+.
, 
79
Br, 
37
Cl, 25%], 367 [M
+.
, 
81
Br, 
35
Cl, 45%], 365 [M
+.
, 
79
Br, 
35
Cl, 15%], 195 [100], 167 [40], 
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117 [90]. 
HRMS (EI) calcd for C8H4Cl3O3S
79
Br (M
+.
) 364.81246, found 364.81281. 
 
1-Bromo-ethenesulfonic acid pentafluorophenyl ester [126] 
PFPO
S
O O
Br  
Bromine (5.6 mL, 0.11 mol) in CHCl3 (50 mL) was added dropwise to a stirring 
suspension of ethenesulfonic acid pentafluorophenyl ester 85 (16.0 g, 0.055 mol) and 
AIBN (1.30 g) in CHCl3 (150 mL). After addition, another equivalent of AIBN was 
added (1.30 g) and the reaction mixture stirred at reflux for 4 hours, followed by 40 
hours at 20 °C. The solvent was removed in vacuo and the crude oil remaining re-
suspended in toluene (150 mL). To this stirring solution was added NEt3 (7.7 mL, 
0.055 mol) and the reaction stirred at 20 °C for 3 hrs. The reaction mixture was 
washed with 2M HCl (2 x 50 mL), the organic layer dried (MgSO4), filtered and 
concentrated in vacuo. The crude residue was purified by flash chromatography (10-
100% Et2O in petroleum ether 40-60 °C) to give the title compound 126 as yellow oil 
(15.0 g, 0.043 mol, 77%); 
1
H NMR (300 MHz, CDCl3) δ 7.05 (d, J = 3.5 Hz, 1 H, SCCHH), 6.54 (d, J 
= 3.5 Hz, 1 H, SCCHH). 
13
C NMR (75 MHz, CDCl3) δ 133. 8 (t), 122.0 (s). 
IR (neat) 3025 (w), 1555 (s, C=C), 1430 (s, C=C), 1391 (s, S=O) cm
-1
 
LRMS (EI) 354 [M
+.
, 
81
Br, 10%], 352 [M
+.
, 
79
Br, 8%], 184 [100], 155 [47], 
117, [53], [69 [37]. 
HRMS (EI) calcd for C8H2
79
BrF5O3S (M
+
) 351.8823, found 351.8827. 
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4-Bromo-2-(4-methoxybenzyl)-3-(4-methoxyphenyl)isoxazolidine-4-
sulfonic acid 2,4,6-trichlorophenyl ester [138b] 
TCPO
S
N
O
O O
PMB
MeO
Br
 
1-Bromoethenesulfonic acid 2,4,6-trichlorophenyl ester 135 (200 mg, 0.55 mmol) 
and DABCO (6.2 mg, 0.055 mmol) was dissolved in PhMe (5 mL) and stirred at 20 
°C for 5 mins, then treated with N-(4-methoxybenzyl)-N-(4-methoxyphenyl) 
methylidene amine oxide 118a (180 mg, 0.66 mmol). The resulting suspension was 
stirred at reflux for 2.5 hours. Solvent was removed in vacuo and the crude residue 
purified by flash chromatography (10-100% Et2O /petroleum ether 40-60 °C) to give 
the title compound 138b as a white solid and a single diastereoisomer (250 mg, 0.39 
mmol, 71%):  
MP 54.0 – 55.0 °C. 
1
H NMR (300 MHz, CDCl3) δ 7.50 (2 H, d, J = 9.1 Hz, ArH), 7.43 (2 H, s, 
ArH), 7.24 (2 H, d, J = 9.1 Hz, ArH), 6.96 (2 H, d, J = 8.8 Hz, 
ArH), 6.85 (2 H, d, J = 8.8 Hz, ArH), 5.25 (1 H, d, J = 10.7 Hz, 
OCHH), 4.73 (1 H, s, NCH), 4.56 (1 H, d, J = 10.7 Hz, OCHH), 
4.09 (1 H, d, J = 14.5 Hz, NCHHAr), 3.84 (3 H, s, OCH3), 3.78 (3 
H, s, OCH3), 3.77 (1 H, d, J = 14.5 Hz, NCHHAr). 
13
C NMR (125 MHz, CDCl3)  160.4 (s), 159.2 (s), 140.1 (s), 133.8 (s), 
131.3 (s), 130.4 (d), 129.7 (d), 128.8 (d), 128.1 (s), 126.0 (s), 
114.2 (d), 113.8 (d), 83.5 (s), 80.5 (t), 74.6 (d), 58.9 (t), 55.3 (q). 
IR (neat) 3071 (w), 2935 (w), 1737 (w), 1612 (m), 1512 (s, C=C), 1438 (m), 
1381 (s, S=O). 
LRMS (CI) 640 [(M+H)
+
, 
81
Br, 
37
Cl, 5%], 638 [(M+H)
+
, 
81
Br, 
35
Cl, 15%], 636 
[(M+H)
+
, 
79
Br, 
37
Cl, 34%], 634 [(M+H)
+
, 
79
Br, 
35
Cl, 25%].  
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HRMS (CI) calcd for C24H21
79
BrCl3NO6S (M+H)
+
 635.93385, found 
635.93379. 
4-Bromo-2-(4-methoxybenzyl)-3-phenyl-isoxazolidine-4-sulfonic acid 
2,4,6-trichlorophenyl ester [138a] 
TCPO
S
N
O
O O
PMB
Br
 
1-Bromoethenesulfonic acid 2,4,6-trichlorophenyl ester 135 (0.50 g, 1.36 mmol) and 
DABCO (15.0 mg, 0.136 mmol) was dissolved in PhMe (10 mL) and stirred at 20 °C 
for 5 mins, then treated with N-(4-methoxybenzyl)-N-phenylmethylidene amine 
oxide 118c (492 mg, 2.04 mmol). The resulting suspension was stirred at reflux for 3 
hours. Solvent was removed in vacuo and the crude residue purified by flash 
chromatography (10-100% Et2O in petroleum ether 40-60 °C) to give the title 
compound 138a as a white waxy solid as an inseparable 3:1 mixture of 
diastereoisomers (0.67 g, 1.10 mmol, 81%);  
1
H NMR (400 MHz, CDCl3) δ  7.66 – 7.52 (m, 2 H, ArH), 7.49 – 7.40 (m, 5 
H, ArH), 7.28 – 7.23 (m, 2 H, ArH), 6.97 – 6.88 (m, 2 H, ArH, 
minor), 6.88 – 6.82 (m, 2 H, ArH, major), 5.28 (d, J = 11.0 Hz, 1 
H, OCHH), 4.80 (s, 1 H, NCH, major),  4.73 (s, 1 H, NCH, 
minor), 4.68 (d, J = 11.0 Hz, 1 H, OCHH, minor), 4.58 (d, J = 
11.0 Hz, 1 H, OCHH, major), 4.16 (d, J = 14.4 Hz, 1 H, 
NCHHAr, minor), 4.12 (d, J = 14.3 Hz, 1 H, NCHHAr, major), 
3.94 (s, 3 H, OCH3, minor), 3.80 (s, 3 H, OCH3, major), 3.72 (d, J 
= 14.4 Hz, 1 H, NCHHAr). 
13
C NMR (125 MHz, CDCl3) δ 160.3 (s), 159.2 (s), 133.8 (s), 130.3 (s), 
129.6 (d), 129.2 (s), 128.8 (d), 128.6 (d), 125.8 (d), 123.8 (s), 
113.7 (d), 82.9 (s), 78.0 (t), 74.5 (d), 58.9 (t), 55.2 (q). 
IR (neat) 2930 (w), 1612 (m), 1560 (m), 1513 (s, C=C), 1437 (s, C=C), 
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1378 (s, S=O) cm
-1
. 
LRMS (EI) 611 [(M
+.
, 
81
Br, 
37
Cl, 7%], 609 [(M
+.
, 
81
Br, 
35
Cl, 18%], 607 [(M
+.
, 
79
Br, 
37
Cl, 25%], 605 [(M
+.
, 
79
Br, 
35
Cl, 15%]. 
HRMS (EI) calcd for C23H19
79
BrCl3NO5S (M
+.
) 604.91778, found 604.91586. 
Microanalysis Calcd C, 45.46, H, 3.15, N, 2.30; found C, 45.20, H, 3.21, N, 2.24.   
 
4-Bromo-2-(4-methoxybenzyl)-3-naphthalen-2-yl-isoxazolidine-4-sulfonic 
acid 2,4,6-trichlorophenyl ester [138d] 
TCPO
S
N
O
O O
PMB
Br
 
1-Bromoethenesulfonic acid 2,4,6-trichlorophenyl ester 135 (0.50 g, 1.36 mmol) and 
DABCO (15.0 mg, 0.136 mmol) was dissolved in PhMe (5 mL) and stirred at 20 °C 
for 5 mins, then treated with N-(4-methoxybenzyl)-N-naphthalen-2-ylmethylidene 
amine oxide 118e (475 mg). The resulting suspension was stirred at reflux for 2 
hours. Solvent was removed in vacuo and the crude residue purified by flash 
chromatography (10-100% Et2O in petroleum ether 40-60 °C) to give the title 
compound 138d a clear syrup as inseparable 4:1 mixture of diastereoisomers (421 
mg, 0.73 mmol, 54%);  
1
H NMR (500 MHz, CDCl3) δ 8.06 (s, 1 H, ArH), 7.89 – 7.82 (m, 4 H, 
ArH, major), 7.83 – 7.81 (m, 2 H, ArH, minor), 7.71 (br s, 2 H, 
ArH, minor), 7.54 – 7.51 (m, 2 H, ArH, major), 7.50 – 7.45 (m, 2 
H, ArH, minor), 7.27 – 7.21 (m, 4 H, ArH), 6.89 (d, J = 8.6 Hz, 2 
H, ArH, minor), 6.84 (d, J = 8.6 Hz, 2 H, ArH, major), 5.31 (d, J = 
11.1 Hz, 1 H, CHHO, minor), 5.30 (d, J = 11.1, 1 H, CHHO, 
major), 4.95 (s, 1 H, CH, major), 4.87 (s, 1 H, CH, minor), 4.71 
(d, J = 11.1 Hz, 1 H, CHHO, minor), 4.63 (d, J = 11.1 Hz, 1 H, 
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CHHO, major), 4.13 (d, J = 14.3 Hz, 1 H, NCHH), 3.86 (d, J = 
14.3 Hz, 1 H, NCHH), 3.81 (s, 3 H, CH3, minor), 3.78 (s, 3 H, 
CH3, major). 
13
C NMR (125 MHz, CDCl3) δ 159.3 (s), 140.2 (s), 133.9 (s), 133.0 (s), 
131.8 (s), 131.0 (s), 130.5 (d), 129.7 (d), 129.5 (d), 128.5 (d), 
128.1 (d), 128.0 (s), 127.9 (s), 127.8 (d), 126.9 (d), 126.5 (d), 
113.8 (d), 82.9 (s), 78.1 (t), 75.0 (d), 59.1 (t), 55.3 (q). 
IR (neat) 2919 (m), 1610 (m), 1555 (m), 1437 (s, C=C), 1378 (s, S=O) cm
-1
. 
LRMS (CI) 659 [(M+H)
+
, 
81
Br, 
37
Cl, 1%], 657 [(M+H)
+
, 
81
Br, 
35
Cl, 3%], 655 
[(M+H)
+
, 
79
Br, 
37
Cl, 5%], 653 [(M+H)
+
, 
79
Br, 
35
Cl, 3%], 583 [10], 
412 [45], 367 [60], 292 [100], 195 [15]. 
HRMS (CI) calcd for C27H21
79
BrCl3NO5S (M+H)
+
 654.94676, found 
654.94692. 
 
4-Bromo-3-(4-chlorophenyl)-2-(4-methoxybenzyl)isoxazolidine-4-sulfonic 
acid 2,4,6-trichloro-phenyl ester [138e] 
TCPO
S
N
O
O O
PMB
Br
Cl  
1-Bromoethenesulfonic acid 2,4,6-trichlorophenyl ester 135 (0.50 g, 1.36 mmol) and 
DABCO (15.0 mg, 0.136 mmol) was dissolved in PhMe (20 mL) and stirred at 20 °C 
for 5 mins, then treated with N-(4-chlorophenyl) methylidene-N-(4-
methoxybenzyl)amine oxide
81
 (0.56 g, 2.04 mmol). The resulting suspension was 
stirred at reflux for 4 hours. Solvent was removed in vacuo and the crude residue 
purified by flash chromatography (10-100% Et2O in petroleum ether 40-60 °C) to 
give the title compound 138e a white solid as a single distereoisomer (440 mg, 0.69 
mmol, 52%). 
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MP 146 – 148 °C 
1
H NMR (500 MHz, CDCl3) δ 7.52 (2 H, d, J = 8.7 Hz, ArH), 7.43 (2 H, s, 
ArH), 7.41 (2 H, d, J = 8.8 Hz, ArH), 7.23 (2 H, d, J = 8.8 Hz, 
ArH), 6.84 (2 H, d, J = 8.7 Hz, ArH), 5.25 (1 H, d, J = 11.0 Hz, 
SCBrCHH), 4.75 (1 H, s, SCBrCHN), 4.55 (1 H, d, J = 11.0 Hz, 
SCBrCHH), 4.08 (1 H, d, J = 14.5 Hz, NCHHAr), 3.81 (1 H, d, J 
= 14.5 Hz, NCHHAr), 3.78 (3 H, s, CH3). 
13
C NMR (125 MHz, CDCl3) δ 159.3 (s), 147.0 (s), 140.0 (s), 139.9 (s), 
135.5 (s), 133.9 (s), 132.8 (s), 131.0 (d), 130.4 (d), 129.7 (d), 
113.8 (d), 83.6 (s), 80.1 (t), 74.2 (d), 59.0 (t), 55.4 (q). 
IR (neat) 2852 (br, CH), 1562 (s, C=C), 1456 (s, C=C), 1377 (s, S=O) cm
-1
. 
LRMS (EI) 645 [(M
+.
, 
81
Br, 
37
Cl, 
37
Cl, 1%], 643 [(M
+.
, 
81
Br, 
37
Cl, 
35
Cl, 2%], 
641 [(M
+.
, 
79
Br, 
37
Cl, 
35
Cl, 5%], 639 [(M
+.
, 
79
Br, 
35
Cl, 
35
Cl, 5%], 
366 [55], 195 [100]. 
HRMS (EI) calcd for C23H18
79
BrCl4NO5S (M
+.
) 638.88377, found 638.88529. 
 
4-Bromo-3-(4-methoxyphenyl)-2-methyl-isoxazolidine-4-sulfonic acid 
2,4,6-trichlorophenyl ester [136b] 
S
O O
N
O
Me
TCPO
Br
MeO  
1-Bromo-ethenesulfonic acid 2,4,6-trichloro-phenyl ester 135 (0.50 g, 1.36 mmol) 
was dissolved in PhMe (5 mL) and treated with N-(4-methoxyphenyl) methylidene-
N-methylamine oxide 114b (270 mg, 1.63 mmol). The resulting suspension was 
stirred at reflux for 30 mins. Solvent was removed in vacuo and the crude residue 
purified by flash chromatography (10-100% Et2O in petroleum ether 40-60 °C) to 
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give the title compound 136b a white solid as a single diastereoisomer (0.50 g, 0.94 
mmol, 70%). 
MP 75 – 76 °C. 
1
H NMR (500 MHz, CDCl3) δ 7.45 – 7.38 (m, 4 H, ArH), 6.93 (d, J = 8.8 
Hz, 2 H, ArH), 5.27 (d, J = 11.0 Hz, 1 H, OCHH), 4.60 (d, J = 
11.0 Hz, 1 H, OCHH), 4.48 (s, 1 H, NCH), 3.82 (s, 3 H, CH3), 
2.76 (s, 3 H, CH3). 
13
C NMR (125 MHz, CDCl3) δ 160.4 (s), 140.2 (s), 133.8 (s), 131.2 (d), 
129.7 (d), 129.2 (s), 125.8 (s), 113.7 (d), 83.8 (s), 78.1 (t), 77.4 
(d), 55.3 (q), 43.2 (q). 
IR (neat) 1611 (s, C=C), 1558 (s), 1512 (s), 1433 (s), 1383 (s, S=O), 1250 
(s) cm
-1
. 
LRMS (EI) 535 [(M
+.
, 
81
Br, 
37
Cl, 1%], 533 [(M
+.
, 
81
Br, 
35
Cl, 2%], 531 [(M
+.
, 
79
Br, 
37
Cl, 5%], 529 [(M
+.
, 
79
Br, 
35
Cl, 3%], 366 [15], 195 [20], 164 
[100]. 
HRMS (EI) calcd for C17H15
79
BrCl3NO5S (M
+.
) 528.89144, found 528.89153. 
 
4-Bromo-2-methyl-3-phenylisoxazolidine-4-sulfonic acid 2,4,6-
trichlorophenyl ester [136a] 
TCPO
S
N
O
O O
Me
Br
 
1-Bromoethenesulfonic acid 2,4,6-trichlorophenyl ester 135 (0.50 g, 1.36 mmol) was 
dissolved in PhMe (5 mL) and treated with N-methyl-N-phenylmethylidene amine 
oxide 114a (220 mg, 1.63 mmol). The resulting suspension was stirred at reflux for 
30 mins. Solvent was removed in vacuo and the crude residue purified by flash 
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chromatography (10-100% Et2O in petroleum ether 40-60 °C) to give the title 
compound 136a a white solid as a single distereoisomer (0.53 g, 1.06 mmol, 78%).  
MP 79.8 – 80.0 °C. 
1
H NMR (500 MHz, CDCl3) δ 7.57 – 7.54 (m, 7 H, ArH), 5.12 (d, J = 11.1 
Hz, 1 H, OCHH), 4.64 (d, J = 11.1 Hz, 1 H, OCHH), 4.41 (s, 1 H, 
NCHAr), 2.78 (s, 3 H, NCH3). 
13
C NMR (125 MHz, CDCl3) δ 140.2 (s), 134.0 (s), 131.1 (s), 130.0 (d), 
129.6 (d), 129.5 (d), 128.4 (d), 123.8 (s), 83.5 (s), 78.1 (t), 77.7 
(d), 43.2 (q). 
IR (neat) 3077 (w), 1561 (s, C=C), 1438 (s, C=C), 1380 (s, S=O), 1223 (s), 
1193 (s), 1057 (s) cm
-1
. 
LRMS (EI) 500 [M
+.
, 15%], 504 [(M
+.
, 
81
Br, 
37
Cl, 5%], 502 [(M
+.
, 
81
Br, 
35
Cl, 
10%], 500 [(M
+.
, 
79
Br, 
37
Cl, 15%], 498 [(M
+.
, 
79
Br, 
35
Cl, 12%], 366 
[15], 195 [40]. 
HRMS (EI) calcd for C16H13NO4SCl3
79
Br (M
+.
) 498.88088, found 498.88059.  
 
4-Bromo-3-(4-chlorophenyl)-2-methylisoxazolidine-4-sulfonic acid 2,4,6-
trichlorophenyl ester [136c] 
TCPO
S
N
O
O O
Me
Br
Cl  
1-Bromoethenesulfonic acid 2,4,6-trichlorophenyl ester 135 (0.50 g, 1.36 mmol) was 
dissolved in PhMe (5 mL) and treated with N-(4-chlorophenyl) methylidene-N-
methylamine oxide
81
 (280 mg, 1.63 mmol). The resulting suspension was stirred at 
reflux for 30 mins. Solvent was removed in vacuo and the crude residue purified by 
flash chromatography (10-100% Et2O in petroleum ether 40-60 °C) to give the title 
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compound 136c a white waxy solid as a single distereoisomer (150 mg, 0.28 mmol, 
21%);  
 
1
H NMR (500 MHz, CDCl3) δ 7.51 – 7.41 (m, 6 H, ArH), 5.28 (d, J = 10.9 
Hz, 1 H, OCHH), 4.59 (d, J = 11.0 Hz, 1 H, OCHH), 4.51 (s, 1 H, 
NCHAr), 2.77 (s, 3 H, NCH3). 
13
C NMR (125 MHz, CDCl3) δ 140.1 (s), 135.5 (s), 134.0 (s), 132.5 (s), 
131.2 (d), 129.8 (d), 128.7 (d), 123.6 (s), 83.0 (s), 78.2 (t), 77.1 
(d), 43.2 (q). 
IR (neat) 3080 (w), 2878 (w), 1561 (s, C=C), 1492 (s), 1379 (s, S=O), 1222 
(s), 1193 (s), 1057 (s) cm
-1
. 
LRMS (EI) 537 [(M
+.
, 
81
Br, 
37
Cl, 
37
Cl, 3%], 535 [(M
+.
, 
81
Br, 
37
Cl, 
35
Cl, 7%], 
533 [(M
+.
, 
79
Br, 
37
Cl, 
35
Cl, 20%], 531 [(M
+.
, 
79
Br, 
35
Cl, 
35
Cl, 15%], 
366 [20], 196 [78]. 
HRMS (EI) calcd for C16H12NO4SCl4
79
Br (M
+.
) 532.84190, found 532.83911. 
 
4-Bromo-2-(4-methoxybenzyl)-3-phenylisoxazolidine-4-sulfonic acid 
pentafluorophenyl ester [139a] 
PFPO
S
N
O
O O
PMB
Br
 
1-Bromoethenesulfonic acid pentafluorophenyl ester 126 (0.50 g, 1.42 mmol) and 
DABCO (16.0 mg, 0.142 mmol) was dissolved in PhMe (5 mL) and treated with N-
(4-methoxybenzyl)-N-phenylmethylidene amine oxide 118c (410 mg, 1.70 mmol). 
The resulting suspension was stirred at reflux for 1 hour. Solvent was removed in 
vacuo and the crude residue purified by flash chromatography (10-100% Et2O in 
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petroleum ether 40-60 °C) to give the title compound 139a as yellow oil and an in 
separable 3:1 mixture of diastereoisomers (0.55 g, 0.92 mmol, 65%):  
1
H NMR (500 MHz, CDCl3) δ 7.53 – 7.50 (m, 3 H, ArH), 7.48 – 7.39 (m, 3 
H, ArH), 7.27 – 7.23 (m, 2 H, ArH), 6.89 (d, J = 8.7 Hz, 2 H, 
ArH, minor), 6.82 (d, J = 8.8 Hz, 2 H, ArH, major), 5.08 (d, J = 
11.1 Hz, 1 H, OCHH, minor), 5.06 (d, J = 11.1 Hz, 1 H, OCHH, 
major), 4.67 (s, 1 H, NCHAr, minor), 4.65 (s, 1 H, NCHAr, 
major), 4.60 (d, J = 11.0, 1 H, OCHH, minor), 4.57 (d, J = 11.2, 1 
H, OCHH, major), 4.16 (d, J = 14.5 Hz, 1 H, NCHHAr, minor), 
4.10 (d, J = 14.3 Hz, 1 H, NCHHAr, major), 3.81 (s, 3 H, OCH3, 
minor), 3.79 (s, 3 H, OCH3, major), 3.71 (d, J = 14.5 Hz, 1 H, 
NCHHAr, minor). 
13
C NMR (125 MHz, CDCl3) δ 159.3 (s), 134.5 (s), 130.5 (s), 129.7 (d), 
128.6 (d), 125.8 (d), 113.9 (d), 83.1 (s), 77.9 (t), 74.9 (d), 59.0 (t), 
55.3 (q). 
IR (neat) 2943 (s, CH), 1611 (s), 1511 (s, C=C), 1393 (s, S=O), 1245 (s), 
1176 (s), 980 (s) cm
-1
. 
LRMS (FAB) 618 [(M+Na)
+
, 
81
Br, 11%], 616 [(M+Na)
+
, 
79
Br, 11%], 314 [26], 
176 [100]. 
HRMS (FAB) calcd for C23H17
79
BrF5NNaO5S (M+Na)
+
 615.9829, found 
615.9817. 
4-Bromo-2-(4-methoxybenzyl)-3-(4-methoxyphenyl)isoxazolidine-4-
sulfonic acid pentafluorophenyl ester [139b] 
S
O O
N
O
PMB
PFPO
Br
MeO  
1-Bromoethenesulfonic acid pentafluorophenyl ester 126 (0.50 g, 1.42 mmol) and 
DABCO (16.0 mg, 0.142 mmol) was dissolved in PhMe (5 mL) and treated with N-
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(4-methoxybenzyl)-N-(4-methoxyphenyl) methylidene amine oxide 118a (410 mg, 
1.70 mmol). The resulting suspension was stirred at reflux for 1 hour. Solvent was 
removed in vacuo and the crude residue purified by flash chromatography (starting 
9:1 petroleum ether 40-60 °C/Et2O) to give the title compound 139b a yellow oil as a 
single diastereoisomer (0.76 g, 1.22 mmol, 86%).  
1
H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 7.9 Hz, 2 H, ArH), 7.26 – 7.21 
(m, 2 H, ArH), 6.98 (d, J = 7.7 Hz, 2 H, ArH), 6.88 – 6.84 (m, 2 
H, ArH), 5.07 (d, J = 11.1 Hz, 1 H, OCHH), 4.61 (s, 1 H, NCH), 
4.57 (d, J = 11.2 Hz, 1 H, OCHH), 4.10 (d, J = 14.3 Hz, 1 H, 
NCHH), 3.86 (s, 3 H, CH3), 3.80 (s, 3 H, CH3), 3.76 (d, J = 14.3 
Hz, 1 H, NCHH).
 
13
C NMR (125 MHz, CDCl3) δ 160.5 (s), 159.3 (s), 131.3 (s), 130.5 (d), 
129.3 (d), 127.9 (s), 114.2 (d), 113.7 (d), 83.6 (s), 77.8 (t), 74.7 
(d), 58.9 (t), 55.2 (q). 
IR (neat) 2943 (s, CH), 1611 (s), 1511 (s, C=C), 1393 (s, S=O), 1245 (s), 
1176 (s), 980 (s) cm
-1
. 
LRMS (FAB) 649 [(M+Na)
+
, 
81
Br, 20%], 647 [(M+Na)
+
, 
79
Br, 18%], 329 [20], 
176 [100]. 
HRMS (FAB) calcd for C24H19NO6SF5
79
BrNa (M+Na)
+
 646.99343, found 
646.99188. 
 
4-Bromo-3-(4-bromophenyl)-2-(4-methoxybenzyl)isoxazolidine-4-sulfonic 
acid pentafluorophenyl ester [139c] 
PFPO
S
N
O
O O
PMB
Br
Br  
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1-Bromoethenesulfonic acid pentafluorophenyl ester 126 (0.50 g, 1.42 mmol) and 
DABCO (16.0 mg, 0.142 mmol) was dissolved in PhMe (5 mL) and treated with N-
(4-bromobenzyl)-N-(4-methoxyphenyl) methylidene amine oxide
81
 (0.54 g, 1.70 
mmol). The resulting suspension was stirred at reflux for 24 hours. Solvent was 
removed in vacuo and the crude residue purified by flash chromatography (10-100% 
Et2O in petroleum ether 40-60 °C) to give the title compound 139c a yellow oil as a 
single diastereoisomer (350 mg, 0.52 mmol, 37%):  
1
H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 8.7 Hz, 2 H, ArH), 7.44 (d, J = 
7.5 Hz, 2 H, ArH), 7.24 (d, J = 8.6 Hz, 2 H, ArH), 6.86 (d, J = 8.6 
Hz, 2 H, ArH), 5.10 (d, J = 11.2 Hz, 1 H, OCHH), 4.63 (s, 1 H, 
NCHAr), 4.57 (d, J = 11.2 Hz, 1 H, OCHH), 4.11 (d, J = 14.3 Hz, 
1 H, NCHHAr), 3.86 (d, J = 14.3, 1 H, NCHHAr), 3.81 (s, 3 H, 
OCH3). 
13
C NMR (125 MHz, CDCl3) δ 207.0 (s), 159.3 (s), 132.9 (s), 132.5 (d), 
130.9 (d), 129.1 (d), 127.3 (s), 123.9 (s), 113.7 (d), 82.7 (s), 77.8 
(d), 74.1 (t), 59.0 (d), 55.2 (q). 
IR (neat) 1611 (s), 1561 (s, C=C), 1386 (s, S=O), 1247 (s), 1191 (s), 998 (s) 
cm
-1
. 
LRMS (EI) 673  [M
+.
, 
81
Br, 
81
Br, 3%], 671 [M
+.
, 
81
Br, 
79
Br, 5%], 669 [M
+.
, 
79
Br, 
79
Br, 3%],  354 [54], 184 [70]. 
HRMS (EI) calcd for C23H16NO5SF5
79
Br2 (M
+.
) 670.90306, found 670.90470. 
 
4-Bromo-2-methyl-3-phenyl-isoxazolidine-4-sulfonic acid pentafluoro 
phenyl ester [137a] 
S
O O
N
O
Me
PFPO
Br
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1-Bromoethenesulfonic acid pentafluorophenyl ester 126 (0.50 g, 1.42 mmol) and 
DABCO (16.0 mg, 0.142 mmol) was dissolved in PhMe (5 mL) and treated with N-
methyl-N-phenylmethylidene amine oxide 114a (230 mg, 1.70 mmol). The resulting 
suspension was stirred at reflux for 2 hours. Solvent was removed in vacuo and the 
crude residue purified by flash chromatography (10-100% Et2O in petroleum ether 
40-60 °C) to give the title compound 137a a white solid as a single diastereoisomer 
(490 mg, 1.00 mmol, 71%):  
MP 88 – 90 °C 
1
H NMR (500 MHz, CDCl3) δ 7.57 – 7.54 (m, 5 H, ArH), 5.12 (d, J = 11.1 
Hz, 1 H, OCHH), 4.64 (d, J = 11.1 Hz, 1 H, OCHH), 4.41 (s, 1 H, 
NCHAr), 2.78 (s, 3 H, NCH3). 
13
C NMR (150 MHz, CDCl3) δ 137.1 (s), 130.0 (d), 129.6 (d), 83.5 (s), 78.1 
(t), 77.7 (d), 43.2 (q). 
IR (neat) 2878 (w), 1612 (s), 1561 (s, C=C), 1467 (s), 1384 (s, S=O), 1250 
(s), 1181 (s), 994 (s) cm
1
. 
LRMS (EI) 489 [M
+.
, 
81
Br, 20%], 487 [M
+.
, 
79
Br, 18%], 354 [5], 184 [55], 160 
[44], 134 [100]. 
HRMS (EI) calcd for C16H11NO4SF5
79
Br (M
+.
) 486.95068, found 486.94927. 
 
4-Bromo-3-(4-methoxyphenyl)-2-methylisoxazolidine-4-sulfonic acid 
pentafluorophenyl ester [137b] 
S
O O
N
O
Me
PFPO
Br
MeO  
1-Bromoethenesulfonic acid pentafluorophenyl ester 126 (0.50 g, 1.42 mmol) was 
dissolved in PhMe (5 mL) and treated with N-(4-methoxyphenyl) methylidene-N-
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methylamine oxide 114b (230 mg, 1.70 mmol). The resulting suspension was stirred 
at reflux for 30 mins. Solvent was removed in vacuo and the crude residue purified 
by flash chromatography (10-100% Et2O in petroleum ether 40-60 °C) to give the 
title compound 137b a colourless syrup as one single diastereoisomer (0.53 g, 1.02 
mmol, 72%).  
1
H NMR (500 MHz, CDCl3) δ 7.36 (d, J = 8.6 Hz, 2 H, ArH), 6.93 (d, J = 
8.9 Hz, 2 H, ArH), 5.10 (d, J = 11.1 Hz, 1 H, OCHH), 4.60 (d, J = 
11.1 Hz, 1 H, OCHH), 4.35 (s, 1 H, NCHAr), 3.83 (s, 3 H, CH3), 
2.75 (s, 3 H, CH3). 
13
C NMR (125 MHz, CDCl3) δ 160.5 (s), 131.1 (d), 125.3 (s), 113.8 (d), 
84.0 (s), 78.0 (t), 77.6 (d), 55.3 (q), 43.1 (q). 
IR (neat) 2878 (w), 1612 (s), 1561 (s, C=C), 1467 (s), 1384 (s, S=O), 1250 
(s), 1181 (s), 994 (s) cm
-1
. 
LRMS (EI) 519 [M
+.
, 
81
Br, 10%], 517 [M
+.
, 
79
Br, 8%], 354 [10], 184 [50], 165 
[100]. 
HRMS (EI) calcd for C17H13NO5SF5
79
Br (M
+.
) 516.96124, found 516.96194. 
 
4-Bromo-3-(4-bromophenyl)-2-methyl-isoxazolidine-4-sulfonic acid 
pentafluorophenyl ester [137d] 
S
O O
N
O
Me
PFPO
Br
Br  
1-Bromoethenesulfonic acid pentafluorophenyl ester 126 (0.50 g, 1.42 mmol) was 
dissolved in PhMe (5 mL) and treated with N-(4-bromophenyl) methylidene-N-
methylamine oxide
81
 (230 mg, 1.70 mmol). The resulting suspension was stirred at 
reflux for 30 mins. Solvent was removed in vacuo and the crude residue purified by 
flash chromatography (10-100% Et2O in petroleum ether 40-60 °C) to give the title 
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compound 137d a light yellow syrup as a single diastereoisomer (0.61 g, 1.08 mmol, 
76%):  
1
H NMR (500 MHz, CDCl3) δ 7.55 (d, J = 8.7 Hz, 2 H, ArH), 7.33 (d, J = 
8.7 Hz, 2 H, ArH), 5.09 (d, J = 11.1 Hz, 1 H, OCHH), 4.58 (d, J = 
11.1 Hz, 1 H, OCHH), 4.35 (s, 1 H, NCHAr), 2.76 (s, 3 H, CH3). 
13
C NMR (125 MHz, CDCl3) δ 132.6 (s), 131.8 (d), 131.4 (d), 124.0 (s), 
83.1 (s), 78.0 (t), 77.2 (d), 43.1 (q). 
IR (neat) 2880 (w), 1561 (s, C=C), 1472 (s), 1388 (s, S=O), 1194 (s), 994 
(s) cm
-1
. 
LRMS (EI) 567 [M
+.
, 
81
Br, 
81
Br, 63%], 565 [M
+.
, 
81
Br, 
79
Br, 65%], 563 [M
+.
, 
79
Br, 
79
Br, 63%],  240 [20], 213 [100], 165 [55]. 
HRMS (EI) calcd for C16H10NO4SF5
79
Br2 (M
+.
) 564.86120, found 564.86034. 
 
4-Bromo-3-(4-chlorophenyl)-2-methyl-isoxazolidine-4-sulfonic acid 
pentafluorophenyl ester [137c] 
S
O O
N
O
Me
PFPO
Br
Cl  
1-Bromoethenesulfonic acid pentafluorophenyl ester 126 (0.50 g, 1.42 mmol) was 
dissolved in PhMe (5 mL) and treated with N-(4-chlorophenyl) methylidene-N-
methylamine oxide
81
 (290 mg, 1.70 mmol). The resulting suspension was stirred at 
reflux for 30 mins. Solvent was removed in vacuo and the crude residue purified by 
flash chromatography (10-100% Et2O in petroleum ether 40-60 °C) to give the title 
compound 137c a light yellow syrup as a single diastereoisomer (0.61 g, 1.16 mmol, 
82%):  
1
H NMR (500 MHz, CDCl3) δ 7.39 (s, 4 H, ArH), 5.10 (d, J = 11.1 Hz, 1 H, 
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OCHH), 4.58 (d, J = 11.1 Hz, 1 H, OCHH), 4.37 (s, 1 H, NCHAr), 
2.76 (s, 3 H, CH3). 
13
C NMR (125 MHz, CDCl3) δ 135.7 (s), 132.1 (s), 131.2 (d), 128.8 (d), 
83.1 (s), 78.0 (t), 77.2 (d), 43.1 (q). 
IR (neat) 2933 (w), 1517 (s, C=C), 1493 (s, C=C), 1383 (s, S=O), 1192 (s), 
994 (s) cm
-1
. 
LRMS (EI) 523 [M
+.
, 15%], 525 [M
+.
, 
81
Br, 
37
Cl, 13%], 523 [M
+.
, 
79
Br, 
37
Br, 
15%], 521 [M
+.
, 
79
Br, 
35
Cl, 13%],  352 [5], 276 [3], 169 [100]. 
HRMS (EI) calcd for C16H10NO4SF5
79
BrCl (M
+.
) 520.91171, found 520.91295. 
 
4-Bromo-3-(5-bromofuran-2-yl)-2-methylisoxazolidine-4-sulfonic acid 
pentafluorophenylester [137e] 
S
O O
N
O
Me
PFPO
Br
O
Br  
1-Bromoethenesulfonic acid pentafluorophenyl ester 126 (0.50 g, 1.42 mmol) was 
dissolved in PhMe (5 mL) and treated with N-(5-bromofuran-2-yl) methylidene-N-
methylamine oxide
81
 (350 mg, 1.70 mmol). The resulting suspension was stirred at 
reflux for 30 mins. Solvent was removed in vacuo and the crude residue purified by 
flash chromatography (10-100% Et2O in petroleum ether 40-60 °C) to give the title 
compound 137e a light yellow syrup as a single diastereoisomer (350 mg, 0.63 
mmol, 45%):  
1
H NMR (400 MHz, CDCl3) δ 6.54 (d, J = 3.4 Hz, 1 H, BrCH), 6.40 (d, J = 
3.4 Hz, 1 H, CCH), 5.07 (d, J = 11.1 Hz, 1 H, OCHH), 4.59 (d, J = 
11.1 Hz, 1 H, OCHH), 4.56 (s, 1 H, NCH), 2.86 (s, 3 H, NCH3). 
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13
C NMR (125 MHz, CDCl3) δ 148.2 (s), 123.9 (s), 115.1 (d), 112.6 (d), 
81.2 (s), 77.8 (t), 72.9 (d), 43.5 (q). 
IR (neat) 2927 (w), 1684 (w), 1516 (s, C=C), 1473 (s, C=C), 1396 (s, S=O), 
1197 (s), 997 (s) cm
-1
. 
LRMS (EI) 557 [M
+.
, 
81
Br, 
81
Br, 13%], 555 [M
+.
, 
81
Br, 
79
Br, 15%], 553 [M
+.
, 
79
Br, 
79
Br, 13%],  205 [100]. 
HRMS (EI) calcd for C14H8NO5SF5
79
Br2 (M
+
) 554.84046, found 554.84020. 
 
4-Bromo-3-furan-2-yl-2-methyl-isoxazolidine-4-sulfonic acid 
pentafluorophenyl ester [137f] 
S
O O
N
O
Me
PFPO
Br
O  
1-Bromoethenesulfonic acid pentafluorophenyl ester 126 (0.50 g, 1.42 mmol) was 
dissolved in PhMe (5 mL) and treated with N-furan-2-ylmethylidene-N-methylamine 
oxide 114e (210 mg, 1.70 mmol). The resulting suspension was stirred at reflux for 
30 mins. Solvent was removed in vacuo and the crude residue purified by flash 
chromatography (10-100% Et2O in petroleum ether 40-60 °C) to give the title 
compound 137f a light yellow syrup as a single diastereoisomer (250 mg, 0.52 mmol, 
36%):  
1
H NMR (400 MHz, CDCl3) δ 7.52 (dd, J = 0.8, 1.8 Hz, 1 H, OCH), 6.56 
(d, J = 3.3 Hz, 1 H, CH), 6.46 (dd, J = 1.8, 3.3 Hz, 1 H, CCH), 
5.08 (m, 1 H, OCHH), 4.62 (m, 2 H, OCHH, NCH), 2.85 (s, 3 H, 
CH3). 
13
C NMR (125 MHz, CDCl3) δ 146.6 (s), 144.0 (d), 112.5 (d), 110.7 (d), 
81.7 (s), 77.9 (t), 73.1 (d), 43.5 (q). 
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IR (neat) 2976 (w), 1515 (s, C=C), 1473 (s, C=C), 1390 (s, S=O), 1197 (s), 
993 (s) cm
-1
. 
LRMS (CI) 480 [(M+H)
+
, 
81
Br, 7%], 478 [(M+H)
+.
, 
79
Br, 5%], 355 [35]. 
HRMS (CI) calcd for C14H10NO5SF5
79
Br (M+H)
+
 477.93832, found 
477.93608. 
 
4-Bromo-2-methyl-3-(4-nitrophenyl)-isoxazolidine-4-sulfonic acid 
pentafluorophenyl ester [137g] 
S
O O
N
O
Me
PFPO
Br
O2N  
1-Bromoethenesulfonic acid pentafluorophenyl ester 126 (0.50 g, 1.42 mmol) was 
dissolved in PhMe (5 mL) and treated with N-methyl-N-(4-nitrophenyl) methylidene 
amine oxide 114c (310 mg, 1.70 mmol). The resulting suspension was stirred at 
reflux for 30 mins. Solvent was removed in vacuo and the crude residue purified by 
flash chromatography (10-100% Et2O in petroleum ether 40-60 °C) to give the title 
compound 137g a light yellow syrup in an inseparable 7:1 mixture of 
diastereoisomers (350 mg, 0.66 mmol, 46%):  
1
H NMR (400 MHz, CDCl3) δ 8.28 (d, J = 8.7 Hz, 2 H, ArH, major), 8.24 
(d, J = 8.6 Hz, 2 H, ArH, minor), 7.77 (d, J = 8.6 Hz, 2 H, ArH, 
major), 7.68 (d, J = 8.7 Hz, 2 H, ArH, minor), 5.12 (d, J = 11.1 
Hz, 1 H, OCHH, major), 5.11 (d, J = 11.1 Hz, 1 H, OCHH, 
minor), 4.66 (d, J = 11.0 Hz, 1 H, OCHH, minor), 4.61 (d, J = 
11.2 Hz, 1 H, OCHH, major), 4.57 (s, 1 H, NCH, minor), 4.51 (s, 
1 H, NCH, major), 2.80 (s, 3 H, CH3, major), 2.77 (s, 3 H, CH3, 
minor). 
13
C NMR (125 MHz, CDCl3) δ 148.7 (s), 141.9 (s), 130.9 (d), 123.6 (d), 
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82.5 (s), 78.1 (t), 76.9 (d), 43.2 (q). 
IR (neat) 2254 (w), 1609 (w), 1519 (s, C=C), 1390 (s, NO2), 1350 (s, S=O), 
1196 (s), 999 (s) cm
-1
. 
LRMS (EI) 532 [M
+.
 15 %], 534 [M
+.
, 
81
Br, 13%], 532 [M
+.
, 
79
Br, 15%], 354 
[15], 184 [100]. 
HRMS (EI) calcd for C16H10N2O6SF5
79
Br (M
+.
) 531.93576, found 531.93529. 
 
2-Phenyl-ethenesulfonic acid pentafluorophenyl ester [122] 
PFPO
S
O O
Ph 
Trans-β-styrene sulfonyl chloride 121 (5.50 g, 27.2 mmol) was dissolved in CH2Cl2 
(40 mL) and cooled to -78
 
°C. Pentafluorophenol (5.00 g, 27.2 mol) and NEt3 (8.7 
mL, 62.5 mmol) were pre-mixed in CH2Cl2 (10 mL) and added dropwise to the 
stirred solution of trans-β-styrene sulfonyl chloride. The reaction was stirred for 1 
hour at 20 °C after which it was diluted with Et2O (50 mL) and washed with 2M HCl 
(50 mL) and sat. NaHCO3 (50 mL). The combined organic fractions were dried 
(MgSO4), filtered and concentrated in vacuo. The crude product was purified by 
flash column chromatography (10-100% Et2O in petroleum ether 40-60 °C) to yield 
the title compound as a white solid 122 (7.60 g, 21.6 mmol, 80%);  
MP 96 – 98 °C 
1
H NMR (500 MHz, CDCl3) δ 7.69 (d, J = 15.4 Hz, 1 H, CH), 7.58 – 7.44 
(m, 5 H, ArH), 6.95 (d, J = 15.4 Hz, 1 H, CH). 
13
C NMR (125 MHz, CDCl3) δ 206.6 (s), 148.1 (d), 132.5 (d), 131.3 (s), 
129.5 (d), 129.0 (d), 119.8 (d). 
IR (neat) 2921 (w), 2853 (w), 1613 (s, C=C), 1518 (s, C=C), 1394 (s, S=O), 
1175 (s) cm
-1
. 
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LRMS (EI) 350 [M
+.
, 7%], 167 [60], 103 [100]. 
HRMS (EI) calcd for C14H7O3SF5 (M
+
) 350.00306, found 350.00341. 
 
2-Phenyl-ethenesulfonic acid 2,4,6-trichlorophenyl ester [123] 
TCPO
S
O O
Ph 
Trans-β-styrene sulfonyl chloride 121 (2.80 g, 13.8 mmol) was dissolved in CH2Cl2 
(20 mL) and cooled to -78
 
°C. 2,4,6 Trichlorophenol (2.72 g, 13.8 mmol) and NEt3 
(4.4 mL, 31.8 mmol) were pre-mixed in CH2Cl2 (10 mL) and added dropwise to the 
stirred solution of trans-β-styrene sulfonyl chloride. The reaction was stirred for 1 
hour after which it was diluted with Et2O (50 mL) and washed with 2M HCl (50 mL) 
and sat. NaHCO3 (50 mL). The combined organic fractions were dried (MgSO4), 
filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (10-100% Et2O in petroleum ether 40-60 °C) to yield the title 
compound 123 as a white solid (4.30 g, 11.9 mmol, 86%);  
MP 126 – 128 °C 
1
H NMR (500 MHz, CDCl3) δ 7.71 (d, J = 15.5 Hz, 1 H, CH), 7.52 – 7.48 
(m, 5 H, ArH), 7.40 (s, 2 H, ArH), 6.95 (d, J = 15.4 Hz, 1 H, CH). 
13
C NMR (125 MHz, CDCl3) δ 146.1 (d), 142. 3 (s), 133.1 (s), 132.1 (d), 
131.7 (s), 129.4 (d), 129.3 (d), 128.9 (d), 122.4 (d). 
IR (neat) 3081 (w), 1613 (s, C=C), 1561 (s, C=C), 1440 (s), 1366 (s, S=O), 
1227 (s), 1169 (s) cm
-1
. 
LRMS (EI) 364 [M
+.
, 
37
Cl, 7%], 362 [M
+.
, 
35
Cl, 5%], 198 [5], 167 [80], 103 
[100]. 
HRMS (EI) calcd for C14H9O3SCl3 (M
+.
) 361.93325, found 361.93428. 
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3-(4-Methoxyphenyl)-2-methyl-5-phenyl-isoxazolidine-4-sulfonic acid 
pentafluorophenyl ester [124a] 
PFPO
S
N
O
O O
Me
MeO
Ph
 
 
2-Phenylethenesulfonic acid pentafluorophenyl ester 122 (0.50 g, 1.43 mmol) was 
dissolved in PhMe (5 mL) and treated with N-(4-methoxyphenyl) methylidene-N-
methylamine oxide 114b (280 mg, 1.71 mmol). The resulting suspension was stirred 
at reflux for 4 hours. Solvent was removed in vacuo and the crude residue purified by 
flash chromatography (10-100% Et2O in petroleum ether 40-60 °C) to give the title 
compound 124a a clear syrup as a single diastereoisomer (390 mg, 0.76 mmol, 53%);  
 
1
H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 7.2 Hz, 2 H, ArH), 7.52 – 7.41 
(m, 2 H, ArH), 7.40 – 7.33 (m, 1 H, ArH), 7.31 – 7.21 (m, 2 H, 
ArH), 6.94 – 6.82 (m, 2 H, ArH), 5.78 (d, J = 4.1 Hz, 1 H, 
OCHAr), 4.44 (dd, J = 4.2, 7.7 Hz, 1 H, SO2CH), 4.25 (d, J = 7.7 
Hz, 1 H, NCH), 3.79 (s, 3 H, CH3), 2.77 (s, 3H, CH3).
 
13
C NMR (125 MHz, CDCl3) δ 172.1 (s), 160.2 (s), 129.4 (d), 128.9 (d), 
128.3 (d), 127.0 (s), 125.9 (d), 114.5 (d), 81.1 (d), 78.7 (d), 75.0 
(d), 42.8 (q), 31.0 (q).  
IR (neat) 2960 (w), 1612 (w), 1515 (s, C=C), 1458 (w), 1384 (s, S=O), 
1250 (s), 1176 (s), 994 (s) cm
-1
. 
LRMS (EI) 515 [M
+.
, 10%], 165 [100], 103 [35]. 
HRMS (EI) calcd for C23H18 F5O5NS (M
+.
) 515.08203, found 515.08055. 
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2-Methyl-3,5-diphenyl-isoxazolidine-4-sulfonic acid pentafluorophenyl 
ester [124b] 
PFPO
S
N
O
O O
Me
Ph
 
2-Phenyl-ethenesulfonic acid pentafluorophenyl ester 122 (0.50 g, 1.43 mmol) was 
dissolved in PhMe (5 mL) and treated with N-methyl-N-phenylmethylidene amine 
oxide 114a (290 mg, 2.14 mmol). The resulting suspension was stirred at reflux for 5 
hours. Solvent was removed in vacuo and the crude residue purified by flash 
chromatography (chloroform) to give the title compound 124b a clear syrup as a 
single diastereoisomer (420 mg, 0.87 mmol, 61%);  
 
1
H NMR (500 MHz, CDCl3) δ 7.59 – 7.50 (m, 2 H, ArH), 7.49 – 7.40 (m, 2 
H, ArH), 7.39 – 7.29 (m, 6 H, ArH), 5.79 (d, J = 4.2 Hz, 1 H, 
OCHAr), 4.47 (dd, J = 4.2, 7.6 Hz, 1 H, SO2CH), 4.30 (d, J = 7.5 
Hz, 1 H, NCH), 2.79 (s, 3 H, CH3). 
13
C NMR (125 MHz, CDCl3) δ 138.8 (s), 135.4 (s), 129.2 (d), 129.1 (d), 
128.9 (d), 128.3 (d), 125.9 (d), 125.8 (d), 81.2 (d), 78.9 (d), 75.4 
(d), 42.9 (q). 
IR (neat) 3035 (w), 2873 (w), 1516 (s, C=C), 1456 (w), 1384 (s, S=O), 
1183 (s), 994 (s) cm
-1
. 
LRMS (EI) 485 [M
+.
, 25%], 167 [30], 135 [100], 103 [40]. 
HRMS (EI) calcd for C22H16 F5O4NS (M
+.
) 485.0715, found 485.0705. 
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3-(4-Bromo-phenyl)-2-methyl-5-phenyl-isoxazolidine-4-sulfonic acid 
pentafluorophenyl ester [124c] 
PFPO
S
N
O
O O
Me
Ph
Br  
2-Phenyl-ethenesulfonic acid pentafluorophenyl ester 122 (0.50 g, 1.43 mmol) was 
dissolved in PhMe (5 mL) and treated with N-(4-bromophenyl) methylidene-N-
methylamine oxide
81
 (1.50 g, 7.14 mmol). The resulting suspension was stirred at 
reflux for 4 hours. Solvent was removed in vacuo and the crude residue purified by 
flash chromatography (chloroform) to give the title compound 124c a clear syrup as a 
single diastereoisomer (300 mg, 0.54 mmol, 38%).  
1
H NMR (400 MHz, CDCl3) δ 7.66 – 7.57 (m, 2 H, ArH), 7.55 – 7.34 (m, 5 
H, ArH), 7.34 – 7.23 (m, 2 H, ArH), 5.83 (d, J = 4.2 Hz, 1 H, 
OCHAr), 4.45 (dd, J = 4.3, 7.5 Hz, 1 H, SO2CH), 4.34 (d, J = 7.5 
Hz, 1 H, NCH), 2.84 (s, 3 H, CH3). 
13
C NMR (126 MHz, CDCl3) δ 139.8 (s), 134.7 (s), 132.4 (d), 129.8 (d), 
129.0 (d), 128.4 (d), 125.8 (d), 123.3 (s), 81.1 (d), 79.0 (d), 74.6 
(d), 42.9 (q). 
IR (neat) 2921 (w), 1517 (s, C=C), 1488 (w), 1383 (s, S=O), 1183 (s), 994 
(s) cm
-1
. 
LRMS (EI) 563 [M
+.
, 21%], 213 [65], 167 [85]. 
HRMS (EI) calcd for C22H15 BrF5O4NS (M
+.
) 562.98198, found 562.98286. 
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2-Methyl-3-(4-nitrophenyl)-5-phenyl-isoxazolidine-4-sulfonic acid 
pentafluorophenyl ester [124f] 
PFPO
S
N
O
O O
Me
Ph
O2N  
2-Phenylethenesulfonic acid pentafluorophenyl ester 122 (0.50 g, 1.43 mmol) was 
dissolved in PhMe (5 mL) and treated with N-(4-nitrophenyl) methylidene-N-
methylamine oxide 114c (1.20 g, 7.14 mmol). The resulting suspension was stirred at 
reflux for 18 hours. Solvent was removed in vacuo and the crude residue purified by 
flash chromatography (chloroform) to give the title compound 124f as a light yellow 
syrup as a single distereoisomer (210 mg, 0.39 mmol, 27%);  
1
H NMR (500 MHz, CDCl3) δ 8.27 – 8.18 (m, 2 H, ArH), 7.61 – 7.56 (m, 2 
H, ArH), 7.54 (d, J = 7.3 Hz, 2 H, ArH), 7.46 – 7.40 (m, 2 H, 
ArH), 7.40 – 7.34 (m, 1 H, ArH), 5.83 (d, J = 4.4 Hz, 1 H, 
OCHAr), 4.48 (d, J = 7.2 Hz, 1 H, NCH), 4.39 (dd, J = 4.4, 7.2 
Hz, 1 H, SO2CH), 2.85 (s, 3 H, CH3). 
13
C NMR (126 MHz, CDCl3) δ 148.6 (s), 143.4 (s), 138.9 (s), 129.1 (d), 
129.0 (d), 128.7 (d), 125.9 (d), 124.4 (d), 80.7 (d), 79.7 (d), 74.2 
(d), 43.4 (q). 
IR (neat) 2972 (w), 1517 (s, C=C), 1376 (s, NO2), 1355 (S=O), 1183 (s), 
993 (s) cm
-1
. 
LRMS (EI) 530 [M
+.
, 21%], 180 [100], 103 [50]. 
HRMS (EI) calcd for C22H15 F5O6N2S (M
+.
) 530.05655, found 530.05785. 
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2-Methyl-3-naphthalen-2-yl-5-phenyl-isoxazolidine-4-sulfonic acid 
pentafluorophenyl ester [124g] 
PFPO
S
N
O
O O
Me
Ph
 
2-Phenylethenesulfonic acid pentafluorophenyl ester 122 (0.50 g, 1.43 mmol) was 
dissolved in PhMe (5 mL) and treated with N-methyl-N-naphthalen-2-ylmethylidene 
amine oxide 114d (0.53 g, 2.86 mmol). The resulting suspension was stirred at 80 °C 
for 48 hours. Solvent was removed in vacuo and the crude residue purified by flash 
chromatography (chloroform) to give the title compound 124g a clear syrup as a 
single diastereoisomer (490 mg, 0.92 mmol, 65%):  
 
1
H NMR (500 MHz, CDCl3) δ 7.88 (d, J = 1.3 Hz, 1 H, ArH), 7.85 – 7.78 
(m, 3 H, ArH), 7.66 (d, J = 7.3 Hz, 2 H, ArH), 7.57 – 7.43 (m, 4 
H, ArH), 7.40 – 7.38 (m, 2 H, ArH), 5.86 (d, J = 4.2 Hz, 1 H, 
OCHAr), 4.59 (dd, J = 4.2, 7.5 Hz, 1 H, SO2CH), 4.50 (d, J = 7.5 
Hz, 1 H, NCH), 2.84 (s, 3 H, CH3). 
13
C NMR (125 MHz, CDCl3) δ 140.0 (s), 136.9 (s), 133.6 (s), 133.3 (s), 
132.7 (s), 129.2 (d), 129.0 (d), 128.4 (d), 128.3 (d), 128.1 (d), 
127.8 (d), 126.8 (d), 126.6 (d), 125.9 (d), 124.6 (d), 80.9 (d), 79.0 
(d), 75.6 (d), 43.1 (q). 
IR (neat) 3056 (w), 2873 (w), 1516 (s, C=C), 1470 (w), 1381 (s, S=O), 1183 
(s), 992 (s) cm
-1
. 
LRMS (EI) 535 [M
+.
, 35%], 243 [20], 185 [95], 167 [85]. 
HRMS (EI) calcd for C26H18O4NSF5 (M
+.
) 535.08712, found 535.08682. 
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3-Cyclohexyl-2-methyl-5-phenyl-isoxazolidine-4-sulfonic acid 
pentafluorophenyl ester [124e] 
PFPO
S
N
O
O O
Me
Ph
 
2-Phenylethenesulfonic acid pentafluorophenyl ester 122 (0.50 g, 1.43 mmol) was 
dissolved in PhMe (5 mL) and treated with N-cyclohexylmethylidene-N-
methylamine oxide
81
 (400 mg, 2.86 mmol). The resulting suspension was stirred at 
reflux for 4 hours. Solvent was removed in vacuo and the crude residue purified by 
flash chromatography (chloroform) to give the title compound 124e a clear syrup as a 
single diastereoisomer (230 mg, 0.66 mmol, 33%):  
1
H NMR (400 MHz, CDCl3) δ 7.50 (m, 2 H, ArH), 7.45 – 7.33 (m, 3 H, 
ArH), 5.82 (d, J = 7.3 Hz, 1 H, CHAr), 4.22 (dd, J = 4.5, 7.3 Hz, 1 
H, SO2CH), 3.48 (dd, J = 4.5, 6.6 Hz, 1 H, NCH), 2.99 (s, 3 H, 
CH3), 1.90 – 1.58 (m, 6 H, cyclohexyl-H), 1.20 (m, 5 H, 
cyclohexyl-H). 
13
C NMR (125 MHz, CDCl3) δ 135.9 (s), 129.2 (d), 128.9 (d), 127.2 (d), 
80.2 (d), 75.6 (d), 75.6 (d), 45.5 (q), 30.0 (t), 29.5 (t), 26.2 (t), 26.1 
(s), 26.0 (t). 
IR (neat) 2928 (s, CH), 2855 (s, CH), 1516 (s, C=C), 1450 (s), 1384 (s, 
S=O), 1182 (s), 998 (s) cm
-1
. 
LRMS (EI) 491 [M
+.
, 20%], 408 [100]. 
HRMS (EI) calcd for C22H22O4NSF5 (M
+.
) 491.11842, found 491.11943. 
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3-Cyclopropyl-2-methyl-5-phenyl-isoxazolidine-4-sulfonic acid 
pentafluorophenyl ester [124d] 
PFPO
S
N
O
O O
Me
Ph
 
2-Phenylethenesulfonic acid pentafluorophenyl ester 122 (0.50 g, 1.43 mmol) was 
dissolved in PhMe (5 mL) and treated with N-cyclopropylmethylidene-N-
methylamine oxide 114f (280 mg, 2.86 mmol). The resulting suspension was stirred 
at 80 °C for 18 hours. Solvent was removed in vacuo and the crude residue purified 
by flash chromatography (chloroform) to give the title compound 124d a clear syrup 
as a single diastereoisomer (140 mg, 0.31 mmol, 22%).  
1
H NMR (500 MHz, CDCl3) δ 7.53 (d, J = 7.4 Hz, 2 H, ArH), 7.43 – 7.31 
(m, 3 H, ArH), 5.65 (s, 1 H, CHAr), 4.37 (t, J = 5.4 Hz, 1 H, 
SO2CH), 2.98 (s, 3 H, CH3), 1.18 (m, 2 H, cyclopropyl-H), 0.77 – 
0.45 (m, 4 H, cyclopropyl-H). 
13
C NMR (150 MHz, CDCl3) δ 129.2 (d), 128.8 (d), 127.2 (d), 80.2 (d), 75.6 
(d), 75.6 (d), 45.5 (q), 30.0 (t), 29.5 (t), 14.1 (d), 4.4 (t), 2.3 (t). 
IR (neat) 1516 (s, C=C), 1470 (s), 1381 (s,S=O), 1183 (s), 992 (s) cm
-1
. 
LRMS (EI) 449 [M
+.
, 20%], 184 [100]. 
HRMS (EI) calcd for C19H16O4NSF5 (M
+.
) 449.07147, found 449.07247. 
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3-(4-Methoxyphenyl)-2-methyl-5-phenyl-isoxazolidine-4-sulfonic acid 
2,4,6-trichlorophenyl ester [125a] 
TCPO
S
N
O
O O
Me
Ph
MeO  
2-Phenylethenesulfonic acid 2,4,6-trichlorophenyl ester 123 (0.50 g, 1.38 mmol) was 
dissolved in PhMe (5 mL) and treated with N-(4-methoxyphenyl) methylidene-N-
methylamine oxide 114b (450 mg, 2.75 mmol). The resulting suspension was stirred 
at 80 °C for 48 hours. Solvent was removed in vacuo and the crude residue purified 
by flash chromatography (chloroform) to give the title compound 125a a clear syrup 
as a single stereoisomer (340 mg, 0.64 mmol, 46%):  
1
H NMR (400 MHz, CDCl3) δ 7.66 – 7.60 (m, 2 H, ArH), 7.46 – 7.39 (m, 2 
H, ArH), 7.38 – 7.28 (m, 5 H, ArH), 6.90 – 6.81 (m, 2 H, ArH), 
5.84 (d, J = 4.3 Hz, 1 H, OCHAr), 4.63 (dd, J = 4.3, 7.6 Hz, 1 H, 
SO2CH), 4.33 (d, J = 7.5 Hz, 1 H, NCH), 3.79 (s, 3 H, CH3), 2.80 
(s, 3 H, CH3). 
13
C NMR (125 MHz, CDCl3) δ 160.0 (s), 141.5 (s), 133.2 (s), 130.7 (s), 
129.5 (d), 129.2 (d), 128.8 (d), 128.1 (d), 127.5 (d), 126.1 (d), 
114.3 (d), 81.7 (d), 79.1 (d), 75.1 (d), 55.3 (q), 42.8 (q). 
IR (neat) 2964 (w), 1612 (s, C=C), 1513 (s, C=C), 1441 (s), 1384 (s, S=O), 
1249 (s), 1174 (s), 1029 (s) cm
-1
. 
LRMS (EI) 529 [M
+.
, 
37
Cl, 10%], 527 [M
+.
, 
35
Cl, 8%], 165 [100]. 
HRMS (EI) calcd for C23H20O5NSCl3 (M
+.
) 527.01223, found 527.01345. 
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2-Methyl-3,5-diphenyl-isoxazolidine-4-sulfonic acid 2,4,6-trichlorophenyl 
ester [125b] 
TCPO
S
N
O
O O
Me
Ph
 
2-Phenylethenesulfonic acid 2,4,6-trichlorophenyl ester 123 (0.50 g, 1.38 mmol) was 
dissolved in PhMe (5 mL) and treated with N-methyl-N-phenylmethylidene amine 
oxide 114a (370 mg, 2.75 mmol). The resulting suspension was stirred at 80 °C for 
48 hours. Solvent was removed in vacuo and the crude residue purified by flash 
chromatography (chloroform) to give the title compound 125b a clear syrup as a 
single diastereoisomer (440 mg, 0.89 mmol, 65%):  
1
H NMR (400 MHz, CDCl3) δ 7.66 – 7.59 (m, 2 H, ArH), 7.48 – 7.30 (m, 
10 H, ArH), 5.86 (d, J = 4.3 Hz, 1 H, OCHAr), 4.66 (dd, J = 4.3, 
7.4 Hz, 1 H, SO2CH), 4.40 (d, J = 7.4 Hz, 1 H, NCH), 2.83 (s, 3 
H, CH3). 
13
C NMR (125 MHz, CDCl3) δ 141.53 (s), 136.03 (s), 133.30 (s), 130.76 (s), 
129.21 (d), 129.01 (d), 128.94 (d), 128.85 (d), 128.29 (d), 128.19 
(d), 126.14 (d), 81.94 (d), 79.25 (d), 75.45 (d), 43.03 (q). 
IR (neat) 3078 (w), 2873 (w), 1561 (s, C=C), 1441 (s), 1385 (s, S=O), 1227 
(s), 1175 (s), 1027 (w) cm
-1
. 
LRMS (EI) 499 [M
+.
, 
37
Cl, 10%], 497  [M
+.
, 
35
Cl, 8%], 196 [100]. 
HRMS (EI) calcd for C22H18O4NSCl3 (M
+.
) 497.00166, found 497.00207. 
 
 
 
 
121 
 
3-(4-Bromophenyl)-2-methyl-5-phenyl-isoxazolidine-4-sulfonic acid 2,4,6-
trichlorophenyl ester [125c] 
TCPO
S
N
O
O O
Me
Ph
Br  
2-Phenylethenesulfonic acid 2,4,6-trichlorophenyl ester 123 (0.50 g, 1.43 mmol) was 
dissolved in PhMe (5 mL) and treated with N-(4-bromophenyl) methylidene-N-
methylamine oxide
81
 (0.59 g, 2.75 mmol). The resulting suspension was stirred at 80 
°C for 48 hours. Solvent was removed in vacuo and the crude residue purified by 
flash chromatography (chloroform) to give the title compound 125c a clear syrup as a 
single stereoisomer (200 mg, 0.35 mmol, 25%):  
1
H NMR (400 MHz, CDCl3) δ 7.63 – 7.57 (m, 2 H, ArH), 7.50 – 7.39 (m, 4 
H, ArH), 7.38 – 7.32 (m, 3 H, ArH), 7.31 – 7.25 (m, 3 H, ArH), 
5.85 (d, J = 4.4 Hz, 1 H, OCHAr), 4.66 (dd, J = 4.4, 7.3 Hz, 1 H, 
SO2CH), 4.38 (d, J = 7.3 Hz, 1 H, NCH), 2.83 (s, 3 H, CH3). 
13
C NMR (125 MHz, CDCl3) δ 141.5 (s), 136.0 (s), 133.3 (s), 130.8 (s), 
129.2 (d), 129.0 (d), 128.9 (d), 128.8 (d), 128.3 (d), 128.2 (d), 
126.1 (d), 81.9 (d), 79.2 (d), 75.4 (d), 43.0 (q). 
IR (neat) 3080 (w), 1561 (s, C=C), 1441 (s), 1385 (s, S=O), 1227 (s), 1176 
(s), 906 (w) cm
-1
. 
LRMS (EI) 575 [M
+.
, 10%], 577 [M
+.
, 
81
Br, 
37
Cl, 8%], 575 [M
+.
, 
79
Br, 
37
Cl, 
10%], 573 [M
+.
, 
79
Br, 
35
Cl, 8%], 213 [100]. 
HRMS (EI) calcd for C22H17O4NS
79
BrCl3 (M
+.
) 574.91218, found 574.91124. 
 
 
 
122 
 
1-Bromo-2-phenylethenesulfonic acid pentafluorophenyl ester [142] 
PFPO
S
O O
Ph
Br  
Bromine (5.9 mL, 114.2 mmol) in CHCl3 (30 mL) was added dropwise over a period 
of 10 minutes to a stirring solution of 2-Phenylethenesulfonic acid pentafluorophenyl 
ester 122 (4.00 g, 11.4 mmol) in CHCl3 (70 mL). After addition, the reaction mixture 
was heated at reflux for 4 hours, followed by 40 hours at 20 °C. The solvent was 
removed in vacuo and the crude oil remaining resuspended in CH2Cl2 (100 mL). To 
this stirring solution was added NEt3 (3.2 mL, 22.8 mmol) and the reaction stirred at 
20 °C for 3 hrs. The reaction mixture was washed with 2M HCl (100 mL), the 
organic layer dried (MgSO4), filtered and concentrated in vacuo. The crude residue 
was purified by flash chromatography (10-100% Et2O in petroleum ether 40-60 °C) 
to give the titled compound 142 as a white solid (4.20 g, 9.4 mmol, 83%);  
MP 64 – 66 °C 
1
H NMR (400 MHz, CDCl3) δ 8.19 (s, 1 H, CH), 7.94 – 7.80 (m, 2 H, ArH), 
7.63 – 7.44 (m, 3 H, ArH). 
13
C NMR (125 MHz, CDCl3) δ 143.8 (d), 132.2 (s), 131.1 (d), 130.6 (d), 
129.0 (d), 112.6 (s). 
IR (neat) 3080 (w), 1561 (s, C=C), 1441 (s), 1385 (s, S=O), 1227 (s), 1176 
(s), 906 (w) cm
-1
. 
LRMS (EI) 430 [M
+.
, 
81
Br, 10%], 428 [M
+.
, 
79
Br, 8%], 245 [25], 183 [45]. 
HRMS (EI) calcd for C14H6O3S
79
BrF5 (M
+.
) 427.91357, found 427.91237. 
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4-Bromo-3-(4-methoxy-phenyl)-2-methyl-5-phenyl-isoxazolidine-4-
sulfonic acid pentafluorophenyl ester [143] 
PFPO
S
N
O
O O
Me
Ph
MeO
Br
 
1-Bromo-2-phenyl-ethenesulfonic acid pentafluorophenyl ester 142 (0.50 g, 1.12 
mmol) was dissolved in PhMe (5 mL) and treated with N-(4-methoxyphenyl) 
methylidene-N-methylamine oxide 114b (0.93 g, 5.61 mmol). The resulting 
suspension was stirred at 50 °C for 48 hours. Solvent was removed in vacuo and the 
crude residue purified by flash chromatography (chloroform) to give the title 
compound 143 a clear syrup as a single diastereoisomer (20 mg, 0.034 mmol, 3%):  
1
H NMR (400 MHz, CDCl3) δ 7.66 – 7.57 (m, 2 H, ArH), 7.46 – 7.33 (m, 5 
H, ArH), 6.93 – 6.87 (m, 2 H, ArH), 6.10 (s, 1 H, OCH), 4.71 (s, 1 
H, NCH), 3.82 (s, 3 H, CH3), 2.86 (s, 3 H, CH3). 
13
C NMR (125 MHz, CDCl3) δ 141.5 (s), 136.0 (s), 133.3 (s), 130.7 (s), 
129.2 (d), 129.0 (d), 128.9 (d), 128.8 (d), 128.2 (d), 128.1 (d), 
126.1 (d), 81.9 (s), 79.2 (d), 75.4 (d), 55.3 (q), 43.0 (q). 
IR (neat) 3080 (w), 1561 (s, C=C), 1441 (s), 1385 (s, S=O), 1227 (s), 1176 
(s), 906 (w) cm
-1
. 
LRMS (EI) 595 [M
+.
, 
81
Br, 5%], 593 [M
+.
, 
79
Br, 3%], 430 [15], 247 [35], 183 
[75], 102 [100]. 
HRMS (EI) calcd for C23H17O5NS
79
BrF5 (M
+.
) 592.99255, found 592.99341. 
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4.6 Crystal structure data for 4-Bromo-2-methyl-3-phenyl-
isoxazolidine-4-sulfonic acid pentafluoro phenyl ester 
[118a] 
Table 1.  Crystal data and structure refinement for str0758. 
Identification code  str0758 
Chemical formula  C16H11BrF5NO4S 
Formula weight  488.23 
Temperature  150(2) K 
Radiation, wavelength   
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 7.1179(16) Å  
 b = 10.832(2) Å  
 c = 12.340(3) Å )° 
Cell volume 864.3(3) Å
3
 
Z 2 
Calculated density  1.876 g/cm
3
 
 2.576 mm
1
 
F(000) 484 
Crystal colour and size colourless, 0.50  0.20  0.04 mm3 
Data collection method Bruker SMART APEX CCD diffractometer 
 mes 
 2.30 to 28.31° 
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Index ranges h 9 to 9, k 14 to 14, l 15 to 16 
 96.7 %  
Reflections collected 7291 
Independent reflections 3911 (Rint = 0.0262) 
Reflections with F
2
 3436 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.3591 and 0.9040 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0669, 0.5665 
Data / restraints / parameters 3911 / 0 / 253 
Final R indices [F
2
>2 ] R1 = 0.0373, wR2 = 0.1065 
R indices (all data) R1 = 0.0429, wR2 = 0.1154 
Goodness-of-fit on F
2
 1.069 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.800 and 0.759 e Å3 
 
Table 2.  Atomic coordinates and equivalent isotropic displacement parameters (Å
2
) 
for str0758.  Ueq is defined as one third of the trace of the orthogonalized U
ij
 tensor. 
 
      x      y      z      Ueq 
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Br(1) 1.16668(4) 0.66791(3) 0.61916(3) 0.02941(12) 
S(1) 0.93804(10) 0.49763(7) 0.75672(6) 0.02657(17) 
O(1) 0.7043(3) 0.5182(2) 0.77933(19) 0.0290(5) 
O(2) 1.0139(3) 0.3907(2) 0.7031(2) 0.0369(5) 
O(3) 1.0290(4) 0.4905(2) 0.8571(2) 0.0376(5) 
O(4) 0.5860(3) 0.7458(2) 0.57224(17) 0.0251(4) 
N(1) 0.6156(3) 0.8535(2) 0.6127(2) 0.0230(5) 
F(1) 0.6776(3) 0.3906(2) 1.00299(15) 0.0344(4) 
F(2) 0.5069(3) 0.1922(2) 1.06511(16) 0.0405(5) 
F(3) 0.3790(3) 0.1074(2) 0.90613(18) 0.0427(5) 
F(4) 0.4257(3) 0.2187(2) 0.68461(17) 0.0373(4) 
F(5) 0.5927(3) 0.4177(2) 0.62192(15) 0.0355(4) 
C(1) 0.6169(4) 0.3491(3) 0.9244(2) 0.0248(6) 
C(2) 0.5294(4) 0.2481(3) 0.9563(2) 0.0269(6) 
C(3) 0.4637(4) 0.2044(3) 0.8752(3) 0.0281(6) 
C(4) 0.4859(4) 0.2614(3) 0.7626(3) 0.0264(6) 
C(5) 0.5730(4) 0.3622(3) 0.7311(2) 0.0258(6) 
C(6) 0.6384(4) 0.4073(3) 0.8112(2) 0.0235(6) 
C(7) 0.9004(4) 0.6605(3) 0.6565(2) 0.0217(5) 
C(8) 0.7838(4) 0.6750(3) 0.5509(2) 0.0259(6) 
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C(9) 0.4219(4) 0.9194(3) 0.6548(3) 0.0277(6) 
C(10) 0.7639(4) 0.7772(3) 0.7057(2) 0.0199(5) 
C(11) 0.8543(4) 0.8698(3) 0.7376(2) 0.0217(5) 
C(12) 0.8602(4) 0.9904(3) 0.6625(2) 0.0254(6) 
C(13) 0.9348(4) 1.0776(3) 0.6967(3) 0.0301(6) 
C(14) 1.0040(4) 1.0448(3) 0.8069(3) 0.0311(7) 
C(15) 1.0008(5) 0.9239(3) 0.8809(3) 0.0338(7) 
C(16) 0.9244(4) 0.8371(3) 0.8478(3) 0.0273(6) 
 
Table 3.   Bond lengths [Å] and angles [°] for str0758. 
 
Br(1)–C(7)  1.940(3) S(1)–O(3)  1.411(3) 
S(1)–O(2)  1.426(2) S(1)–O(1)  1.619(2) 
S(1)–C(7)  1.802(3) O(1)–C(6)  1.378(3) 
O(4)–C(8)  1.412(3) O(4)–N(1)  1.467(3) 
N(1)–C(9)  1.463(4) N(1)–C(10)  1.481(3) 
F(1)–C(1)  1.325(3) F(2)–C(2)  1.333(3) 
F(3)–C(3)  1.330(3) F(4)–C(4)  1.326(3) 
F(5)–C(5)  1.332(3) C(1)–C(2)  1.382(4) 
C(1)–C(6)  1.385(4) C(2)–C(3)  1.386(4) 
C(3)–C(4)  1.377(4) C(4)–C(5)  1.378(4) 
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C(5)–C(6)  1.383(4) C(7)–C(8)  1.539(4) 
C(7)–C(10)  1.565(4) C(10)–C(11)  1.500(4) 
C(11)–C(12)  1.388(4) C(11)–C(16)  1.393(4) 
C(12)–C(13)  1.391(4) C(13)–C(14)  1.391(5) 
C(14)–C(15)  1.380(5) C(15)–C(16)  1.388(4) 
 
O(3)–S(1)–O(2) 119.90(15) O(3)–S(1)–O(1) 108.53(14) 
O(2)–S(1)–O(1) 107.99(13) O(3)–S(1)–C(7) 111.09(14) 
O(2)–S(1)–C(7) 110.98(14) O(1)–S(1)–C(7) 95.48(12) 
C(6)–O(1)–S(1) 119.98(18) C(8)–O(4)–N(1) 100.85(19) 
C(9)–N(1)–O(4) 104.8(2) C(9)–N(1)–C(10) 111.7(2) 
O(4)–N(1)–C(10) 102.98(19) F(1)–C(1)–C(2) 119.4(3) 
F(1)–C(1)–C(6) 120.5(3) C(2)–C(1)–C(6) 120.1(3) 
F(2)–C(2)–C(1) 120.5(3) F(2)–C(2)–C(3) 119.4(3) 
C(1)–C(2)–C(3) 120.1(3) F(3)–C(3)–C(4) 120.0(3) 
F(3)–C(3)–C(2) 120.0(3) C(4)–C(3)–C(2) 120.0(3) 
F(4)–C(4)–C(3) 120.2(3) F(4)–C(4)–C(5) 120.1(3) 
C(3)–C(4)–C(5) 119.7(3) F(5)–C(5)–C(4) 119.4(3) 
F(5)–C(5)–C(6) 119.7(3) C(4)–C(5)–C(6) 120.9(3) 
O(1)–C(6)–C(5) 120.6(3) O(1)–C(6)–C(1) 119.9(3) 
C(5)–C(6)–C(1) 119.2(3) C(8)–C(7)–C(10) 103.2(2) 
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C(8)–C(7)–S(1) 111.82(19) C(10)–C(7)–S(1) 110.98(18) 
C(8)–C(7)–Br(1) 111.31(19) C(10)–C(7)–Br(1) 115.26(18) 
S(1)–C(7)–Br(1) 104.47(14) O(4)–C(8)–C(7) 103.8(2) 
N(1)–C(10)–C(11) 110.7(2) N(1)–C(10)–C(7) 101.2(2) 
C(11)–C(10)–C(7) 118.9(2) C(12)–C(11)–C(16) 119.2(3) 
C(12)–C(11)–C(10) 121.9(3) C(16)–C(11)–C(10) 118.8(3) 
C(11)–C(12)–C(13) 120.5(3) C(14)–C(13)–C(12) 120.1(3) 
C(15)–C(14)–C(13) 119.2(3) C(14)–C(15)–C(16) 121.0(3) 
C(15)–C(16)–C(11) 120.0(3)  
 
Table 4.   Anisotropic displacement parameters (Å
2
) for str0758.  The anisotropic 
displacement factor exponent takes the form:  2[h2a*2U11 + ...+ 2hka*b*U12] 
 
      U
11
      U
22
      U
33
      U
23
      U
13
      U
12
 
 
Br(1) 0.02202(16)  0.02796(18) 0.03648(18)   0.00917(13) 0.00622(12)   
0.00640(12) 
S(1) 0.0227(3)  0.0177(3) 0.0356(4)   0.0057(3) 0.0013(3)   
0.0030(3) 
O(1) 0.0230(10)  0.0170(10) 0.0450(12)   0.0081(9) 0.0058(9)   
0.0051(8) 
O(2) 0.0288(11)  0.0210(11) 0.0592(15)   0.0161(10) 0.0073(10)   
0.0028(9) 
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O(3) 0.0368(12)  0.0326(13) 0.0353(12)  0.0016(10)  0.0066(10)   
0.0076(10) 
O(4) 0.0241(10)  0.0263(10) 0.0280(10)   0.0134(8)  0.0005(8)   
0.0069(8) 
N(1) 0.0228(11)  0.0189(11) 0.0278(11)   0.0078(9)  0.0040(9)   
0.0049(9) 
F(1) 0.0373(10)  0.0367(11) 0.0319(9)   0.0145(8)  0.0053(8)   
0.0099(8) 
F(2) 0.0436(11)  0.0473(12) 0.0273(9)  0.0011(8) 0.0040(8)   
0.0199(10) 
F(3) 0.0399(11)  0.0341(11) 0.0565(13)  0.0001(9)  0.0091(9)   
0.0231(9) 
F(4) 0.0350(10)  0.0348(10) 0.0440(11)   0.0208(9)  0.0113(8)   
0.0027(8) 
F(5) 0.0407(10)  0.0350(10) 0.0229(8)   0.0037(7) 0.0023(7)   
0.0055(8) 
C(1) 0.0249(13)  0.0216(14) 0.0273(14)   0.0075(11)  0.0038(11)   
0.0050(11) 
C(2) 0.0248(13)  0.0244(15) 0.0278(14)   0.0031(11) 0.0001(11)   
0.0061(11) 
C(3) 0.0233(13)  0.0208(14) 0.0376(16)   0.0038(12)  0.0034(12)   
0.0061(11) 
C(4) 0.0218(13)  0.0228(14) 0.0329(15)   0.0124(12)  0.0067(11) 
 0.0008(11) 
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C(5) 0.0253(13)  0.0201(14) 0.0255(13)   0.0056(11)  0.0014(11) 
 0.0014(11) 
C(6) 0.0216(13)  0.0151(13) 0.0307(14)   0.0033(10)  0.0004(11)   
0.0040(10) 
C(7) 0.0203(12)  0.0180(13) 0.0268(13)   0.0072(10) 0.0033(10)   
0.0058(10) 
C(8) 0.0256(14)  0.0250(14) 0.0277(14)   0.0119(11) 0.0025(11)   
0.0054(11) 
C(9) 0.0229(13)  0.0259(15) 0.0322(15)   0.0101(12)  0.0034(11)   
0.0023(11) 
C(10) 0.0184(12)  0.0167(12) 0.0239(12)   0.0053(10)  0.0013(10)   
0.0044(10) 
C(11) 0.0166(11)  0.0191(13) 0.0289(13)   0.0090(11) 0.0000(10)   
0.0028(10) 
C(12) 0.0240(13)  0.0233(14) 0.0287(14)   0.0060(11) 0.0007(11)   
0.0081(11) 
C(13) 0.0262(14)  0.0237(15) 0.0437(17)   0.0142(13) 0.0037(13)   
0.0087(12) 
C(14) 0.0210(13)  0.0304(16) 0.0499(18)   0.0229(14)  0.0014(12)   
0.0080(12) 
C(15) 0.0321(16)  0.0321(17) 0.0374(16)   0.0156(14)  0.0099(13)   
0.0028(13) 
C(16) 0.0281(14)  0.0233(14) 0.0292(14)   0.0070(11)  0.0034(12)   
0.0055(11) 
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Table 5.   Hydrogen coordinates and isotropic displacement parameters (Å
2
) 
for str0758. 
 
      x       y       z       U 
 
H(8A) 0.8331 0.7270 0.4822 0.031 
H(8B) 0.7946 0.5851 0.5416 0.031 
H(9A) 0.3279 0.9692 0.5912 0.042 
H(9B) 0.4354 0.9826 0.6950 0.042 
H(9C) 0.3725 0.8506 0.7064 0.042 
H(10A) 0.6950 0.7366 0.7728 0.024 
H(12A) 0.8129 1.0134 0.5871 0.030 
H(13A) 0.9384 1.1599 0.6447 0.036 
H(14A) 1.0530 1.1048 0.8309 0.037 
H(15A) 1.0517 0.8998 0.9556 0.041 
H(16A) 0.9200 0.7553 0.9002 0.033 
 
Table 6.  Torsion angles [°] for str0758. 
 
O(3)–S(1)–O(1)–C(6)  93.6(2) O(2)–S(1)–O(1)–C(6) 37.8(3) 
C(7)–S(1)–O(1)–C(6) 152.0(2) C(8)–O(4)–N(1)–C(9)  170.9(2) 
C(8)–O(4)–N(1)–C(10)  54.0(2) F(1)–C(1)–C(2)–F(2)  0.3(4) 
C(6)–C(1)–C(2)–F(2)  179.5(3) F(1)–C(1)–C(2)–C(3) 179.5(3) 
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C(6)–C(1)–C(2)–C(3) 0.2(4) F(2)–C(2)–C(3)–F(3) 0.0(4) 
C(1)–C(2)–C(3)–F(3)  179.8(3) F(2)–C(2)–C(3)–C(4) 179.9(3) 
C(1)–C(2)–C(3)–C(4) 0.2(5) F(3)–C(3)–C(4)–F(4)  0.9(4) 
C(2)–C(3)–C(4)–F(4) 179.1(3) F(3)–C(3)–C(4)–C(5) 179.7(3) 
C(2)–C(3)–C(4)–C(5)  0.2(4) F(4)–C(4)–C(5)–F(5) 1.2(4) 
C(3)–C(4)–C(5)–F(5)  179.5(3) F(4)–C(4)–C(5)–C(6)  179.4(3) 
C(3)–C(4)–C(5)–C(6)  0.1(4) S(1)–O(1)–C(6)–C(5)  92.1(3) 
S(1)–O(1)–C(6)–C(1) 94.9(3) F(5)–C(5)–C(6)–O(1) 6.8(4) 
C(4)–C(5)–C(6)–O(1)  172.5(3) F(5)–C(5)–C(6)–C(1) 179.9(2) 
C(4)–C(5)–C(6)–C(1) 0.5(4) F(1)–C(1)–C(6)–O(1)  6.7(4) 
C(2)–C(1)–C(6)–O(1) 172.5(3) F(1)–C(1)–C(6)–C(5)  179.8(3) 
C(2)–C(1)–C(6)–C(5)  0.6(4) O(3)–S(1)–C(7)–C(8)  174.68(19) 
O(2)–S(1)–C(7)–C(8) 49.3(2) O(1)–S(1)–C(7)–C(8)  62.4(2) 
O(3)–S(1)–C(7)–C(10)  60.0(2) O(2)–S(1)–C(7)–C(10) 163.95(19) 
O(1)–S(1)–C(7)–C(10) 52.3(2) O(3)–S(1)–C(7)–Br(1) 64.82(17) 
O(2)–S(1)–C(7)–Br(1)  71.23(16) O(1)–S(1)–C(7)–Br(1) 177.10(13) 
N(1)–O(4)–C(8)–C(7) 46.0(2) C(10)–C(7)–C(8)–O(4)  22.1(3) 
S(1)–C(7)–C(8)–O(4) 97.2(2) Br(1)–C(7)–C(8)–O(4)  146.33(19) 
C(9)–N(1)–C(10)–C(11)  83.2(3) O(4)–N(1)–C(10)–C(11) 164.8(2) 
C(9)–N(1)–C(10)–C(7) 149.8(2) O(4)–N(1)–C(10)–C(7) 37.8(2) 
C(8)–C(7)–C(10)–N(1)  10.0(3) S(1)–C(7)–C(10)–N(1)  129.92(19) 
Br(1)–C(7)–C(10)–N(1) 111.6(2) C(8)–C(7)–C(10)–C(11)  131.4(3) 
S(1)–C(7)–C(10)–C(11) 108.6(2) Br(1)–C(7)–C(10)–C(11)  9.8(3) 
N(1)–C(10)–C(11)–C(12)  24.4(3) C(7)–C(10)–C(11)–C(12) 92.0(3) 
N(1)–C(10)–C(11)–C(16) 152.0(2) C(7)–C(10)–C(11)–C(16)  91.5(3) 
C(16)–C(11)–C(12)–C(13)  0.1(4) C(10)–C(11)–C(12)–C(13) 176.3(3) 
C(11)–C(12)–C(13)–C(14)  0.1(4) C(12)–C(13)–C(14)–C(15) 1.1(4) 
C(13)–C(14)–C(15)–C(16)  1.9(5) C(14)–C(15)–C(16)–C(11) 1.7(5) 
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C(12)–C(11)–C(16)–C(15)  0.6(4) C(10)–C(11)–C(16)–C(15)  177.2(3) 
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